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Abstract 
Most adults are infected by Epstein-Barr virus (EBV), which establishes persistent 
infection in B cells. EBV nuclear antigen 3C (EBNA3C) is a latent viral protein that co-
regulates many cellular genes, but little is known about the mechanisms by which EBNA3C 
acts as repressor or activator of gene expression. This study aimed to further explore 
molecular mechanisms that underlie EBNA3C host gene regulation. For this, four EBNA3C 
target genes – three repressed (COBLL1, ADAM28 and ADAMDEC1) and one induced 
(AICDA) – were selected based on a previous exon microarray on EBV-recombinant 
lymphoblastoid cell lines (LCL) carrying conditional EBNA3C (3CHT). 
Using EBV recombinants to infect primary B cells, EBNA3C was shown to be the 
main regulator of all four genes. Surprisingly, regulation by EBNA3C over orders of 
magnitude followed highly exponential activation or repression profiles and required ~30 
days after infection. This could be reproduced efficiently in the 3CHT LCLs by activating 
EBNA3C, proving the utility of these cells to replicate EBNA3C gene regulation. Analysis of 
chromatin immunoprecipitation (ChIP) coupled to deep-sequencing identified EBNA3C 
binding to distal regulatory elements at all four genes and detailed ChIP analysis of histone 
modifications and cellular factors was performed. Unexpectedly, recruitment and/or 
stabilisation of the DNA-sequence binding factor RBPJ was observed at the EBNA3C 
binding sites only when EBNA3C was functional. This challenges existing models of how 
RBPJ functions in EBV-regulated gene expression. EBNA3C failed to regulate all four genes 
when it is unable to bind to RBPJ. Recruitment of a polycomb protein, generally linked to 
gene repression, was observed at all four genes irrespective of whether repression or 
activation by EBNA3C occurred. Changes to histone modifications at these loci correlated 
well with gene expression and indicate a two-step mechanism for EBNA3C-mediated 
repression and suggest the activation is linked to a very complex pattern of chromatin 
looping.  
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APE1   apurinic/apyridimic endonuclease 1 
APOBEC  apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like  
APS   ammonium persulfate 
ATR   ataxia telangiectasia and Rad3 related 
AUTS2  autism susceptibility gene 2 
BAC   bacterial artificial chromosome 
BCL2   B cell lymphoma 2 protein 
BCL2L11  gene encoding BCL2-interacting mediator (BIM) 
BCL6   B cell lymphoma 6 protein 
BER   base excision repair 
BIM   BCL2-interacting mediator 
BL   Burkitt’s lymphoma 
BM   binding mutant 
bp   base pair 
C/EBP   CCAAT-enhancer binding protein 
CART   C-terminal activation regions 
CBX   chromobox-domain family 
CD   cluster of differentiation 
CD40L   CD40 ligand 
CDK   cyclin-dependent kinase 
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CDKN2A  gene encoding cyclin-dependent kinase inhibitor 2A (p16INK4A) 
cDNA   complementary DNA 
CDR   complementarity determining region 
ChIA-PET  chromatin interaction analysis by paired-end tag sequencing 
ChIP   chromatin immunoprecipitation 
ChIP-qPCR  chromatin immunoprecipitation followed by qPCR 
ChIP-Seq  chromatin immunoprecipitation followed by deep-sequencing 
CIR   CBF1-interacting co-repressor 
CML   chronic myelogenous leukemia 
COBL   Cordon-bleu 
COBLL1  Cordon-bleu like 1 
Cp   C promoter 
CpG   Cytosine-phosphate-guanine dinucleotide 
cPRC1   canonical PRC1 complex 
CSR   class switch recombination 
CTAR   C terminal activation region 
CtBP   C-terminal binding protein 
CTBP2  C terminal binding protein 2 
CTCF   CCCTC-binding factor 
CtIP   CtBP-interacting protein 
CTL   cytotoxic T cells 
CXCR4  C-X-C chemokine receptor type 4 
DMSO   dimethyl sulphoxide 
DNA   deoxyribonucleic acid 
DNMT   DNA methyltransferase 
DSB   double strand break 
DTT   dithiothreitol 
DZ   dark zone 
E. coli   Escherichia coli 
EBER   Epstein-Barr virus-encoded small RNA 
EBF   early B cell factor 
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eBL   endemic Burkitt’s lymphoma 
EBNA   Epstein-Barr nuclear antigen 
EBV   Epstein-Barr virus 
EDTA   ethylenediaminetetraacetic acid 
EED   embryonic ectoderm development 
eEF1A   eukaryotic elongation factor 1 
EGF   epidermal growth factor 
EGR-1   early growth response 1 
ENCODE  ENCyclopedia Of DNA Elements 
ePICh   end-targeting proteomics of isolated chromatin fragments 
ESC   embryonic stem cell 
Exo1   exonuclease 1 
EZH   enhancer of zeste 
FBS   foetal bovine serum 
FDC   follicular dendritic cells 
FISH   fluorescence in situ hybridisation 
GAPHD  glyceraldehyde 3-phosphate dehydrogenase 
GC   germinal centres 
GFP   green fluorescent protein 
GNB2L1  guanine nucleotide binding protein beta polypeptide 2-like 1 
GRU   green Raji unit 
H   histone 
H3K27ac  histone 27 lysine 27 acetylation 
H3K27me3  histone 27 lysine 27 trimethylation 
H3K4me3  histone 3 lysine 4 trimethylation 
H3K9ac  histone 3 lysine 9 acetylation 
HAT   histone acetyltransferase 
HBV   hepatitis B virus 
HCV   hepatitis C virus 
HDAC   histone deacetylase 
Hi-C   chromosome conformation capture technique 
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HIV   human immunodeficiency virus 
HL   Hodgkin lymphoma 
HOTAIR  HOX transcript antisense RNA 
HOX   homeobox gene cluster 
HoxC4   Homeobox C4 
HPH   human polyhomeotic homolog family 
HPV   human papilloma virus 
HRP   horseradish peroxidase 
HRS   Hodgkin-Reed-Sternberg cells 
HSC   haematopoietic stem cells 
HSP90   heat-shock protein 90 kDa 
HT   4-hydroxytamoxifen 
HTLV-1  human T lymphotropic virus 1 
Id   inhibitor of differentiation 
Ig   immunoglobulin 
Ig-α    signaling molecule of BCR (also known as CD79a) 
Ig-β   signaling molecule of BCR (also known as CD79b) 
IGF2   insulin-like growth factor 2 
IgH   immunoglobulin heavy chain 
IgL   immunoglobulin light chain 
IL-4   interleukin-4 
IP   immunoprecipitation 
IPTG   isopropyl β-D-1-thiogalactopyranoside 
IRF   interferon regulatory factor 
ITAM   immunoreceptor tyrosine-based activation motifs 
kb   kilo base pairs 
kDa   kilo Daltons 
KO   knock-out 
KSHV   Kaposi’s sarcoma associated herpes virus 
LCL   lymphoblastoid cell line 
LID   lipofectin/integrin-targeting peptide/DNA 
List of abbreviations 
 21 
LMP   latent membrane protein 
LP   leader protein 
LZ   light zone 
MACS   model-based analysis of ChIP-Seq 
MAPK   mitogen-activated protein kinase 
MHCII   major histocompatibility complex II 
miR   microRNA 
MMR   mismatch repair 
mRNA   messenger RNA 
NCoR   nuclear receptor co-repressor 
ncPRC1  non-canonical PRC1 complex 
NF-κB   nuclear factor κB 
NICD   Notch intracellular domain 
OriP   origin of replication 
P-Rb   phosphorylated retinoblastoma protein 
PAGE   polyacrylamid gel electrophoresis 
PBMC   peripheral blood mononuclear cells 
PBS   phosphate-buffered saline 
PBS-T   phosphate-buffered saline containing 0.1% (v/v) Tween-20 
PcG   polycomb group 
PCGF   polycomb group factor 
PCR   polymerase chain reaction 
PI3-K   phosphatidylinositol 3-kinase 
PMSF   phenylmethanesulfonyl fluoride 
PRC   polycomb repressive complex 
PTLD   post-transplant lymphoproliferative disease 
PTM   post-translational modification 
Qp   Q promoter 
qPCR   quantitative PCR 
RAG   recombination activating gene 
RAM   RBPJ-associated molecule 
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Rb   retinoblastoma protein 
RBPJ   recombination binding protein-J (aka CBF1, Su(H), and Lag 1) 
Rev   revertant 
RING1   ring finger protein 1 
RIPA buffer  radioimmunoprecipitation assay buffer 
RLU   relative luciferase units 
RNA   ribonucleic acid 
RPA   replication protein A 
RPA70   replication protein A 70 
RPMI   Roswell Park Memorial Institute medium 
RT   reverse transcription 
RT-qPCR  reverse transcription quantitative polymerase chain reaction 
RUNX   RUNT-related transcription factor 
RYBP   RING1/YY1 binding protein 
S region  switch region 
sBL   sporadic Burkitt’s lymphoma 
SD   standard deviation 
SDS   sodium dodecyl sulfate 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SHARP  SMRT/HDAC1-associated repressor protein (aka MINT or SPEN) 
SHM   somatic hypermutation 
shRNA   short-hairpin RNA 
SL chain  surrogate light chain 
SMRT   silencing mediator of retinoid and thyroid hormone receptors 
Spt5   suppressor of Ty5 homolog 
SSB   single strand break 
ssDNA   single stranded DNA 
STAT6   signal transducers and activators of transcription 6 
SUZ12   suppressor of zeste 12 
TAD   topologically associating domains 
TAF   TATA-binding protein associated factor 
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TAP   tandem affinity purification tag (2x Strep and 1x Flag) 
TBE   Tris-Borate-EDTA 
TBP   TATA box-binding protein 
TCR   T cell receptor 
TE   Tris-EDTA 
TEMED  tetramethylethylenediamine 
TET   ten eleven translocation 
TF   transcription factor 
TFH cell  follicular T helper cell 
TFII   transcription factor II 
TGF-β   tumour growth factor β 
Th cell   T helper cell 
TP53   tumour protein 53 
TPA   12-O-tetradecanoylphorbol-13-acetate 
TR   terminal repeats 
TSS   transcription start site 
UNG   uracil-DNA-glycosylase 
UTR   untranslated region 
v/v   volume by volume 
w/v   weight by volume 
Wp   W promoter 
wt   wild type 
YAF2   YY1-asociated factor 2  
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1 Chapter I: Introduction 
This study investigates the role of Epstein-Barr virus nuclear antigen 3C (EBNA3C) in 
the regulation of host genes expression. Epstein-Barr virus (EBV) biology is tightly 
associated with B cells and although EBV infects other cell types, expression of EBNA3C 
appears to be exclusive to EBV-infected B cells. Therefore, first of all, general B cell biology 
will be introduced followed by an introduction of EBV and mechanisms of gene regulation. 
1.1 B cell biology 
1.1.1 Immunoglobulins 
B cells form the main part of the humoral immune response of the adaptive immune 
system. They are specialised cells that express immunoglobulins (Ig), special molecules 
able to bind to an almost unlimited number of antigens. Ig consist of two heavy chains (IgH) 
and two light chains (IgL) comprised of different combinations of numerous variable (V), 
diversity (D, IgH only) and joining (J) segments together with a constant (C) segment. The 
IgH chain consists of a N-terminal variable region (VH, D and JH) and a C-terminal constant 
(CH) region (Figure 1.1A). The CH segment determines the Ig class, Cµ (IgM), Cδ (IgD), Cγ 
(IgG), Cα (IgA) and Cε (IgE), with each class having different effector fuctions. IgL chains 
also contain a N-terminal variable region (VL and JL), but no D segment and a shorter C-
terminal constant region (Figure 1.1B). Furthermore, there are two different isoforms of IgL 
chains (κ and λ). The variable regions of the combined IgH and IgL chains are responsible 
for antigen binding and especially three complementarity determining regions (CDR 1-3) 
influence the antigen specificity. CDR1 and CDR2 are located within the VH and VL 
segments, whereas CDR3 is spanning the different VH(D)JH and VL-JL segments [reviewed in 
(Hwang et al., 2015)]. There are two forms of Ig, transmembrane Ig (Figure 1.1C) form the B 
cell receptor (BCR) together with Ig-α (CD79a) and Ig-β (CD79b), which contain 
immunoreceptor tyrosine-based activation motifs (ITAMs) that can be phosphorylated by 
tyrosine protein kinases, and secreted Ig (Figure 1.1D), also known as antibody. 
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Figure 1.1: Schematic overview of immunoglobulin heavy (IgH) and light (IgL) chains as part of 
the B cell receptor on the cell surface or as secreted antibody. 
(A) Schematic overview of the IgH chain consisting of variable (VH), diversity (D), joining (JH) and 
constant (CH) segments. Different combinations of individual VH, D and JH segments form the variable 
N-terminal part and CH1-3 the constant C-terminal part. (B) Schematic overview of the IgL chain 
consisting of variable (VL), joining (JL) and constant (CL) segments. Different combinations of 
individual VL and JL segments form the variable N-terminal part and CL the constant C-terminal part. 
(C) B cell receptors are formed by two IgL and two IgH chains anchored in the cell membrane and the 
co-receptor transmembrane proteins Ig-α and Ig-β. Disulphide bridges link the two IgH chains and 
antigen-binding specificity is determined predominantly by the complementarity determining regions 
(CDR) 1-3 of the variable region of the combined IgH and IgL chains. (D) As in C, but for secreted 
antibodies that do not contain a transmembrane domain of IgH. 
1.1.2 B cell development 
During adult life, B cells are continuously produced in the bone marrow where they 
originate from CD34+ haematopoietic stem cells (HSC). HSCs give rise to multipotent 
myeloid/lymphoid progenitors that further differentiate into common lymphoid progenitors, 
the progenitors of both B and T cells (Figure 1.2A). 
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The B cell lineage begins in pro-B cells with the expression of enzymes of the 
recombination machinery, such as recombination activating gene 1 [RAG1, (Schatz et al., 
1989)] and RAG2 (Oettinger et al., 1990), that catalyse the rearrangement of the IgH locus 
by first joining one D segment to one JH segment (DJH rearrangement) followed by one VH 
segment resulting in VH(D)JH rearrangement (Figure 1.2B). In large pre-B cells, the 
rearranged IgH locus is expressed as Cµ isotype alongside a surrogate light (SL) chain 
(Sakaguchi and Melchers, 1986; Kudo and Melchers, 1987; Karasuyama et al., 1990; 
Tsubata and Reth, 1990) allowing the formation of pre-BCR on the cell surface in the case of 
productive IgH rearrangement (Figure 1.2A). Unproductive IgH rearrangement does not 
result in pre-BCR formation and additional rounds of VH(D)JH recombination are performed 
until productive rearrangement is achieved from either of the two IgH alleles or no more 
rearrangements are possible, in which case the pro-B undergoes apoptosis. Productive 
rearrangement results in signalling through the pre-BCR [review on BCR signalling (Dal 
Porto et al., 2004)], resulting in down regulation of recombination enzymes to prevent 
continued VH(D)JH rearrangement (Grawunder et al., 1995; Galler et al., 2004), allelic 
exclusion of the second IgH locus ensuring expression of a single IgH allele (Kitamura and 
Rajewsky, 1992) and proliferation (Karasuyama et al., 1994; Hess et al., 2001). 
Pre-BCR signalling also down regulates expression of the surrogate light chain 
(Parker et al., 2005) resulting in a cessation of proliferation and differentiation into resting 
small pre-B cells. Small pre-B cells re-express RAG1 and RAG2 (Grawunder et al., 1995) 
that are now targeted to generate IgL VL-JL rearrangements [(Constantinescu and Schlissel, 
1997), Figure 1.2C]. The newly rearranged IgL locus is expressed and tested for 
compatibility with the previously rearranged IgH chain to assemble as functional IgM on the 
surface of the immature B cell. In the case of incompatibility, additional rounds of IgL VL-JL 
rearrangements occur on either allele of the κ- or λ-L chain loci until productive 
rearrangement is achieved and the immature B cell exits the bone marrow and migrates to 
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the spleen to become a mature B cell expressing predominantly IgD and less IgM (Figure 
1.2A). 
A number of checkpoints exist to ensure that only non-self-reactive B cells end up as 
mature B cells [reviewed in (Melchers, 2015)]. An enormous pool of B cells each containing 
an individual B cell receptor able to recognise almost any possible antigen is created 
through the combinatorial joining of a large number of individual segments, e.g. for IgH alone 
there are at least 44 functional VH genes, 23 functional DH genes and 6 functional JH genes 
(Watson and Breden, 2012), the junctional diversity through insertion of additional 
nucleotides in between the rearranged segments (Alt and Baltimore, 1982) together with the 
pairing of one light and one heavy chain. 
 
Figure 1.2: B cell development and overview of VH(D)JH and VL-JL recombination. 
(A) Overview of different B cell developmental stages within the bone marrow. Haematopoietic stem 
cells (HSCs) give rise to pro-B cells that initiate immunoglobulin heavy chain (IgH) VH(D)JH 
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recombination. Productive IgH rearrangement results in the expression of heavy chains of µ isotype 
that together with a surrogate light (SL) chain can form pre-B cell receptors (pre-BCR) on the surface 
of large pre-B cells. Pre-BCR signalling induces proliferation of large pre-B cells and differentiation 
into resting, small pre-B cells, which undergo CL-JL recombination of the light chain (IgL). Only 
compatible IgH and IgL are expressed as functional IgM on the surface of immature B cells that then 
exit the bone marrow and become mature B cells expressing predominantly IgD and less IgM. (B) 
Schematic overview of VH(D)JH recombination at the IgH locus that joins one of 44 functional VH 
segments, one of 23 functional D segments and one of 6 functional JH segments. Productive 
recombination products can be expressed together with the constant region of IgM (Cµ) or IgD (Cδ). 
(C) Schematic overview of VL-JL recombination at one of the two IgL loci (Igκ or Igλ) that joins one VL 
segment and one JL segment. Productive recombination products can be expressed together with the 
constant region of the light chain (CL). 
1.1.3 T cell dependent B cell activation 
Mature, but naïve B cells continuously circulate throughout the body and migrate from 
peripheral circulation into secondary lymphoid organs (e.g. the spleen or lymph nodes) that 
contain follicles rich in naïve B cells separated by an interfollicular region from the T cell 
zone. Naïve B cells scan the lymphoid tissue and the humoral immune response begins 
when a naïve B cell encounters a T cell dependent antigen that can be bound by its cell 
surface BCR. Antigen binding by the BCR results in BCR crosslinking, which induces 
signalling through the ITAM motifs of Ig-α and Ig-β leading to the internalisation of the 
BRC:antigen complex and fragmentation of the antigen into shorter peptides. These short 
peptides are then loaded on major histocompatibility complex (MHC) II and are presented on 
the B cell surface (Blum et al., 2013). B cell activation requires additional signals, which can 
be provided by a CD4+ T helper (Th) cell that was activated by the same antigen and whose 
T cell receptor (TCR) recognises the MHCII:antigen complex on the B cell surface (Crotty, 
2015). Recognition of MHCII:antigen complexes by TCRs of the activated Th cells induces 
the expression of the cell surface protein CD40 ligand [CD40L, (Armitage et al., 1992)] and 
secretion of cytokines, e.g. interleukin-4 [IL-4, (Howard et al., 1982)]. CD40L binds to CD40 
on the surface of the B cell (Armitage et al., 1992) leading to B cell activation that is further 
modulated by the different secreted cytokines. The activated B blasts aggregate in primary 
follicles and start to express the transcriptional repressor B cell lymphoma 6 [BCL6, (Flenghi 
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et al., 1995; Cattoretti et al., 1995; Onizuka et al., 1995)], the master regulator essential for 
the formation of germinal centres (GC, see Section 1.1.4) within the centre of these follicles 
(Dent et al., 1997; Ye et al., 1997). Through repression of members of the DNA damage 
signalling pathway, e.g. tumour protein 53 [TP53, (Phan and Dalla-Favera, 2004)] and ataxia 
telangiectasia and Rad3 related [ATR, (Ranuncolo et al., 2007)], BCL6 ensures that cells are 
more resistant to DNA damage to which they are exposed during the GC reaction (see 
below). On the other side, BCL6 establishes a pro-apoptotic state by repressing the anti-
apoptotic protein B cell lymphoma 2 [BCL2, (Saito et al., 2009)], promoting apoptosis (see 
below) unless positive signals are provided (Liu et al., 1991). Furthermore, BCL6 controls 
the end of the GC reaction through repression of transcription factors that control 
downstream differentiation programmes (Shaffer et al., 2000). Additional functions of BCL6 
have been recently reviewed (Basso and Dalla-Favera, 2012) together with other factors 
involved in the formation of GC (De Silva and Klein, 2015; Basso and Dalla-Favera, 2015). 
Not all antigen-activated B cells enter the GC reaction, a subset of them remain 
outside GCs and differentiate into short-lived plasmablasts that secrete low-affinity antibody 
(Jacob and Kelsoe, 1992). 
1.1.4 Germinal centre reaction 
GC are composed of a dark zone (DZ) that is densely populated by B cells, and a 
light zone (LZ) that is less densely populated by B cells and contains a network of follicular 
dendritic cells (FDC) and follicular Th (TFH) cells (Figure 1.3). In the classic GC reaction 
model (MacLennan, 1994), larger and highly proliferative B cells within the DZ, named 
centroblasts, undergo clonal expansion and somatic hypermutation (SHM, see Section 
1.1.5.2) of their Ig variable region. Centroblasts then differentiate into smaller, resting 
centrocytes and migrate into the LZ, where those mutations that increase the binding affinity 
to the antigen are selected through interactions with antigen-presenting follicular dendritic 
cells (FDC) and antigen-specific follicular T helper (TFH). FDC provide long-term presentation 
of intact antigen on their cell surface (Mandel et al., 1980; 1981) enabling the centrocytes to 
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bind and process the antigen. Originally it was thought that positive selection is 
predominantly based on the competition between B cells for available antigen with high 
affinity B cells sequestering all available antigen (MacLennan, 1994). However, more 
recently it has been suggested that competition for TFH help is the major factor for selection 
with high affinity B cells being able to present more processed antigen to a limiting amount 
of TFH cells (Allen et al., 2007a). It was demonstrated that high-affinity B cells present more 
antigen:MHCII on their surface, which allowed prolonged contacts with a limiting number of 
TFH cells (Victora et al., 2010) resulting in a refinement of the classic GC reaction model 
(Victora and Nussenzweig, 2012). Further to this, low affinity or self-reactive centrocytes 
(Melchers, 2015) who do not receive enough survival signals either undergo apoptosis, due 
to their default pro-apoptotic state (see above), or re-cycle back to the DZ to undergo 
additional rounds of SHM and selection for mutations that increase the antigen binding 
affinity. Upon emergence of Ig with high antigen binding affinity, B cells can undergo class 
switch recombination (CSR, see Section 1.1.5.2) to IgG, IgA or IgE depending on the type of 
antigen that triggered the immune response. However, CSR can also occur outside the GC 
(Stavnezer and Schrader, 2014). Repression of BCL6 expression leads to GC exit and 
differentiation to either antibody producing plasma cells [reviewed in (Nutt et al., 2015)] or 
long-lived CD27+ memory B cells [reviewed in (Kurosaki et al., 2015)]. Interestingly, recent 
studies also report memory B cells derived independently from a GC reaction, but the 
mechanisms behind this remain unclear (Kurosaki et al., 2015). 
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Figure 1.3: Germinal centre reaction after antigen-specific B cell activation. 
Mature IgMlow/IgDhigh B cells with distinct antigen binding specificity (represented by the different 
colours of the mature B cells) are screening secondary lymphoid tissue for their cognate antigen. 
Encounter between a mature B cell, its cognate antigen and an antigen-specific T cell results in B cell 
activation. The activated B blast proliferates and expresses BCL6 that initiates the formation of 
germinal centres (GC). GCs form in the centre of primary follicle and are divided into a dark zone (DZ) 
and a light zone (LZ). GC B cells express activation-induced cytidine deaminase (AID). Within the DZ, 
proliferating centroblasts undergo somatic hypermtation (SHM) of their immunoglobulins. Mutations 
that increase the binding affinity to the antigen are selected for in the LZ through interactions with 
follicular T helper (TFH) and follicular dendritic cells (FDC). Centrocytes re-enter the DZ where they 
undergo additional rounds of SHM. Upon emergence of high affinity antigen binding, B cells undergo 
class switch recombination (CSR) to IgG, IgA or IgE and exit the GC to become either antibody 
producing plasma cells or long-lived memory B cells. Figure adapted from Prof Martin Allday. 
Based on morphological criteria [reviewed in (Nieuwenhuis and Opstelten, 1984)], the 
larger, proliferating B cells in the DZ were described as centroblasts and the smaller, resting 
B cells in the LZ as centrocytes. However, more recently studies employing two-photon 
intravital microscopy allowing direct in vivo GC imaging revealed that B cells in the DZ and 
LZ had similar size and morphology (Schwickert et al., 2007; Allen et al., 2007b; Hauser et 
al., 2007). The discovery that chemokine receptor CXCR4 (Allen et al., 2004) and the 
activation molecules CD83 and CD68 (Victora et al., 2010) can be used as markers to 
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distinguish between centroblasts (CXCR4highCD83lowCD86low) and centrocytes 
(CXCR4lowCD83highCD86high), both in mice and humans (Caron et al., 2009; Victora et al., 
2012), allowed further investigation of the differences between DZ and LZ GC B cells. Again, 
no difference in size could be detected and differences in gene expression between the two 
populations were limited (Victora et al., 2010; 2012). However, higher expression of genes 
involved in the regulation of the cell cycle, particularly mitosis, and DNA damage was 
detected in centroblasts, whereas centrocytes expressed higher levels of genes involved in 
cell activation (e.g. CD40, CD83, CD86), transcription factors (e.g. c-MYC) and different 
regulators of apoptosis (Victora et al., 2010; 2012). 
C-MYC can be found in almost all proliferating cells as it supports robust proliferation 
through transcriptional and non-transcriptional regulation of cellular processes, such as cell 
cycle progression and metabolism. However, C-MYC was considered to be absent in 
proliferating GC B cells (Klein et al., 2003). Recently, it has been shown that c-MYC is 
essential in the early formation of the GC, after which it is repressed by BCL6 in the highly 
proliferative DZ B cells, before being re-expressed in a subset of LZ B cells that are selected 
for re-entry into the DZ to undergo further rounds of proliferation and SHM (Dominguez-Sola 
et al., 2012; Calado et al., 2012; Victora et al., 2010; 2012). 
1.1.5 Activation-induced cytidine deaminase 
The search for factors involved in SHM and CSR identified activation-induced cytidine 
deaminase (AID), which is encoded by the gene AICDA. AID is a member of the 
apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like (APOBEC) family of 
cytidine deaminases. Expression of AID is low in naïve B cells, but increases highly in GC B 
cells and B cells in vitro activated with IL-4, CD40L and tumour growth factor β (TGF-β) 
(Muramatsu et al., 1999). AID has been shown to be essential for both SHM and CSR. Aicda 
knock-out mice failed to undergo SHM and CSR (Muramatsu et al., 2000) and mutations in 
AICDA were detected in humans patients with hyper-IgM syndrome, characterised by high 
serum levels of low affinity IgM due to defective SHM and CSR (Revy et al., 2000). In order 
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to understand the role of AID in SHM and CSR, first the mechanisms that underlie AID-
induced mutations have to be explained. 
1.1.5.1 Mechanisms underlying AID-induced mutations 
AID requires access to single-stranded DNA (ssDNA), e.g. at regions transcribed by 
RNA polymerase II (Chaudhuri et al., 2003), to catalyse the deamination of cytidines (C) to 
uridines (U) producing uracil/guanine (U/G) mismatches (Figure 1.4A). Normally, U/G 
mismatches are detected and repaired by error-free DNA repair mechanisms, but when DNA 
replication over the U/G site precedes its repair, it results in a C>T and G>A transition 
[purine > purine (A and G) or pyrimidine > pyrimidine (C and T)] mutation (Figure 1.4B). 
U/G mismatches can be detected by the base excision repair [BER, (Krokan and 
Bjørås, 2013)]. This leads to the excision of uracil from the DNA backbone by uracil-DNA-
glycosylase (UNG) creating an abasic site (Figure 1.4C). Replication over this abasic site 
results in both transition and transversion (purine > pyrimidine or pyrimidine > purine) 
mutations, which are however restricted to the original U/G lesion. UNG deficient mice 
exhibit a near complete shift towards transition mutations at the U/G site (Rada et al., 
2002a). During the normal BER, apurinic/apyridimic endonuclease 1 (APE1) cleaves the 
DNA backbone at the excised uracil creating a single strand break (SSB), which can lead to 
a double strand break (DSB) if another SSB is created on the opposite strand (Figure 1.4C). 
Beside the BER, the U/G mismatch can be detected by the MSH2-MSH6 heterodimer 
(Rada et al., 1998; Wiesendanger et al., 2000) of the mismatch repair [MMR, (Fishel, 2015)]. 
MSH2-MSH6 dimers then recruits exonuclease 1 [Exo1, (Bardwell et al., 2004)], which 
excises a larger piece of DNA of the mismatch-containing strand producing a SSB (Figure 
1.4D). Error-prone polymerase η can fill in the missing nucleotides resulting in a spread of 
mutations from the original U/G lesion (Zeng et al., 2001; Delbos et al., 2007). Again, the 
presence of another SSB on the opposite strand results in a DSB (Figure 1.4D). Deficiencies 
in the MMR pathway, e.g. in MSH2 knock-out mice (Rada et al., 1998), results in a reduction 
in the overall number of mutations and restriction of mutations to the G/C site. Deficiency in 
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both BER and MMR pathways in UNG and MSH2 double knock-out mice, produces 
exclusively C/G transition mutations via replication over the U/G lesion and eliminates C/G 
transversions and mutational spreading (Rada et al., 2004). 
 
Figure 1.4: Mutations caused by activation-induced cytidine deaminase (AID). 
(A) AID requires access to single stranded DNA (e.g. at sites of active transcription by RNA 
polymerase II) to deaminate cytidine (C) residues resulting in an uracil/guanine (U/G) mismatch. (B) 
DNA replication of the U/G mismatch leads to one strand with the original C/G and one strand with a 
T/A mutation (C->T and G->A transitions). (C) The U/G mismatch is detected by the base excision 
repair pathway. Uracil-DNA-glycosylase (UNG) creates an abasic site through excision of uracil. 
Replication over this abasic site results in transition or transversion mutations limited to the U/G 
lesion. Recruitment of apurinic/apyridimic endonuclease 1 (APE1) creates a DNA single strand break 
(SSB). The presence of another SSB on the opposite strand can result in a DNA double strand break 
(DSB). (D) The heterodimer MSH2-MSH6 of the mismatch repair recognises the U/G mismatch and 
recruits Exonuclease 1 (Exo1) that excises a larger piece of DNA on the mismatch-containing strand 
creating a SSB. Error-prone polymerases lead to a spread of mutations from the U/G mismatch to 
neighbouring sites (e.g. A/T). Again, two SSB on opposite strands can create a DSB. Figure adapted 
from (Hwang et al., 2015).  
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1.1.5.2 Somatic hypermutation (SHM) and class switch recombination (CSR) 
AID-induced mutations are essential for both SHM and CSR (Muramatsu et al., 2000; 
Revy et al., 2000) and occur in GC B cells that express high levels of AID (Muramatsu et al., 
1999), with centroblasts expressing higher levels of AID compared to centrocytes (Victora et 
al., 2012). Replication over AID induced U/G lesions is an important contributing factor for 
AID-induced mutations (see above) and centroblasts are rapidly proliferating, so mutation 
rates of up to 10-3 per base per generation have been estimated (McKean et al., 1984; 
Radic, 2008). 
For the process of SHM (Figure 1.5A), AID induces predominantly point mutations in 
the transcribed variable regions [VH(D)JH and VLJL] of the recombined IgH and IgL chains. 
Transcription is required for SHM (Fukita et al., 1998) and mutations occur on both the 
productive and non-productive IgH and IgL loci, but only mutations on the productive loci 
affect the positive selection. Mutations accumulate sequentially and particularly within the 
three CDRs, which mostly affect the antigen binding affinity [(McKean et al., 1984) and 
reviewed in (Di Noia and Neuberger, 2007; Hwang et al., 2015)]. AID preferentially targets 
cytidines (highlighted in bold) within WRCH or related sequence motifs [(Rogozin and Diaz, 
2004) with W = A or T, R = A or G, H = T, C or A]. These WRCH sequences are slightly 
enriched within the variable region of IgH and IgL (Hwang et al., 2015). The mechanisms 
that target AID, particularly to CDRs, still remain unknown. A recent study employing a 
VH(D)JH passenger allele system, in which SHM can be followed in vivo on a passenger IgH 
locus that is not subjected to antigen binding selection, has shown that not all WRCH motifs 
within the variable region are targeted at the same rate (Yeap et al., 2015). SHM is not a 
unique feature of Ig sequences and similar frequencies of SHM were observed upon 
replacement by non-Ig genes, in which WRCH motifs were also differentially targeted 
depending on their position within the sequence. Frequent DSB that caused deletions were 
detected on the passenger allele, most of which would have probably been eliminated during 
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the selection, as predominantly point mutations are observed in SHM on the productive IgH 
alleles (Di Noia and Neuberger, 2007). 
For the process of CSR (Figure 1.5B), AID deaminates cytosine residues within 
switch (S) regions that are long (1 to 10 kb), highly repetitive, noncoding regions upstream of 
the CH exons of each Ig isotype class (except IgD which is positioned immediately 
downstream of IgM). Importantly, each Ig isotype class (except IgD) is part of a separate 
transcription unit that is under the control of specific cytokine responsive promoters 
controlling transcription through the corresponding S region and CH exons (Stavnezer and 
Schrader, 2014; Hwang et al., 2015). Promoter-specific transcription is induced depending 
on the cytokines that are secreted by TFH cells or FDCs with the aim to direct CSR to the 
most effective Ig class to eliminate the antigen. S regions are highly enriched in AGCT, a 
canonical WRCH motifs that provides cytidines on both opposite strands, which is thought to 
promote a higher frequency of DSB at the two S regions that are selected to undergo CSR 
(Hwang et al., 2015). The formation of DSB is essential for CSR with deficiencies in either 
BER [e.g. UNG knock-out (Rada et al., 2002a)] or MMR [e.g. MSH2 knock-out (Rada et al., 
1998)] reducing the rate of CSR and deficiency in both pathways [e.g. UNG and MSH2 
knock-out (Rada et al., 2004)] completely abrogating it. Deletional DNA recombination 
between the DSB at the upstream and the downstream S regions causes the excision of the 
intermediate region (known as switch circle) and positioning of the new Ig isotype class CH 
exons immediately downstream of the VH(J)DH region (Stavnezer and Schrader, 2014). This 
results in the expression of another Ig class with a more appropriate effector function, while 
retaining the high-affinity antigen binding specificity of the VH(D)JH region. 
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Figure 1.5: Somatic hypermutation (SHM) and class switch recombinantion (CSR) induced by 
activation-induced cytidine deaminase (AID). 
(A) AID requires transcription of the immunoglobulin locus (black arrow) to induces mutations within 
the variable region [schematically shown for IgH VH(D)JH, but similarly for VLJL] in a process known as 
SHM. Some of these mutations increase the antigen binding affinity of the immunoglobulin and are 
positively selected for during the germinal centre (GC) reaction. (B) CSR is induced when exogenous 
signals received by the GC B cell lead to the transcription (black arrows) of two different 
immunoglobulin classes [shown for IgM (Cµ) and IgG (Cγ)]. AID-induced mutations cause DNA 
double strand breaks (DSB) in the switch regions (Sµ and Sγ) of the different antibody classes 
resulting in IgM to IgG class switching through recombination and excision of the intermediate region 
known as switch circle. 
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1.1.5.3 Regulation of AID activity 
AID has the ability to induce mutations and DSB so it is not surprising that there are 
several layers of regulation that control the activity of AID (Figure 1.6). High level of AID 
expression is normally limited to GC B cells (Muramatsu et al., 1999). 
 
Figure 1.6: Activity of AID is controlled on multiple layers. 
(A) Regulation of AID transcription (black arrow) is controlled by at least six regulatory regions shown 
schematically for the human AICDA locus (blue boxes represent exons). Region I is a ubiquitously 
active basal promoter, region II contains both enhancer and silencer elements, region III is a putative 
enhancer and region IV, V and VI are upstream enhancer elements. (B) Regulation of AID at post-
transcriptional level through binding of microRNA (e.g. miR-155 and miR-181b) to the 3’ untranslated 
region of AICDA mRNA leading to mRNA destabilisation and degradation. (C) Regulation of AID at 
post-translational level. Most AID protein is being retained in the cytoplasm by elongation factor 
eEF1A and heat-shock protein 90 kDa (HSP90) and requires active nuclear import to translocate into 
the nucleus. Nuclear AID has a short half-life time due to proteosomal degradation and active nuclear 
export. Phosphorylation on various sites controls the activity of AID. (D) AID requires access to single 
stranded DNA (ssDNA) and often targets transcribed regions that are associated with stalled (Spt5) 
RNA polymerase II. The ssDNA binding protein (RPA) stabilises ssDNA and the RNA exosome was 
shown to enable access of AID to both strands. 
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1.1.5.3.1 Transcriptional regulation of AID 
The first layer of control regulates the transcription rate of the AICDA gene encoding 
AID (Figure 1.6A). Comparison between the mouse Aicda and the human AICDA locus 
located on chromosomes 6 and 12, respectively, revealed several regions with high DNA 
sequence conservation in and around the Aicda/AICDA loci (Yadav et al., 2006; Crouch et 
al., 2007; Tran et al., 2010b). 
Region I is located immediately upstream of the transcription start site (TSS) with 
transcription (indicated by the black arrow in Figure 1.6A) from the negative DNA strand 
running from right to left for human AICDA. It contains a minimal promoter and conserved 
binding sites for various transcription factors (TF) (Yadav et al., 2006). Binding of signal 
transducers and activators of transcription (STAT) STAT6 and nuclear factor κB (NF-κB) at 
region I was observed after IL-4 and CD40L-mediated induction of AID in B cell lines ex vivo 
and deficiency of either STAT6 or NF-κB impaired AID expression upon stimulation 
(Dedeoglu et al., 2004). Homeobox C4 (HoxC4), another TF expressed in GC B cells and up 
regulated by NF-κB, binds to region I and induces AID expression (Park et al., 2009; 2013). 
More recent analysis of region I confirmed the basal promoter activity in transient reporter 
assays, but no increase in luciferase activity was observed upon stimulation with IL-4, 
CD40L and TGF-β (Tran et al., 2010b). 
Region II is located within the first intron just downstream of the TSS and has been 
shown to contain both stimulatory (enhancer) and repressive (silencer) elements. B cell 
specific E-proteins, which form homo- or heterodimers to become active TFs, bind to E-box 
DNA binding sites at region II and enhance the expression of Aicda (Sayegh et al., 2003). 
Pax5, a B cell specific TF, has also been shown to bind to region I and region II in activated 
B cells (Gonda et al., 2003), however in later studies no binding at region I was observed 
(Yadav et al., 2006). Overexpression of proteins of the inhibitor of differentiation (Id) family, 
which can disrupt DNA binding of E-proteins and Pax5, reduced Aicda expression (Sayegh 
et al., 2003; Gonda et al., 2003). The enhancer function of the Pax5 and E-protein DNA 
Chapter I: Introduction 
 40 
binding sites was confirmed in more extensive analysis using transient reporter assays, but 
no increase in luciferase activity was observed upon stimulation with IL-4, CD40L and TGF-β 
(Tran et al., 2010b). In contrast, this study also showed that full-length region II acts as an 
overall repressor of luciferase activity in transient reporter assays, primarily caused by c-Myb 
and E2F DNA binding sites (Tran et al., 2010b). Because c-Myb and E2F are expressed in 
naïve and non-B cells, they are thought to prevent expression of AID in those cells, which is 
then overcome by Pax5 and E-proteins in activated B cells. Deletion of the two c-Myb and 
E2F DNA binding sites in transgenic mice, using bacterial artificial chromosomes (BAC) of 
the Aicda locus, increased the number of GC B cells with active Aicda expression, but did 
not result in ectopic expression of Aicda (Huong et al., 2013). Importantly, deletion of the 
entire region II completely abrogated Aicda transcription in vivo. 
Region III is located ~33 kb downstream of the TSS of AICDA. BAC transgenic Aicda-
GFP mice that lack region III did not express Aicda (Crouch et al., 2007), which indicates 
that region III acts as an important enhancer element. In transient reporter assays, however, 
region III did not alter luciferase expression in transient reporter assays in vitro (Tran et al., 
2010b), making it a putative enhancer element. 
Region IV is located ~17 kb upstream of the TSS of AICDA and contains binding sites 
for STAT6, NF-κB, Smad3/4 and enhancer-binding protein C/EBP. This region increased the 
basal luciferase activity of region I in transient reporter assays and further enhanced 
luciferase activity upon stimulation with IL-4, CD40L or TGF-β either alone or in combination 
resulting in an additive increase (Tran et al., 2010b). Furthermore, Tran and colleagues 
suggested that IL-4 promotes signalling through STAT6, CD40L through NF-κB, TGF-β 
through Smad3/4 and C/EBP. Deletion of the C/EBP sites completely abrogated the 
stimulation by IL-4, CD40L and TGF-β, but presence of the C/EBP sites alone was not 
sufficient for stimulation. BAC transgenic mice carrying deletions of either the entire region 
IV or just the C/EBP binding sites within region IV failed to express the Aicda reporter 
(Huong et al., 2013). 
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Region V and VI are located ~32 and 36 kb, respectively, upstream of the TSS of 
AICDA and have been identified as enhancers of Aicda expression through targeted deletion 
using genome editing techniques (Kieffer-Kwon et al., 2013). Deletion of either region V or 
region VI completely abrogated Aicda expression and IgM -> IgA CSR in activated murine 
CH12F3 B cells. 
Regions II, IV, V and VI form what is known as the AID super-enhancer (Qian et al., 
2014). Super-enhancers are formed by clusters of multiple, topologically associated 
enhancers that can potentiate gene expression and are thought to be co-ordinately 
regulated during cell differentiation (Figure 1.6A). 
1.1.5.3.2 Post-transcriptional regulation of AID 
Protein expression can also be modulated at a post-transcriptional level through the 
binding of microRNA (miR) to a target mRNA sequence resulting in blockage of translation 
and/or degradation of the target mRNA. Several miRs have been identified that bind in the 3’ 
untranslated region (3’ UTR) of AICDA mRNA (Figure 1.6B). miR-155 is B lymphocyte 
specific and is induced in murine B cells undergoing CSR (Teng et al., 2008). Binding of 
miR-155 in the 3’UTR destabilises Aicda mRNA and deletion of the miR-155 binding site not 
only increased AID expression (Dorsett et al., 2008), but also resulted in expression of AID 
in post-GC B cells in blood (Teng et al., 2008). In GC B cells, BCL6 inhibits the expression of 
miR-155 and therefore positively regulates AID expression (Basso et al., 2012). This study 
also identified miR-361, another BCL6-repressed miR, that is able to down regulate AID 
protein levels. However, the effect was weaker compared to miR-155 and the role of miR-
361 on AID mRNA stability and CSR remains to be determined. Another miR, miR-181b, 
also binds in the 3’UTR of Aicda resulting in the down regulation of AID at mRNA and 
protein levels and to impair CSR (de Yebenes et al., 2008). 
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1.1.5.3.3 Compartmentalisation and post-translational regulation of AID 
Once AID protein has been translated, there are different ways to control its activity 
(Figure 1.6C). Most of AID protein localises to the cytoplasm (Rada et al., 2002b; 
Pasqualucci et al., 2004), probably to restrict its access to DNA. The C-terminus of AID is 
important for its cytoplasmic retention (Patenaude et al., 2009). Recently the eukaryotic 
elongation factor 1 (eEF1A) and heat-shock protein 90 kDa (HSP90) were proposed to be 
responsible for cytoplasmic retention of AID by forming distinct cytoplasmic complexes with 
AID (Methot et al., 2015). AID localisation is further controlled by nuclear import and nuclear 
export. N-terminal nuclear localisation and C-terminal nuclear export signals have been 
identified (Ito et al., 2004) and despite its small molecular weight of 24 kDa active nuclear 
import is required for AID to enter the nucleus (Patenaude et al., 2009). A short life-span for 
nuclear AID has been reported involving both ubiquitination-dependent (Aoufouchi et al., 
2008) and ubiquitination-independent (Uchimura et al., 2011) proteosomal mechanisms. 
Furthermore, AID can be phosphorylated at various sites, which can have an inhibitory [e.g. 
phosphorylation on serine 3 (Gazumyan et al., 2011)] or stimulatory [e.g. phosphorylation on 
serine 38, threonine 27 or 140 (Basu et al., 2005; Pasqualucci et al., 2006; McBride et al., 
2008)] effect on its activity. For more information about this layer of control please see 
reviews on compartmentalisation (Patenaude and Di Noia, 2010; Orthwein and Di Noia, 
2012) and phosphorylation (Basu et al., 2009). 
1.1.5.3.4 Targeting of AID 
Inside the nucleus, access of AID to ssDNA involves multiple factors (Figure 1.6D). 
Interaction between AID and RNA polymerase II was suggested (Nambu et al., 2003), which 
was shown to be mediated by Suppressor of Ty5 homolog (Spt5), a transcription elongation 
factor associated with stalled RNA polymerase II (Pavri et al., 2010). Spt5 interacts with AID 
and depletion of Spt5 reduced the association of AID with RNA polymerase II and the 
occupancy of AID at the IgH locus reducing the rate of SHM and CSR. Moreover, sites with 
high Spt5 occupancy displayed increased number of somatic mutations, suggesting that 
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Spt5 occupancy is predictive for AID-dependent mutations. In addition, AID can interact with 
the ssDNA binding protein replication protein A (RPA), which promoted deamination of in 
vitro transcribed SHM substrates, but only on the non-template strand, suggesting that 
binding of RPA to the single stranded non-template strand promotes AID activity (Chaudhuri 
et al., 2004). In a more recent study, occupancy of AID was associated with promoter-
proximal sequences with stalled RNA polymerase II genome-wide, but high levels of RPA 
were limited to Ig genes (Yamane et al., 2011). This might promote a higher frequency of 
AID-induced mutations for SHM and CSR, but might be solely a result of introduced DSB, 
whose single strand ends are bound by RPA (Yamane et al., 2013). In vitro DNA 
deamination was always limited to the non-transcribed strand, probably because the 
transcribed strand is blocked by RNA:DNA hybridisation of the nascent RNA. The RNA 
exosome has been shown to enable AID to deaminate the transcribed template strand in 
vitro and to be required for CSR in vivo (Basu et al., 2011; Pefanis et al., 2014). The RNA 
exosome is an exonuclease complex that processes nuclear RNA precursors and can 
degrade RNA, giving AID access to the single-stranded template strand. Furthermore, AID 
has been reported to predominantly target highly transcribed super-enhancers where sense 
and antisense transcription converge, enabling access to both DNA strands (Qian et al., 
2014; Meng et al., 2014). 
All these mechanisms help in targeting AID to the Ig loci where highest AID activity is 
observed in activated B cells, however, AID activity is promiscuous and can induce 
mutations at non-Ig loci (off-target activity). These AID off-targets, e.g. BCL6 and cMYC, 
usually share key characteristics with the Ig loci, e.g. being highly transcribed and controlled 
by super-enhancers, thus enabling AID to access DNA and to introduce mutations [recently 
reviewed in (Casellas et al., 2016)]. 
  
Chapter I: Introduction 
 44 
1.2 Epstein-Barr virus 
1.2.1 Overview 
Epstein-Barr virus (EBV) is a gamma-herpes virus belonging to the herpesviridae 
family of large dsDNA viruses that establish latent infections in their host. EBV persistently 
infects over 90% of the human population and usually infections occur early in childhood 
when they remain mostly asymptomatic. Infections that are delayed until early adolescence 
or later can cause infectious mononucleosis. Once an individual is infected with EBV, the 
virus establishes a persistent infection for the lifetime of the host. EBV is B lymphotropic and 
establishes latent infection within the memory B cell population of the host by closely 
following the normal biology of mature B lymphocytes (see Section 1.1.4) in what is known 
as the germinal centre model of persistence (see in vivo infection below). At this stage, the 
virus remains quiescent in resting memory B cells, invisible to the immune system. Latent 
infection is mostly benign, especially as >90% of the human population is infected, however 
EBV was the first identified human tumour virus with links to various B cell and non-B cell 
malignancies (see Section 1.2.5). 
1.2.2 Establishment of latent infection 
1.2.2.1 In vivo infection 
The germinal centre model of persistence (Figure 1.7), proposed by David Thorley-
Lawson and colleagues (Thorley-Lawson and Babcock, 1999; Thorley-Lawson, 2015), 
explains how EBV establishes a latent infection in vivo and is now generally accepted as it 
describes very accurately most aspects of in vivo EBV studies and can even be used to 
mathematically model persistence (Hawkins et al., 2013). EBV is shed in the saliva of an 
infected person and can infect epithelial cells in a newly infected individual probably to 
amplify the amount of infectious viral particles. 
However, in order to achieve a latent infection, EBV infects mature, resting B cells in 
the lymphoepithelium of the tonsils. EBV binds to CD21 (Fingeroth et al., 1984; Nemerow et 
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al., 1985) and MHC II molecules (Li et al., 1997) to enter the cell and cross-linking of CD21 
induces signalling events that disrupt the quiescent state of the cell (Sinclair and Farrell, 
1995). Newly infected mature B cells express all latent viral gene products (Joseph et al., 
2000b; Babcock et al., 2000), six EBV nuclear antigens (EBNA1, EBNA2, EBNA3A, 
EBNA3B, EBNA3C and EBNA-LP), three latent membrane proteins (LMP1, LMP2A and 
LMP2B), two small, non-polyadenylated RNAs (EBER1 and EBER2) and several viral miRs. 
This viral gene expression programme is known as latency III or the growth programme, as it 
results in the activation and rapid proliferation of the newly infected B cell. The EBV-
activated B cells resemble antigen-activated B blasts (Thorley-Lawson et al., 1982; 1985), 
but this is solely induced by the viral gene expression (Kempkes et al., 1995) and 
independent of antigen or T cell help required for normal B cell activation (see Section 
1.1.3). 
Expression of EBNA2 is not compatible with the GC B cell phenotype (see Section 
1.2.4.1.2 on EBNA2). In order to access GCs and to express GC markers (e.g. BCL6 and 
AID), EBV-infected B cells switch their viral gene expression to latency II (Babcock et al., 
2000), a more restricted expression programme encoding only four of the nine latent 
proteins (EBNA1, LMP1, LMP2A/B) together with the EBV-encoded RNAs. Expression of 
LMP1 and LMP2A/B is thought to provide survival signals in the otherwise pro-apoptotic GC 
B cell environment (see Sections 1.2.4.2.1 and 1.2.4.2.2 below). 
It is thought that the EBV-infected GC B cell then follows the normal differentiation 
pathway to become a memory B cell, which again requires a switch in the viral gene 
expression programme to latency 0, which is a complete shut-down of viral protein 
expression, except expression of EBNA1 (latency I) upon the occasional proliferation of the 
memory B cell (Hochberg et al., 2004). EBV-infected memory B cells have undergone CSR 
(Babcock et al., 1998; Joseph et al., 2000a) and also SHM with a pattern similar to antigen-
selected memory B cells (Souza et al., 2005). Furthermore, it seems that EBV positive 
memory B cells are more likely to have undergone CSR and to carry more somatic 
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mutations compared to EBV negative memory B cells (Souza et al., 2007). It is within the 
memory B cell compartment that EBV can persist for the lifetime of the host due to the long-
life of memory B cells and also because EBV does not need to express any viral proteins 
and therefore remains undetected by the immune system. 
In order to maintain a stable population of infected memory B cells and to spread to a 
new host, periodic reactivation of the lytic cycle occurs when the memory B cell differentiates 
into a plasma cell (Laichalk and Thorley-Lawson, 2005). The plasma cell produces new EBV 
viral particles that can infect mature B cells within the same host or infect a new individual 
through shedding in the saliva. 
 
Figure 1.7: In vivo infection with EBV in the germinal centre model of persistence. 
EBV infects mature, resting B cells in the tonsils by binding to CD21. Through the expression of all 
nine latent viral proteins comprising six EBV nuclear antigens (EBNA-1, -2, -3A, -3B, -3C and -LP) 
and three latent membrane proteins (LMP-1, -2A and -2B) EBV-infected mature B cells become 
activated and undergo rapid proliferation, which resembles antigen-activated B blasts. The viral gene 
expression programme responsible for this is known as latency III. Activated EBV infected B cells 
enter germinal centres and restrict viral gene expression to EBNA1, LMP1, LMP2A and known as 
latency II, resembling centroblasts and centrocytes. These then differentiate and exit the germinal 
centre to become resting memory B cells, in which no viral proteins are expressed (latency 0), except 
upon proliferation, in which case EBNA1 is expressed. Figure adapted from Prof Martin Allday. 
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1.2.2.2 In vitro infection 
Infection of mature B cells with EBV in vitro is also able to establish a stable infection 
(Pope et al., 1968; Henle et al., 1967). However, in contrast to in vivo EBV infection, in vitro 
infection with EBV results in the creation of continuously proliferating lymphoblastoid cell 
lines (LCL) that express all nine latent viral protein of the latency III transcriptional 
programme (Figure 1.8). It is believed that due to the absence of GCs and an immune 
response to expressed latent proteins, differentiation into memory B cells is neither possible 
nor necessary. This transformation process of resting B cells into continuously proliferating 
LCL is sometimes also referred to as immortalisation. 
 
Figure 1.8: In vitro infection with EBV leads to the establishment of continuously proliferating 
lymphoblastoid cell lines (LCL). 
EBV infects mature, resting B cells by binding to CD21. Continuous proliferation is driven by the 
expression of all nine latent viral proteins, six EBV nuclear antigens (EBNAs) and three latent 
membrane proteins (LMPs). Shut-down of viral gene expression as seen after in vivo infection (see 
Figure 1.7) is either not possible or not required due to the absence of a germinal centre and immune 
system. Therefore, EBV-driven proliferation continues and leads to the establishment of continuously 
proliferating LCL. 
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1.2.3 Latent gene transcription from the circular EBV genome 
After infection, the linear EBV genome from the virion circularises and forms a viral 
episome (Figure 1.9) upon activation of the infected B cell (Hurley and Thorley-Lawson, 
1988). This involves recombination of the terminal repeats (TR) located at the ends of the 
linear viral genome. Furthermore, the EBV genome contains internal repeats (also known as 
W repeats), which contain the W promoter (Wp) and encode the W exons of EBNA-LP. Early 
latent viral gene expression is initiated from Wp present in multiple copies in the viral 
genome (one copy per W repeat), but changes to the C promoter (Cp) in proliferating EBV-
driven B blasts (Woisetschlaeger et al., 1990). This transcription leads to very long primary 
mRNAs coding for all six EBNAs (B cell transcription unit), which are then alternatively 
spliced to produce functional EBNA proteins. For the latency II and latency I programmes, 
transcription is initiated from the Q promoter (Qp) resulting only in the expression of EBNA1 
(Schaefer et al., 1995; Tsai et al., 1995). LMP1 and LMP2A/B are transcribed independently 
from the EBNAs. 
 
Figure 1.9: Latent protein-coding gene transcription from circular EBV genome. 
Latently EBV-infected B cells contain the EBV genome in form of a circular episome. Early after 
infection, transcription of EBV nuclear antigens (EBNAs, coloured in blue) is initiated from the W 
promoter (Wp) present in multiple copies, but switches to the C promoter (Cp) in activated EBV-
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infected B blasts. All six EBNAs are transcribed as very long primary mRNA and are alternatively 
spliced and translated into the individual EBNA proteins. During latency II and I, when only EBNA 1 is 
expressed, transcription is initiated from the Q promoter (Qp). Latent membrane proteins (LMPs, 
coloured in red) are transcribed independently from the EBNAs. Terminal repeats (TR) and the latent 
origin of replication (OriP) are shown as black boxes. Figure adapted from (Kalla and 
Hammerschmidt, 2012). 
1.2.4 Latent viral proteins 
1.2.4.1 EBV nuclear antigens 
1.2.4.1.1 EBNA1 
EBNA1 is expressed in all replicating EBV infected B cells, as one of its essential 
roles is to prevent the loss of the viral genome in the dividing cell. The latent origin of 
replication (OriP) on the EBV genome (Figure 1.9) enables replication and retention of viral 
episomes in latently EBV infected cells (Yates et al., 1984) and EBNA1 is essential for both 
replication and retention (Yates et al., 1985). Binding of EBNA1 to OriP enables the 
replication of the viral episome (Wysokenski and Yates, 1989), but also tethers the viral 
episome to cellular chromosomes during metaphase ensuring equal segregation of viral 
episomes between the two daughter cells (Grogan et al., 1983; Kanda et al., 2001). In 
addition to this, binding of EBNA1 to OriP transactivates transcription from the Cp (Sugden 
and Warren, 1989) and LMP promoters (Gahn and Sugden, 1995). Binding of EBNA1 to 
sequences downstream of its own Qp promoter had an inhibitory effect possibly to auto-
regulate its own expression levels (Sample et al., 1992). 
1.2.4.1.2 EBNA2 
EBNA2 is the first expressed viral gene (Allday et al., 1989) and absolutely essential 
for B cell transformation (Cohen et al., 1989; Hammerschmidt and Sugden, 1989), as it is 
required for both initiation (Sinclair et al., 1994) and maintenance (Kempkes et al., 1995) of 
proliferation of EBV infected B cells. According to sequence differences in the EBNA2 gene, 
two major EBV clades (type I and type II EBV) are distinguished sharing only 56% of EBNA2 
amino acid identity between each other. Type I EBV strains are more efficient in 
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transforming B cells into LCLs compared to type II strains, which is due to a single amino 
acid difference between the two types (Tzellos et al., 2014). It should be noted, however, 
that there are no obvious differences in the pathologies associated with type I or type II EBV. 
EBNA2 contains N-terminal (Peng et al., 2004) and C-terminal transactivation 
domains (Cohen and Kieff, 1991) enabling EBNA2 to interact with transcriptional activators 
(Tong et al., 1995a; b) – e.g. transcription factor IIB (TFIIB), TFIIH , TATA-binding protein 
associated factor 40 (TAF40) and replication protein A 70 (RPA70) – and co-activators like 
histone acetyltransferases p300, CBP and PCAF (Wang et al., 2000). This transactivation 
ability of EBNA2 strongly activates the Cp (Woisetschlaeger et al., 1991; Sung et al., 1991) 
and LMP promoters (Wang et al., 1990; Ghosh and Kieff, 1990; Fåhraeus et al., 1990; Abbot 
et al., 1990), probably resulting in the Wp to Cp switch and LMP expression. EBNA2 does 
not exhibit direct DNA-binding capacity, but is tethered to its responsive promoters through 
binding to the cellular DNA-binding factor recombination binding protein-J (RBPJ, RBP or 
RBPJκ) (Grossman et al., 1994; Henkel et al., 1994; Waltzer et al., 1994; Zimber-Strobl et 
al., 1994). RBPJ is the DNA-binding component of the Notch signalling pathway (see 
Section 1.4.1) and is also known as CSL protein [C-promoter binding factor 1 (CBF1), 
Suppressor of hairless Su(H) in Drosophila melanogaster and Lag1 in Caenorhabditis 
elegans]. In addition to RBPJ, analysis of the bidirectional LMP1/LMP2B promoter identified 
a binding site for transcription factor PU.1/SPI1 that was important for EBNA2-mediated 
induction of the LMP1/LMP2B promoter (Laux et al., 1994; Johannsen et al., 1995) and an 
interaction between EBNA2 and PU.1/SPI1 was shown in GST-pulldowns (Johannsen et al., 
1995; Zhao and Sample, 2000) and co-IP (Yue et al., 2004). 
Beside the regulation of viral genes, EBNA2 also differentially regulates a large 
number of cellular genes. Some of the genes directly activated by EBNA2 are the B cell 
activation markers CD21 and CD23 (Wang et al., 1987; Cordier et al., 1990; Jochner et al., 
1996), HES-1 (Sakai et al., 1998) and c-MYC (Kempkes et al., 1995; Jochner et al., 1996; 
Kaiser et al., 1999). In contrast to its role as transactivator, EBNA2 was shown to repress 
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expression of IgM (Jochner et al., 1996), Ig-β (Maier et al., 2006) and the GC-associated 
genes BCL6 (Boccellato et al., 2007) and AID (Tobollik et al., 2006). Induction of CD21, 
CD23 and other EBNA2-induced genes has been found to be strictly dependent on the 
expression of RBPJ, whereas repression of IgM and BCL6 was suggested to be only 
partially dependent on RBPJ, but no mechanisms have been proposed (Maier et al., 2005; 
2006; Boccellato et al., 2007). The induction of c-MYC and repression of BCL6 by EBNA2 is 
not compatible with GC B cells (see Section 1.1.4). Expression of BCL6 is absolutely 
required for GC B cells and c-MYC is only expressed before B blasts enter GCs, but not 
within the GC except for the small subset of centrocytes in the LZ that recycle back into the 
DZ (Dominguez-Sola et al., 2012; Calado et al., 2012; Victora et al., 2010; 2012). By 
switching from latency III to latency II, EBV-infected B cells stop expressing EBNA2 and are 
able to express BCL6 to enter GCs. 
See Section 1.4.2 for a model of EBNA2-mediated gene regulation. 
1.2.4.1.3 EBNA3A, EBNA3B, EBNA3C 
The EBNA3 family of genes is comprised of EBNA3A, EBNA3B and EBNA3C, which 
are arranged in tandem repeat on the EBV genome and share a similar gene structure with 
a short 5’ exon and a long 3’ exon. Alternative splicing of very long primary mRNA 
transcripts that originate from either the Wp or Cp promoter produces mRNAs for each of the 
EBNA3s (Figure 1.9). Transcription of EBNA3 is tightly regulated as there are only a few 
copies of EBNA3 mRNAs in LCLs, e.g. less than 3 mRNA copies of EBNA3C per cell 
(Davies et al., 2010). However, the half-life of EBNA3 proteins is at least 24 hours (Touitou 
et al., 2005). The two major EBV clades (type I and type II) also differ in their EBNA3 
proteins with a amino acid identity between type I and type II of 84%, 80% and 72% for 
EBNA3A, EBNA3B and EBNA3C, respectively (Sample et al., 1990; Palser et al., 2015). 
EBNA3s are very large proteins (>900 aa, Figure 1.10A) that do not resemble any known 
cellular or viral proteins (Allday et al., 2015). However, they do resemble each other 
although they share only limited amount of sequence similarity. All three contain a N-
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terminal homology domain with an amino acid sequence identity of 23-28% between all 
three (Le Roux et al., 1994). Protein structures have not been solved for any of the EBNA3s, 
but global protein structure prediction analysis reported a similarity in their secondary 
structure elements of 71-88% (Yenamandra et al., 2009). The homology domains, in 
particular, are predicted to fold into alpha helices and beta strands, while no obvious 
secondary structure was predicted for most of the remaining regions of the proteins [Figure 
1.10A, (Allday et al., 2015)]. Although EBNA3s resemble each other there is no indication 
that they are redundant or can substitute for each other. Early studies indicated that 
EBNA3A and EBNA3C were essential for B cell transformation (Tomkinson et al., 1993), 
whereas EBNA3B was dispensable (Tomkinson and Kieff, 1992). More recent studies have 
shown, however, that under certain conditions (see below), EBNA3A and EBNA3C are 
dispensable for B cell transformation and therefore not absolutely essential (Hertle et al., 
2009; Skalska et al., 2013). 
All EBNA3s exhibit strong repressor activity in reporter assays when targeted directly 
to DNA by fusion with the DNA-binding domain of Gal4 (Bain et al., 1996; Waltzer et al., 
1996; Bourillot et al., 1998; Allday et al., 2015), probably through interaction with cellular 
factors that are involved in transcriptional repression (Figure 1.10B), e.g. EBNA3C can 
interact with histone deacetylase 1 (HDAC1), HDAC2, C-terminal binding protein (CtBP), 
transcriptional co-repressors Sin3A and silencing mediator of retinoid and thyroid hormone 
receptors (SMRT/NcoR) (Radkov et al., 1999; Knight et al., 2003; Touitou et al., 2001). 
Similar to EBNA2, EBNA3 proteins do not contain intrinsic DNA-binding ability, but like 
EBNA2, all EBNA3s can bind to the DNA sequence binding factor RBPJ (Robertson et al., 
1995; 1996; Krauer et al., 1996; Zhao et al., 1996; Marshall and Sample, 1995) and 
EBNA3C possibly also to PU.1/SPI1 (Zhao and Sample, 2000) and interferon regulatory 
factor 4 (IRF4) and IRF8 [(Banerjee et al., 2013), (Figure 1.10B)]. 
Each EBNA3 forms a unique complex with RBPJ (Ohashi et al., 2015), but for all 
three EBNA3s the RBPJ binding site is situated within their HDs (Robertson et al., 1996; 
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Zhao et al., 1996). Initially, four core residues (209TFGC) within the HD of EBNA3C were 
identified to be important [(Zhao et al., 1996; Radkov et al., 1997), (Figure 1.10C)]. More 
recently and only for EBNA3C an additional site (227WTP, Figure 1.10C) was identified and 
mutation of both sites (209AAAA and W227S) was required for an effective loss of RBPJ 
binding as determined by co-immunoprecipitation (Calderwood et al., 2011). The interaction 
between EBNA3A or EBNA3C and RBPJ was shown to be important for sustaining the 
proliferation of LCLs (Maruo et al., 2005; 2009; Lee et al., 2009). However, recently it was 
possible to establish stable LCL from an EBNA3C virus carrying both 209AAAA and W227S 
mutations, so an interaction between EBNA3C and RBPJ is not absolutely required for B cell 
transformation (Kalchschmidt et al., 2016). 
 
Figure 1.10: Overview of the EBNA3 family of proteins and selected interactions between 
EBNA3C and cellular factors. 
(A) Overview of EBNA3 proteins indicating the homology domain, nuclear localisation signal (NLS), 
predicted alpha helices and beta strands by phyre2 protein fold recognition server. Numbers indicate 
amino acids. (B) Schematic of full-length EBNA3C showing a transactivation domain (TAD) in orange 
and important residues for the interaction with selected cellular factors [histone acetyltransferase 
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p300, histone deacetylases 1 and 2 (HDAC1/2), Nm23-H1, C terminal binding protein (CtBP), and the 
transcription factors IRF4/8, PU.1/SPI1 and RBPJ]. (C) The amino acid residues 209TFGC and 227WTP 
are important for the interaction between EBNA3C and RBPJ. The nucleotide sequence of wild type 
EBNA3C is shown in black and mutations encoding 209AAAA and 227STP in the RBPJ binding mutant 
(BM) EBNA3C are shown in red. Panel A is adapted from (Allday et al., 2015), panel B from a drawing 
by Prof Martin Allday and panel C from (Kalchschmidt et al., 2016). 
Beside their potent repressive activity on gene expression, EBNA3s have been also 
reported in gene activation of viral and cellular genes. EBNA3C has been shown to induce 
expression of LMP1 (Allday et al., 1993; Jiménez-Ramírez et al., 2006) and further studies 
showed that EBNA3C potentiates EBNA2-mediated activation of the LMP1 promoter 
(Marshall and Sample, 1995), which was independent of RBPJ, but required PU.1/SPI1 
binding sites (Zhao and Sample, 2000; Lin et al., 2002). In contrast, repression of the LMP1 
promoter by EBNA3C was also observed, which might depend on the feeding condition of 
the cells during the transient reporter assays (Robertson et al., 1995; Marshall and Sample, 
1995). Furthermore, EBNA3C contains a C-terminal transactivation domain that increases 
transcription in reporter assays when targeted directly to DNA by fusion with the DNA-
binding domain of Gal4 (Marshall and Sample, 1995) and both N- and C-termini have been 
reported to interact with histone acetyltransferase p300 [(Cotter and Robertson, 2000; 
Subramanian et al., 2002), (Figure 1.10A)]. Moreover, EBNA3C interacts with the nucleoside 
diphosphate kinase Nm23-H1 (Subramanian et al., 2001; Subramanian and Robertson, 
2002), which has been reported to co-operate with EBNA3C in induction of matrix 
metalloproteinase 9 (Kuppers et al., 2005) and cyclo-oxygenase-2 gene expression (Kaul et 
al., 2006). 
From gene expression analyses in various EBNA3 knock-out (KO) or conditional cell 
lines, it is now well established that all EBNA3s are transcriptional co-regulators of over 
1000 host genes and often more than one EBNA3 cooperate in the regulation of one gene 
(Hertle et al., 2009; White et al., 2010; Zhao et al., 2011b; Skalska et al., 2010; McClellan et 
al., 2012). Two of the genes more extensively studied are the two tumour suppressors 
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BCL2L11 (BIM) and CDKN2A (p16INK4A) that are both repressed by EBNA3A together with 
EBNA3C. 
BIM (BCL2-interacting mediator) is a pro-apoptotic BCL-2 family member and is up 
regulated upon unscheduled cellular proliferation induced by oncogenes such as Myc (Egle 
et al., 2004). BIM is a potent initiator of apoptosis as it can inactivate BCL-2 and other pro-
survival BCL-2 family members through high affinity binding. Both EBNA3A and EBNA3C 
cooperate in the repression of BIM (Anderton et al., 2007), which involved recruitment of 
polycomb repressive complex 2 (PRC2) and the deposition of repressive epigenetic histone 
modification H3K27me3 [(Paschos et al., 2009; 2012), see Section 1.3 for details on 
epigenetic marks and PRC2]. EBNA3A and EBNA3C were shown to bind proximal to the 
TSS of BIM (Paschos et al., 2012; McClellan et al., 2013). 
p16INK4A is a cyclin-dependent kinase (CDK) inhibitor that binds to cyclin D dependent 
kinases (CDK4 and CDK6), which prevents their binding to D-type cyclins and inhibits the 
phosphorylation of retinoblastoma protein (Rb). Hypo-phosphorylation of Rb produced by 
high levels of p16INK4A results in G1 cell cycle arrest [reviewed in (Gil and Peters, 2006)]. 
Inactivation of EBNA3C in EBNA3C-conditional LCL, which carry an EBNA3C-estrogen 
receptor fusion protein that renders EBNA3C conditional to the presence of 4-
hydroxytamoxifen (HT), through removal of HT resulted in the increase in p16INK4A, 
dephosphorylation of Rb and cell cycle arrest (Maruo et al., 2006). EBNA3A is also involved 
in the repression of p16INK4A and together with EBNA3C is necessary for the establishment 
of repressive state by PRC2 and H3K27me3 (Skalska et al., 2010; Maruo et al., 2011). 
Repression also depends, in part, on the ability of EBNA3A and EBNA3C to interact with 
CtBP (Skalska et al., 2010). Furthermore, it was shown that EBNA3C binds proximal to the 
TSS of p14ARF, located at the same locus as p16INK4A (Jiang et al., 2013), and that 
proliferation of LCL does not decrease after inactivation of EBNA3C in B cells with a 
homozygous deletion in p16INK4A (p16INK4A-null) that ablates expression of functional p16INK4A 
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(Skalska et al., 2013). Therefore, conditional EBNA3C LCL could be established from 
p16INK4A-null primary B cells without expressing functional EBNA3C. 
Least is known about EBNA3B, which is completely dispensable for in vitro B cell 
transformation. However, it appears that in a mouse model, EBNA3B acts as a tumour 
suppressor. Humanised mice infected with EBNA3B KO virus displayed a faster expansion 
of EBV infected B cells and lower secretion of the T cell attractant chemokine CXCL10 
leading to more aggressive lymphoma development (White et al., 2012). Furthermore, 
mutations and deletions in EBNA3B have been identified in human EBV-associated diffuse 
large B cell lymphoma (White et al., 2012). 
See Section 1.4.2 for a model of EBNA3-mediated gene regulation. 
1.2.4.1.4 EBNA-LP 
EBNA leader protein (EBNA-LP), which is alternatively spliced from transcripts 
initiated first from Wp and later from Cp (Figure 1.9), is highly expressed early after latent 
infection (Allday et al., 1989). EBNA-LP is composed of a various number of repeats, 
encoded by the W1 and W2 exons, and a unique C-terminal region encoded by the Y1 and 
Y2 exons (Figure 1.9), resulting in the expression of EBNA-LP with different molecular 
weights depending on the number of W repeats. It is believed that the main function of 
EBNA-LP is to augment EBNA2-mediated gene activation. EBNA-LP co-operates with 
EBNA2 in the induction of cyclin D2 to transition resting B cells from G0 into G1 of the cell 
cycle (Sinclair et al., 1994) and in the activation of the Cp and LMP promoters (Harada and 
Kieff, 1997; Nitsche et al., 1997). The mechanisms by which EBNA-LP co-operates with 
EBNA2 remain mainly unknown. Recently, it was proposed that EBNA-LP displaces the co-
repressor NCoR from RBPJ and thereby promotes transactivation by EBNA2 (Portal et al., 
2011; 2013), but this remains controversial [reviewed in (Kempkes and Ling, 2015)]. 
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1.2.4.2 Latent membrane proteins 
1.2.4.2.1 LMP1 
LMP1 expression is induced by EBNA2 and can be potentiated by EBNA3C and 
EBNA-LP. Originally LMP1 was considered to be absolutely required for B cell 
transformation (Kaye et al., 1993), but in the presence of feeder cells it is possible to 
establish LMP1 KO LCL although at dramatically reduced rate compared to LMP1 
competent wild type virus (Dirmeier et al., 2003). LMP1 consists of a short N-terminal 
cytoplasmic domain followed by six transmembrane domains and a longer C-terminal 
cytoplasmic domain that comprises two C-terminal activation regions (CART1 and CART2), 
which are essential for its signalling function. LMP1 forms a constitutively active receptor, 
because the transmembrane domains mediate homo-oligomerisation, which mimics ligand-
induced cross-linking and results in constitutive signalling (Gires et al., 1997). Therefore, 
LMP1 is often considered to be equivalent to a constitutively active CD40 receptor 
(Hatzivassiliou et al., 1998; Kilger et al., 1998). LMP1 signals via various pathways, e.g. NF-
κB, mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3-K), IRF7 
and STAT pathways and has multiple function in EBV biology [reviewed in (Kieser and 
Sterz, 2015)]. LMP1 expression in vivo is restricted to latency III expressing EBV-induced B 
blast and latency II expressing GC B cells. By mimicking CD40L signals of TFH cells, LMP1 
was considered to help EBV-infected B cells to survive in the GC environment, but more 
recent data suggest that EBV-infected B cells are still undergoing antigen-selection (Souza 
et al., 2005; 2007). However, there is no doubt that LMP1 provides survival signals to EBV-
infected B cells, e.g. through induction of BCL2 (Henderson et al., 1991), which is repressed 
by BCL6 in GC B cells (Saito et al., 2009). Furthermore, when ectopically over expressed 
LMP1 can induce the expression of AID probably through NF-κB signalling (He et al., 2003). 
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1.2.4.2.2 LMP2A and LMP2B 
LMP2A and LMP2B exons span the two ends of the linear EBV genome and can only 
be expressed upon circularisation of the EBV genome (Figure 1.9). They are transcribed 
from two different promoters, but only differ in the first exon and share the remaining eight 
exons (exons 2-9). LMP2A and LMP2B are induced by EBNA2 (Zimber-Strobl et al., 1991) 
and repressed by EBNA3s (Le Roux et al., 1994). The first exon of LMP2A encodes for an 
N-terminal cytoplasmic domain with signalling ability, whereas the first exon of LMP2B is 
non-coding and therefore lacking signalling ability. Both proteins contain 12 transmembrane 
domains that anchor LMP2A and LMP2B in the cell membrane and a short C-terminal 
cytoplasmic tail that mediates homo- or hetero-dimerisation between LMP2A and LMP2B. 
The N-terminal cytoplasmic domain of LMP2A contains a consensus immunoreceptor 
tyrosine-based activation motif (ITAM) that interacts with components of the BCR signalling 
pathway. This allows LMP2A to mimic constitutively active BCR signalling (Engels et al., 
2012) and to activate multiple downstream pathways, e.g. NFκB (Swanson-Mungerson et 
al., 2005), MAPK (Engels et al., 2012) and PI3K (Swart et al., 2000; Portis and Longnecker, 
2004), resulting for example in increased cell survival and proliferation. Furthermore, LMP2A 
is able to induce Notch signalling, which can stimulate LMP2A expression in an auto-
regulatory loop, possibly to maintain LMP2A expression in the absence of EBNA2 
expression (Anderson and Longnecker, 2008). LMP2A and LMP2B expression in vivo is 
restricted to latency III expressing EBV-induced B blast and latency II expressing GC B cells. 
The ability of LMP2A to mimic constitutively active BCR signalling is thought to help EBV-
infected B cells to survive in the absence of strong antigen-binding signals from the 
endogenous BCR (Cen and Longnecker, 2015). 
1.2.5 EBV-associated lymphomas 
EBV infection has been linked with different cancers, including B cell lymphomas, T 
cell lymphomas and different carcinomas. Only some of the more frequent B cell lymphomas 
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will be discussed here, which are derived from different stages of latently EBV infected B 
cells and express different latency programmes. 
1.2.5.1 B cell lymphomagenesis 
B cell lymphomas are far more frequent (up to 95% of lymphomas in the Western 
world) than T cell lymphomas although the number of B and T cells in humans are roughly 
equal. Most B cell lymphomas originate from GC B cells or post-GC B cells [reviewed in 
(Küppers, 2005)]. One hallmark – and possibly an early event in the development of B cell 
lymphomas – is the development of reciprocal chromosomal translocations. Translocations 
require DSB on two heterologous chromosomes that are in proximity of each other in order 
to be ligated together. Translocations found in B cell lymphomas often occur between one of 
the Ig loci and a proto-oncogene (e.g. cMYC), which places the proto-oncogene under the 
transcriptional control of the active Ig locus and therefore causes constitutive oncogene 
expression (Küppers, 2005). Multiple studies have shown that promiscuous AID activity can 
introduce DSB not only at the Ig loci, but also at non-Ig loci that are frequently translocated 
[reviewed in (Robbiani and Nussenzweig, 2013)]. This indicates an important role of AID in 
the development of B cell lymphomas and provides a logical explanation for the frequent GC 
or post-GC origin. 
1.2.5.2 Burkitt’s lymphomas 
Burkitt’s lymphomas (BL) are derived from GC B cells in the DZ that carry a 
characteristic translocation between cMYC and the Ig loci, predominantly IgH and less 
frequently IgL [reviewed in (Schmitz et al., 2014)]. This disrupts BCL6-mediated repression 
of cMYC and leads to constitutive activation of cMYC, but additional mutations of tumour 
suppressors, e.g. TP53, CDKN2A or BCL2L11 (BIM), are required for lymphomagenesis 
(Schmitz et al., 2014). In addition, ~20% of BL cases carry mutations in cMYC that were 
possibly acquired during the SHM-induced translocation process (Dang et al., 2005) and 
some of the cMYC mutants failed to induce the tumour suppressor BIM (Hemann et al., 
2005). The extent of AID expression is directly linked to the frequency of cMYC translocation 
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(Takizawa et al., 2008) and AID is required for these translocations in a mouse model of BL 
(Robbiani et al., 2008). BL can be divided into endemic (eBL), sporadic (sBL) and HIV-
associated BL. Almost 100% of eBL and around 10-20% of sBL and HIV-associated BL 
cases are EBV positive. 
eBL is aetiologically linked to EBV and malaria infection and occurs mostly in children 
in sub-Saharan Africa and Papua New Guinea, where Plasmodium falciparum is present 
resulting in chronic malaria infections. Two recent studies showed that malaria parasite 
extracts induced AID expression in human tonsilar B cells and that chronic malaria infection 
increased the transition of B cells through the GC (Torgbor et al., 2014), which was also 
observed in a mouse model of chronic malaria infection that created a favorable GC 
environment for the development of AID-dependent mature B cell lymphomas (Robbiani et 
al., 2015). It is thought that the role of EBV in the development of eBL is mostly to repress 
tumour suppressors and apoptosis-related factors in order to compensate for the c-MYC 
induced proliferative stress [reviewed in (Allday, 2009; Rowe et al., 2009)]. 
Many BL cell lines express only EBNA1 from the Qp latency I promoter, but showed a 
certain degree of dependence on the presence of EBV as expression of a dominant-
negative EBNA1 that is unable to retain the EBV episome resulted in reduced growth and 
increased apoptosis (Vereide and Sugden, 2011). This effect was stronger in Wp-restricted 
BL cell lines (Kelly et al., 2002) that only express EBNA1, EBNA3A, EBNA3B, EBNA3C and 
EBNA-LP, but not EBNA2, LMP1 and LMP2A/B, because of a genomic deletion of EBNA2 
[reviewed in (Speck, 2002)]. Deletion of EBNA2 in Wp-restricted BL is probably required in 
order to circumvent the strong repressive effect of EBNA2 on the translocated cMYC on the 
IgH locus (Jochner et al., 1996). This Wp-restriction was observed in 3 out of 15 (20%) of BL 
cell lines (Kelly et al., 2002) and more recently in 2 out of 20 (10%) and 4 out of 26 (15%) 
cases of eBL (Abate et al., 2015). The Wp-restricted gene expression programme might be 
positively selected because it allows EBV-infected BL cells to express EBNA3 proteins and 
other viral factors that help to suppress cMYC-induced apoptosis (Allday, 2009). However, it 
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is probably balanced, because EBNA3 proteins are highly immunogenic (see Section 
1.2.5.4), which makes Wp-restricted BL cells good targets for cytotoxic T cells (CTLs). 
1.2.5.3 Hodgkin lymphomas 
Classical Hodgkin lymphomas (HL) are comprised of mononucleated Hodgkin and 
multinucleated Reed-Sternberg cells (HRS) that are derived from GC or post-GC B cells 
(Küppers et al., 1994). Malignant HRS cells represent only a minority of the tumour mass 
with the majority coming from non-malignant T and B lymphocytes that infiltrate tumour. The 
malignant HRS cells often carry crippling mutations that result in expression of non-
functional BCRs (Kanzler et al., 1996). This can occur as part of the GC reaction, but 
normally B cells without a functional BCR undergo apoptosis due to the lack of survival 
signals from absent BCR signalling. It is believed that HSR cells originate from pre-apoptotic 
GC B cells that are rescued from apoptosis. Classical HLs are EBV positive in around 40% 
of cases and express the latency II programme (EBNA1, LMP1, LMP2A and LMP2B) – 
consistent with them being GC-derived. The expression of LMP1 and LMP2A is thought to 
help rescue the pre-apoptotic HRS cells from apoptosis through providing CD40 and BCR 
signalling, respectively [reviewed in (Küppers, 2009)]. 
1.2.5.4 Immunodeficiency-associated lymphoproliferative disease 
The full oncogenic potential of EBV can be observed in immunocompromised 
patients that develop EBV-positive B cell lymphomas. These can be observed in patients on 
immunosuppression after bone marrow or solid organ transplantation (post-transplant 
lymphoproliferative disease, PTLD), in late-stage HIV infected patients or in patients with 
congenital immunodeficiencies. It is believed that the absence of an effective immune 
response against the EBV-infected B cells allows expression of the full set of latent viral 
proteins (latency III), which drives uncontrolled B cell proliferation [reviewed in (Hislop et al., 
2007)]. Particularly the EBNA3 proteins are highly immunogenic (Hislop et al., 2007) and 
PTLDs often respond well when reactive CTLs are used in T cell therapy [reviewed in 
(Gottschalk et al., 2005)].  
Chapter I: Introduction 
 62 
1.3 Gene regulation 
1.3.1 Overview 
Eukaryotic gene regulation is a highly complex process that involves many layers 
whose combinatorial effect determines the gene expression profile of an individual cell. 
Although all cells in the human body contain the same DNA blueprint (genotype), there are a 
multitude of different cell types each with distinct cellular functions (phenotype). Gene 
expression between two cells can differ through genetic and epigenetic mechanisms. 
Genetic mechanisms involve nucleotide changes in the DNA sequence that directly or 
indirectly affect gene expression (different genotype – different phenotype). Beside genetic 
mechanisms, there are epigenetic mechanisms that lead to a heritable phenotype without 
changes in the DNA sequence [same genotype – different phenotype, (Berger et al., 2009)]. 
Here some of the mechanisms that lead to differential gene expression will be described in 
further detail. 
1.3.2 Positioning and higher order chromatin structure of chromatin 
The interphase eukaryotic nucleus is not a uniform compartment, but is comprised of 
discrete compartments, e.g. euchromatin and heterochromatin distinguishable by their 
degree of chromatin compaction (Passarge, 1979). Historically, the organisation within the 
nucleus and the positioning of chromosomes, sub-chromosome structures or individual 
genes were visualised and defined by fluorescence in situ hybridisation (FISH). More 
recently chromosome conformation capture was developed allowing analysis of the spatial 
proximity of two genomic loci (Dekker et al., 2002). This involves crosslinking to preserve 
chromatin contacts, restriction enzyme digestion, ligation of digested fragments and PCR 
quantification of ligation products. PCR products are interpreted as chromatin contacts 
between the two interrogated loci that had to be in close proximity before cross-linking to 
allow subsequent ligation and amplification of the digested fragments. Derivatives of this 
technique such as Hi-C (Lieberman-Aiden et al., 2009) were developed, which allowed the 
analysis of the three-dimensional (3D) conformation of whole genomes by measuring 
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genome-wide chromatin interactions. Both FISH and chromosome conformation capture 
studies have dramatically advanced the understanding of the organisation of the nucleus in 
recent years. 
1.3.2.1 Chromosome territories 
Interphase chromosomes are not randomly distributed, but rather localise in 
chromosome territories, which are distinct spaces particular chromosomes preferentially 
occupy within the nucleus (Figure 1.11A). Generally, gene-dense chromosomes localise 
preferentially in the centre of the nucleus and gene-poor chromosomes are found towards 
the nuclear periphery (Boyle et al., 2001; Cremer et al., 2001). The localisation of 
chromosomes within the interphase nucleus can have a direct effect on their gene 
expression. For instance, artificial tethering of a chromosome to the nuclear periphery can 
prevent the expression of some of the genes located on the tethered chromosome (Kumaran 
and Spector, 2008; Finlan et al., 2008; Reddy et al., 2008). Importantly, chromosomes are 
not isolated within their chromosome territory, as high-resolution FISH studies have 
suggested that up to 40% of each individual chromosome is intermingled with other 
chromosomes (Branco and Pombo, 2006). These intermingled regions are mostly at the 
boundaries of two adjacent chromosome territories and the larger the intermingling volume 
between a pair of chromosomes, the higher the translocation frequency between these two. 
Furthermore, the position of an individual chromosome is not fixed within the nucleus. Rapid 
changes in the positioning of entire chromosomes have been observed after serum 
starvation in human primary fibroblasts (Mehta et al., 2010) or the position of individual gene 
loci during development. The Ig loci for example move from the nuclear periphery in non-Ig 
expressing HSCs, to a more central position within the nucleus in Ig-expressing pro-B cells 
(Kosak et al., 2002).  
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1.3.2.2 Topologically associating domains 
On the sub-chromosomal level, the initial Hi-C study that analysed genome-wide 
chromatin interactions observed a compartmentalisation into two classes termed A and B 
and observed more frequent interaction within the same class compared to in between the 
two classes (Lieberman-Aiden et al., 2009). Compartment A exhibited more open chromatin 
compared to compartment B and also higher gene density and gene expression. With higher 
resolution Hi-C, highly enriched local chromatin interactions were detected in domains with 
an average size of ~900 kb known as topologically associating domains (TADs) that 
spanned ~90% of the murine genome (Dixon et al., 2012). Within TADs a high frequency of 
chromatin interactions between loci is observed and these end abruptly at the boundaries of 
the TAD (Figure 1.11B). The boundary regions adjacent to TADs are enriched in 
housekeeping genes and various genetic elements, such as binding sites for the chromatin 
factors cohesin and CCCTC-binding factor (CTCF). Cohesin links sister chromatids 
throughout S-, G2- and M-phase of the cell cycle and has been found together with CTCF to 
control higher order chromatin structures [reviewed in (Merkenschlager and Odom, 2013)]. 
The exact role of cohesin and CTCF in establishing or maintaining TADs remains to be 
elucidated. Other factors are probably also involved, because mice with conditional knock-
out of CTCF in the limb mesenchyme displayed a similar expression pattern of the Hoxd 
gene cluster, which was suggested to be isolated by CTCF from transcriptional interference 
to enable coordinated regulation during development (Soshnikova et al., 2010). Moreover, 
deletion of CTCF in murine macrophages produced a relatively mild phenotype and weakly 
affected global gene expression compared to wild type macrophages (Nikolic et al., 2014). 
1.3.2.3 Long-range chromatin interactions 
Within a TAD, long-range interactions between genetic elements can directly 
influence gene expression (Figure 1.11C). Such elements are often referred to as enhancers 
or silencers depending on their stimulating or repressive effect, respectively, on gene 
expression. Enhancers and silencers are often distal from the regulated promoter, but 
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through looping out of the intervening chromatin, long-range interactions with the promoter 
can be established and detected by FISH and chromosome conformation capture 
techniques. This can lead to the formation of an active chromatin hub, which might stabilise 
the TAD [reviewed in (Pombo and Dillon, 2015)]. Cohesin and CTCF are two of the factors 
that are thought to mediate these long-range interactions between genetic elements within a 
TAD (Merkenschlager and Odom, 2013). However, in addition to their role in controlling 
long-range interactions, CTCF binding sites that are positioned between an enhancer and its 
promoter can block their interaction, which is why CTCF binding sites are sometimes 
referred to as insulators (Merkenschlager and Odom, 2013). 
 
Figure 1.11: Positioning and higher order chromatin structures in the nucleus. 
(A) Chromosomes have a preferred organisation within the nucleus and localise in distinct 
chromosome territories. (B) The chromatin of each chromosome is arrange in topologically 
associating domains (TADs) with high intra-TAD and low inter-TAD interaction frequency. (C) Within a 
TAD, long-range interactions between regulatory elements control gene expression, e.g. looping 
between the promoter (P) and upstream and downstream enhancers (E) leads to looping-out of a 
silencer (S) and active gene expression (green arrow).  
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1.3.3 Chromatin and chromatin modifications 
Within the nucleus, the DNA double helix is wrapped around a histone octamer 
formed by two H3-H4 dimers and two H2A-H2B dimers (Campos and Reinberg, 2009). The 
complex of DNA wrapped around a histone octamer is known as nucleosomes, which form 
the basic building unit of chromatin (Figure 1.12). Various classes of proteins regulate the 
state and composition of chromatin. For example, histone remodelling complexes (e.g. 
SWI/SNF) can assemble, disassemble, exchange or reposition nucleosomes in an energy 
dependent manner, which can make chromatin more or less accessible to chromatin 
interacting proteins [reviewed in (Becker and Workman, 2013)]. Chromatin can be further 
modified either directly at the level of DNA or at the level of histones. 
 
Figure 1.12: Chromatin structure and modifications. 
DNA is tightly wrapped around a histone octamer formed by two H3-H4 dimers and two H2A-H2B 
dimers forming a nucleosome. Nucleosomes are the building unit of chromatin, which further 
organises into chromatin fibers that are localised in chromosome territories within the nucleus. 
Chromatin can be modified by DNA methylation and posttranscriptional modifications (PTM) of 
histones. Figure taken from (Rosa and Shaw, 2013), licensed under a Creative Commons Attribution 
3.0 Unported License, http://creativecommons.org/licenses/by/3.0/. 
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1.3.3.1 DNA methylation 
DNA methyltransferases (DNMTs) catalyse the methylation of cytosine residues 
resulting in 5-methylcytosines predominantly within cytosine-phosphate-guanine (CpG) 
dinucleotides. Most CpG dinucleotides (70-80%) are methylated in mammalian somatic 
tissue, but CpG islands, genomic regions rich in CpG dinucleotides that often span the 
promoters regions of genes, are often non-methylated. The pattern of DNA methylation is 
maintained after DNA replication by DNMT1 or altered by DNMT3A/B that catalyse de novo 
DNA methylation [reviewed in (Li and Zhang, 2014)]. 
DNA methylation changes during development and is generally associated with gene 
silencing (Li and Zhang, 2014). Methylated CpGs are bound by proteins containing methyl-
CpG binding domains (Meehan et al., 1989), which can recruit corepressor complexes such 
as Sin3A and HDACs (Jones et al., 1998; Nan et al., 1998). Methylated CpGs can also 
prevent binding of activating TFs and thus leading to repression (Watt and Molloy, 1988). In 
contrast, DNA methylation of CTCF binding sites distal to the insulin-like growth factor 2 
(IGF2) gene prevented binding of CTCF to these sites, allowing looping between the 
promoter and a distal enhancer and therefore expression from the methylated paternal 
allele, whereas the non-methylated maternal allele was bound by CTCF, allowing CTCF to 
act as an insulator by preventing enhancer-promoter looping and expression of IGF2 (Bell 
and Felsenfeld, 2000). 
DNA methylation can be removed passively through lack of maintenance of existing 
DNA methylation by DNMT1 after DNA replication. However, active DNA demethylation was 
observed in the absence of DNA replication (Li and Zhang, 2014) and, only recently, ten 
eleven translocation (TET) proteins were discovered that are able to remove DNA 
methylation. TET proteins catalyse the oxidation of 5-methylcytosine to 5-
hydroxymethylcytosine, 5-formylcytosine and 5-carboxylcytosine, which are thought to be 
either actively removed by the BER pathway or passively lost after replication, because they 
do not induce methylation by DNMT1 [reviewed in (Kriaucionis and Tahiliani, 2014; Li and 
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Zhang, 2014)]. In addition, AID has also been proposed to erase CpG DNA methylation by 
either deaminating 5-methylcytosine into thymine or 5-methylcytosine into 5-methyluridine, 
resulting in base pair mismatches that activate the BER. However, the role of AID in DNA 
demethylation is controversial and it appears unlikely that AID is involved in global DNA 
demethylation in all cell types [critically reviewed in (Ramiro and Barreto, 2015)]. 
1.3.3.2 Histone modifications and modifiers 
Histones contain protruding N-terminal and C-terminal tails that can be modified by 
post-translational modifications (PTM), e.g. acetylation, methylation, phosphorylation and 
ubiquitination (Figure 1.13). Because both the type of PTM, but also the position of the 
residue that has been modified can affect the local chromatin state either supporting or 
preventing active transcription, a histone code has been proposed (Strahl and Allis, 2000; 
Turner, 2000). Some histone modifications are mutually exclusive, for example different 
modifications at the same residue, whereas some modifications can enhance or inhibit other 
modifications on neighbouring residues [reviewed in (Bannister and Kouzarides, 2011)]. 
 
Figure 1.13: Overview of histone modifications. 
Schematic nucleosome representation showing posttranscriptional modifications on the N-terminal 
(NH2) or C-terminal (COOH) tails of histone 2A (H2A), H2B, H3, H4 and the linker H1. Arginine (R), 
lysine (K), serine (S) and threonine (T) residues can be modified by acetylation (Ac), methylation 
(Me), phosphorylation (Ph) and ubiquitination (Ub). Figure taken from (Tollervey and Lunyak, 2012), 
licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License, 
https://creativecommons.org/licenses/by-nc/3.0/. 
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Histone modifying proteins catalyse the addition or removal of these histone PTMs. 
For example, histone acetyltransferases (HATs) catalyse the acetylation of lysine residues, 
which neutralises the positive charge of lysine and might loosen the wrapping of DNA 
around the acetylated histone, whereas HDACs remove acetyl groups and therefore restore 
the positive charge of lysine residues and possibly strengthen the association between DNA 
and histones (Bannister and Kouzarides, 2011). Therefore, histone PTMs are thought to 
directly alter the local chromatin state, which can allow or prevent direct access of DNA 
binding proteins. In addition, histone PTMs can facilitate binding of proteins containing 
specific domains or prevent binding of others (Patel and Wang, 2013). For example, 
bromodomains recognise acetylated lysine residues and are often found in HATs and 
histone remodelling complexes, which might facilitate the recruitment of SWI/SNF 
complexes to acetylated promoter regions (Hassan et al., 2002). In contrast, DNMT3L, an 
inactive DNMT that interacts with DNMT3A/B, can only bind to non-methylated, but not to 
methylated histone 3 lysine 4 (H3K4) residues and is therefore thought to establish DNA 
methylation at non-methylated H3K4 nucleosomes (Ooi et al., 2007). 
1.3.3.2.1 Polycomb-group proteins 
Polycomb-group proteins (PcG) form histone modifying complexes, whose founding 
member was first discovered in Drosophila melanogaster, in which mutation of the Polycomb 
gene Pc resulted in additional sex combs, not only on the first, but also on the second and 
third pair of legs of male flies. Subsequently, mutations in other genes causing a similar 
phenotype were identified and grouped into the Polycomb family. PcGs control body 
segmentation during the embryonic development of Drosophila by repressing the homeobox 
(HOX) gene cluster in a coordinated way to regulate cell specific activation of the HOX 
genes (Lewis, 1978). PcGs are evolutionary conserved across species and form complexes 
that are generally considered as repressors of gene expression. 
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The two most studied polycomb complexes are polycomb-repressive complex 1 
(PRC1) and PRC2 (Figure 1.14). PRC1 and PRC2 complexes have different enzymatic 
activities. The PRC1 subunits RING1A and RING1B contain E3 ligase activity and can 
catalyse ubiquitination of histone 2A lysine 119 [H2AK119ub, (de Napoles et al., 2004; 
Wang et al., 2004)], whereas EZH1/2 of PRC2 contain methyltransferase activity and 
catalyse histone 3 lysine 27 mono/di/trimethylation [H3K27me1/me2/me3, (Kuzmichev et al., 
2002; Müller et al., 2002; Czermin et al., 2002; Cao et al., 2002; Ferrari et al., 2013)]. 
H2AK119ub and H3K27me3 are thought to directly block gene transcription [reviewed in 
(Aranda et al., 2015)]. 
At least six distinct PRC1 complexes (Gao et al., 2012) can be distinguished 
depending on the identity of the polycomb group factor (PCGF) subunit (PRC1.1. contains 
PCGF1, PRC1.2 contains PCGF2, etc.). All PRC1 complexes (Figure 1.14A) contain one 
RING1 protein (RING1A or RING1B) and one PCGF member, but can be further divided into 
canonical (cPRC1) and non-canonical (ncPRC1) complexes. There are two cPRC1 
complexes containing either PCGF2 (MEL18) or PCGF4 (BMI1) and proteins of the 
chromobox-domain (CBX) family (CBX2/4/6/7/8) and the human polyhomeotic homolog 
(HPH1-3) family. ncPRC1 complexes lack CBX and HPH proteins, but contain RING1/YY1-
binding protein [RYBP or its homolog YY1-asociated factor 2 (YAF2)] together with 
additional auxiliary proteins [reviewed in (Aranda et al., 2015; Kondo et al., 2016)]. 
The core PRC2 complex (Figure 1.14B) is composed of suppressor of zeste 12 
(SUZ12) and one family member of enhancer of zeste 1 or 2 (EZH1/2) and embryonic 
ectoderm development 1-4 (EED1/2/3/4). Additional proteins associate with PRC2 [reviewed 
in (Vizán et al., 2015)]. 
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Figure 1.14: Composition of mammalian PCR1 and PRC2 complexes. 
(A) There are at least six distinct PRC1 complexes [PRC1.1-PRC1.6 (Gao et al., 2012)] 
distinguishable by the incorporated PCGF protein (PCGF1-6). The two canonical PCR1 complexes 
(PRC1.2 and PRC1.4) contain either PCGF2 (MEL18) or PCGF4 (BMI1), respectively, and 
additionally one member of RING1 (RING1A or RING1B), CBX (CBX2/4/6/7/8) and HPH (HPH1/2/3). 
Non-canonical PRC1 lack CBX and HPH proteins, but contain one RING1 protein (RING1A or 
RING1B), one PCGF protein (PCGF1-6) and RYBP (or its homolog YAF2). Non-canonical PRC1 also 
associate with additional auxiliary proteins. (B) The core PRC2 is composed of SUZ12, EZH (EZH1 or 
EZH2) and EED (EED1/2/3/4). Additional auxiliary proteins interact with PRC2. 
In the sequential model of polycomb recruitment, PRC2 was believed to recruit PRC1 
complexes, because H3K27me3 modified chromatin can be bound by the CBX subunit of 
cPRC1 complexes (Kuzmichev et al., 2002; Czermin et al., 2002; Cao et al., 2002; Min et al., 
2003). The PCGF subunits of cPRC1 (BMI1 and MEL18) have been shown to stimulate the 
ubiquitination activity of RING1 (Cao et al., 2005; Elderkin et al., 2007). In addition to 
inducing H3K27me3 and H2AK119ub, PRC1 and PRC2 can cause chromatin compaction 
and the local formation of heterochromatin during specific gene or genomic locus silencing 
B
A
HPH 
1/2/3 
PCGF1 
CBX 
2/4/6/7/8 
RING1 
A/B 
EED 
1/2/3/4 SUZ12 
EZH 
1/2 
Canonical 
PRC1 
PRC1.1 
PCGF1 
(NSPC1) 
PRC1 complexes 
EZH1 
EZH2 
PRC1.2 
PCGF2 
(MEL18) 
PRC1.3 
PCGF3 
PRC1.4 
PCGF4 
(BMI1) 
PRC1.5 
PCGF5 
PRC1.6 
PCGF6 
(MBLR) 
PCGF2 
RING1 
A/B 
PCGF3 
RING1 
A/B 
PCGF4 
RING1 
A/B 
PCGF5 
RING1 
A/B 
PCGF6 
RING1 
A/B 
HPH 
1/2/3 
CBX 
2/4/6/7/8 
RYBP/
YAF2 
RYBP/
YAF2 
RYBP/
YAF2 
RYBP/
YAF2 
PCGF2 
RING1 
A/B 
RYBP/
YAF2 
PCGF4 
RING1 
A/B 
RYBP/
YAF2 
Non-
Canonical 
PRC1 
PRC2 complexes 
KDM2B 
SKP1 
BCOR/
BCORL1 
AUTS2 
FBRS/
FBRSL1 
CKIIs 
AUTS2 
FBRS/
FBRSL1 
CKIIs 
HDAC1/2 
E2F6 
L3MBTL2 
MAX-MGA 
G9a 
 
JARID2 
PCL1-3 
RBAP46/48 
AEBP2 
C17orf96 
Chapter I: Introduction 
 72 
(Shao et al., 1999; Levine et al., 2002; Francis et al., 2004; Margueron et al., 2008; Eskeland 
et al., 2010). However, this model can only apply to cPCR1 complexes that contain CBX 
subunits, but not the more recently characterised ncPRC1 complexes, which do not contain 
any CBX subunits (Gao et al., 2012; Tavares et al., 2012). 
Furthermore, results of recent studies have challenged the classical, sequential 
recruitment model in which PRC2-induced modifications recruit PRC1. It has been shown 
that PRC1 can be recruited independently from PRC2 and the H3K27me3 modification 
(Schoeftner et al., 2006; Pasini et al., 2007; Tavares et al., 2012; Yu et al., 2012). 
Furthermore, PRC1 can actually recruit PRC2 through the deposition of H2AK119Ub 
(Blackledge et al., 2014; Cooper et al., 2014; Kalb et al., 2014). In addition to PRC1 and 
PRC2 recruiting each other, DNA sequence-specific factors have been proposed to recruit 
PcG complexes. For example murine Pcgf4 (Bmi1) was shown to directly interact with the 
DNA sequence-specific binding factor RUNT-related transcription factor 1 (Runx1) and 
depletion of Runx1 in primary murine thymocytes reduced the occupancy of Ring1b at 
Runx1 binding sites (Yu et al., 2012). Interaction between PRC2 proteins with long non-
coding RNA was also observed, such as HOX transcript antisense RNA (HOTAIR) 
expressed from the HOXC gene locus that target PRC2 to the HOXD gene (Rinn et al., 
2007), and in a RNA sequence-independent manner also with short RNA that are 
transcribed from the 5’ end of polycomb-repressed genes (Kanhere et al., 2010). In addition, 
non-sequence specific DNA elements have been identified, with PRC1 and PRC2 binding 
sites frequently found in or adjacent to CpG islands (Lee et al., 2006; Tanay et al., 2007; Ku 
et al., 2008; Mendenhall et al., 2010). The auxiliary proteins of PRC1.1 (KDM2B) and PRC2 
(AEBP2 and JARID2) could be responsible for this, because they specifically recognise non-
methylated CpG dinucleotides (Farcas et al., 2012; He et al., 2013; Wu et al., 2013) or 
generally GC-rich DNA (Kim et al., 2009; Li et al., 2010), respectively. However, the exact 
mechanism(s) by which different PRC1 and PRC2 complexes are recruited remain poorly 
understood. 
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Promoters of polycomb-repressed genes marked by H3K27me3 in ESCs are likely to 
acquired DNA methylation during differentiation, possibly to further reinforce silencing of 
these genes in somatic cells [reviewed in (Margueron and Reinberg, 2011)]. This promoted 
the idea that polycomb-mediated repression can lead to CpG DNA methylation, but much 
remains unknown about the potential crosstalk between PcG silencing and DNA methylation 
[reviewed in (Jin et al., 2011; Rose and Klose, 2014)]. Consistent with this idea, EZH2 was 
shown to directly interact with DNMTs (Viré et al., 2006). However, PRC2 was also reported 
to interact with TET1 in murine ESCs, but not in murine embryonic fibroblasts (Neri et al., 
2013), which might ensure non-methylated CpG dinucleotides at polycomb-regulated gene 
promoters in ESCs. 
Around 70% of polycomb-repressed genes in murine embryonic stem cells (ESCs) 
are contained in polycomb domains enclosed between two CTCF and cohesin binding sites 
(polycomb-repressed TADs) with an average size of ~110 kb (Dowen et al., 2014). These 
polycomb-repressed TADs exhibit very high levels of EZH2, SUZ12 and H3K27me3 and 
disruption of the TAD through deletion of either of the two CTCF binding sites at the 
boundary de-repressed the enclosed gene to some degree. Polycomb-repressed domains 
are subject to changes, for example during the sequential activation of the HOX genes, 
which are initially in a polycomb-repressed TAD, but progressively cluster in an active TAD 
during embryonic development (Noordermeer et al., 2011). Again, deletion of specific CTCF 
binding sites within the boundaries result in invasion of activation-associated histone marks 
into the polycomb-repressed TAD and expression of some of the HOX genes (Xu et al., 
2014; Narendra et al., 2015). Therefore, CTCF and cohesin binding seem to play a crucial 
role in maintaining polycomb-repressive TADs and possibly TADs in general. Furthermore, 
deletion of both catalytic PRC1 subunits RING1A and RING1B in murine ESCs completely 
disrupted the Hox gene cluster, by abolishing promoter-promoter contacts, but maintaining 
promoter-enhancer contacts, leading to de-repression of Hox genes (Schoenfelder et al., 
2015). The effect of depletion of the PRC2 subunit EED on the organisation of the Hox locus 
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was much more subtle and disrupted only a few interactions, but maintained the overall 
network (Denholtz et al., 2013; Schoenfelder et al., 2015). An interaction between the 
Drosophila PRC1 homolog of CBX and cohesin subunits has been reported (Strübbe et al., 
2011), which might help PRC1 complexes to establish repressive interactions. 
Historically, PcGs have always been associated with repression, however, several 
recent studies implicate PRC1 complexes in gene activation (Kondo et al., 2014; Gao et al., 
2014; Creppe et al., 2014; Frangini et al., 2013; Pemberton et al., 2014; Morey et al., 2015; 
Schaaf et al., 2013). For example, in resting murine B and T cells cPRC1.4 (Ring1B, Bmi1 
and Cbx7) occupy many actively transcribed promoters. cPRC1.4 co-immuniprecipates with 
Aurora kinase B and both co-occupy the same active promoters, at which Aurora kinase B 
phosphorylates H3S28 resulting in the inhibition of PRC1-catalysed ubiquitination of 
H2AK119 and the recruitment of deubiquitinase USP16. Conditional KO of either Ring1B or 
Aurora kinase B resulted in reduced transcription of these genes and decreased cell viability 
(Frangini et al., 2013). 
A role of PRC2 complexes in gene activation has been also reported (Xu et al., 
2012b; Mousavi et al., 2012; Ferrari et al., 2013; Xu et al., 2015). For example, EZH1 
containing PRC2 complexes are recruited to newly activated genes and depletion of EZH1 
impaired the expression of these genes possibly through ablating a stimulatory interaction 
between EZH1 and elongating RNA polymerase II (Mousavi et al., 2012). 
1.3.4 Control of gene expression by chromatin interactions and modifications 
Figure 1.15 provides an overview of chromatin interactions and modifications that 
control gene expression, showing selected histone modifications and histone modifiers 
relevant for this project. 
Transcriptional activation of RNA-polymerase II-transcribed genes (Figure 1.15A) is 
often initiated by TF that bind to regulatory DNA sequences (e.g. distal enhancer elements 
or proximal promoter elements) and recruit co-activators such as HATs and histone 
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remodelling complexes. These catalyse activation-associated histone modifications such as 
histone 3 lysine 4 trimethylation (H3K4me3), histone 3 lysine 9 acetylation (H3K9ac) and 
histone 3 lysine 27 acetylation (H3K27ac) and reorganise nucleosomes making chromatin 
more accessible to chromatin-binding proteins. This also recruits the mediator complex that 
is comprised of 26 core subunits and is considered as bridging factor between TF and RNA 
polymerase II [reviewed in (Allen and Taatjes, 2015)]. Mediator and other factors (e.g. 
cohesin and CTCF) are thought to establish and/or stabilise long-range interactions (see 
Section 1.3.2.3) between distal enhancer elements and the TSS to promote initiation of 
transcription. For example, recently it was shown that mediator was recruited to the IgH 
locus during CSR and depletion of two mediator subunits impaired CSR possibly as a result 
of reduced frequency of long-range chromatin interactions between the IgH enhancer and 
the acceptor S region and reduced rate of transcription through the acceptor S region 
(Thomas-Claudepierre et al., 2016). The Mediator complex recruits and stabilises the RNA 
polymerase II pre-initiation complex. In the classical model of RNA polymerase II pre-
initiation complex assembly [reviewed in (Sainsbury et al., 2015)], the initiation factor TFIID, 
a multiprotein complex containing the TATA box-binding protein (TBP) and 13 distinct TBP-
associated factors (TAFs), binds to the TATA box ~30bp upstream of the TSS of TATA-
containing promoters, but probably also at TATA-less promoters. TFIIA and TFIIB binding on 
either side of TFIID stabilises the complex and facilitates binding of RNA polymerase II and 
TFIIF, which together form the core pre-initiation complex. Binding of TFIIE to RNA 
polymerase II promotes the recruitment of TFIIH, a complex of 10 subunits with energy-
dependent DNA helicase and kinase activity. TFIIH opens the DNA double helix and initiates 
transcription through phosphorylation of the C-terminal domain serine 5 residue of RNA 
polymerase II [reviewed in (Compe and Egly, 2012; Eick and Geyer, 2013)]. 
Gene expression can be repressed (Figure 1.15B) through the recruitment of HDACs, 
PRC1 and PRC2 resulting in histone deacetylation and deposition of the repressive histone 
modifications H2AK119ub and H3K27me3 (see Section 1.3.3.2.1). This can lead to a higher 
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nucleosome density, which makes the distal enhancer element inaccessible to DNA binding 
factors, disturbs the long-range enhancer-TSS interaction and prevents the assembly of the 
RNA polymerase II pre-initiation complex. 
 
Figure 1.15: Regulation of gene expression. 
(A+B) Chromatin is composed of nucleosomes, which consist of DNA (black line) wrapped around a 
histone octamer (blue circle) of two H3-H4 dimers and two H2A-H2B dimers. Histone modifiers 
catalyse posttranscriptional modifications (PTMs) on histone tails that can alter the chromatin state 
(active or repressed). (A) Active chromatin is characterised by a lower nucleosome density, which 
allows DNA-sequence-binding transcription factors (TF) to bind to distal enhancer elements (E) and to 
recruit co-activators that catalyse activation-associated histone marks, such as histone 3 lysine 4 
trimethylation (H3K4me3) and acetylation of H3K9 and H3K27 (H3K9ac and H3K27ac). Mediator and 
cohesin/CTCF promote long-range interactions (arrow) with the transcription start site (TSS). This 
allows the assembly of the RNA polymerase II pre-initiation complex at the TATA-box (see text for 
details) and initiation of transcription. (B) Histone deacetylases remove acetyl groups from histone 
residues and polycomb repressive complexes 1 and 2 (PRC1 and PRC2) catalyse histone H2A lysine 
119 ubiquitination (H2AK119ub) and histone 3 lysine 27 trimethylation (H3K27me3). This results in 
repressed chromatin with a higher nucleosome density, which makes the enhancer element 
inaccessible to TF binding and prevents the assembly of RNA polymerase II pre-initiation complex. 
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1.4 Background to this project 
1.4.1 Notch signalling pathway 
The Notch signalling pathway was first discovered in Drosophila, but is highly 
conserved across species and has an important role in developmental processes in 
embryonic and adult tissue, e.g. cell lineage decisions [reviewed in (Bray, 2006; Hori et al., 
2013)]. RBPJ is the nuclear DNA binding protein of the Notch pathway thought to stably bind 
to Notch target genes (Bray, 2006). 
In the absence of active Notch signalling, RBPJ represses these genes through 
interaction with TFIIA and TFIID (Olave et al., 1998), which prevents transcription, and also 
direct recruitment of repressor complexes containing HDAC1 and 2, SMRT/NcoR, 
SMRT/HDAC1-associated repressor protein (SHARP/MINT/SPEN), CBF1-interacting co-
repressor (CIR), CtBP, CtBP-interacting protein (CtIP) and KyoT2 (Kao et al., 1998; Hsieh et 
al., 1999; Oswald et al., 2002; 2005; Taniguchi et al., 1998). 
Activation of Notch signalling through ligand binding to the Notch receptors in the cell 
membrane induces a series of proteolytic cleavages of the Notch receptor, which result in 
the release of Notch intracellular domain (NICD) from the cell membrane (Mumm and 
Kopan, 2000; Fortini, 2002; Selkoe and Kopan, 2003). Cleaved NICD translocates into the 
nucleus where it binds to RBPJ via its RBPJ-associated molecule (RAM) domain WΦP (Φ = 
hydrophobic residue) motif (Tamura et al., 1995). Binding of NICD to RBPJ leads to the 
displacement of repressor complexes (Kao et al., 1998) and recruitment of the strong co-
activators Mastermind (Petcherski and Kimble, 2000a; b; Wu et al., 2000) and HATs, e.g. 
p300 (Kurooka and Honjo, 2000; Oswald et al., 2001; Wallberg et al., 2002). This forms a 
stable activating complex and induces the expression of the repressed Notch target genes. 
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1.4.2 Gene regulation by EBNA2 and EBNA3 family 
Neither EBNA2 nor EBNA3 proteins bind directly to DNA, but all bind to RBPJ. 
Therefore the following models of EBNA2-mediated gene activation and EBNA3-mediated 
gene repression were proposed (Figure 1.16). RBPJ alone stably binds to DNA and recruits 
co-repressors that inhibit gene expression (Figure 1.16A). Similar to NICD, EBNA2 binds to 
RBPJ via a RAM domain WWP motif, which is thought to displace co-repressors from RBPJ 
and to recruit co-activators through the transactivation domains of EBNA2 resulting in gene 
activation (Figure 1.16B). Therefore, EBNA2 operationally resembles NICD, but NICD 
cannot substitute for EBNA2 in maintaining LCL proliferation, so they are not completely 
equivalent [reviewed in (Zimber-Strobl and Strobl, 2001)]. 
EBNA3 proteins prevented EBNA2-mediated activation in transient reporter assays 
(Le Roux et al., 1994; Waltzer et al., 1996; Robertson et al., 1995), but only when they were 
able to bind to RBPJ (Radkov et al., 1997; Zhao et al., 1996). Concurrently, it was shown 
that EBNA3s compete with EBNA2 for binding to RBPJ and hence form mutually exclusive 
complexes with RBPJ (Robertson et al., 1995; Johannsen et al., 1996). Furthermore, binding 
of EBNA3s to RBPJ disrupted DNA binding of RBPJ in vitro, in electrophoretic mobility shift 
assays (Robertson et al., 1995; 1996; Waltzer et al., 1996). Therefore, a model was 
proposed in which binding of EBNA3s to RBPJ displaces EBNA2 and disrupts DNA-binding 
of RBPJ (Figure 1.16C), which therefore counteracts EBNA2-mediated gene activation 
(Robertson et al., 1995; 1996; Waltzer et al., 1996; Young and Rickinson, 2004; Hayward, 
2004; Hayward et al., 2006). Later, a model was proposed in which EBNA2 is also replaced 
by EBNA3s, but RBPJ remains statically bound to DNA and activators are replaced by 
repressors [Figure 1.16D, (Harth-Hertle et al., 2013; Wang et al., 2015)]. For the 
replacement model, no net change in RBPJ occupancy was observed when EBNA2 was 
replaced by EBNA3s (Wang et al., 2015). 
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Figure 1.16: Model of gene regulation by EBNA2 and EBNA3C. 
(A) RBPJ is bound to its binding site on DNA and recruits co-repressors that prevent gene 
expression. (B) EBNA2 binding to RBPJ replaces co-repressors and recruits co-activators that induce 
gene expression. (C+D) EBNA3C replaces EBNA2 as they bind to the same site on RBPJ. This was 
thought to either disrupt binding of RBPJ to DNA and thereby repressing gene expression through 
loss of co-activators (C) or to remain bound on DNA and to recruit co-repressors that actively inhibit 
gene expression (D). 
However, these models are far from complete or thoroughly proven using EBV-
recombinants and only describe EBNA2 as a potent transactivator and EBNA3 proteins as 
potent repressors without taking into account the fact that both can function as either 
repressor or activator. Therefore, it is fair to say that currently important aspects of the role 
of RBPJ in gene regulation by EBNA2 and EBNA3 proteins remain largely unknown. 
Interestingly, all genes analysed in EBNA2-mediated gene activation (e.g. CD21 and 
CD23) have been found to be strictly dependent on the presence of RBPJ, whereas EBNA2-
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mediated repression (IgM and BCL6) was only partially dependent on RBPJ (Maier et al., 
2005; 2006; Boccellato et al., 2007). Moreover, EBNA3C-mediated gene activation of the 
viral LMP1 promoter was independent of RBPJ, but required PU.1/SPI1 binding sites (Zhao 
and Sample, 2000; Lin et al., 2002). Therefore, it is tempting to speculate that RBPJ is 
required for EBNA2-mediated gene activation and EBNA3-mediated gene repression 
(models above) and that other factors (e.g. PU.1/SPI1 to which both EBNA2 and EBNA3C 
can bind) are involved in EBNA2-mediated repression and EBNA3C-mediated activation. 
Initial chromatin immunoprecipitation (ChIP) coupled to deep-sequencing (ChIP-Seq) 
experiments identified >5,000 EBNA2 binding sites and >10,000 RBPJ binding sites in IB4 
LCL that carry a deletion of EBNA3B (Zhao et al., 2011a). The majority (72%) of EBNA2 
binding sites overlapped with RBPJ binding sites, but only 14% were within 2 kb of a TSS. 
Furthermore, EBNA2 binding sites were enriched in motifs of other TF binding sites beside 
RBPJ, such as RUNX, early B cell factor (EBF) and PU.1. EBNA2 transactivation of the 
LMP1 promoter was shown to be dependent on an EBF binding site, because mutation of 
the EBF site strongly prevented EBNA2-mediated induction of the LMP1 promoter, whereas 
mutation of the previously identified PU.1 site completely abrogated EBNA2-induction (Zhao 
et al., 2011a). 
More recently and only after this study began, ChIP-Seq for EBNA2 and EBNA3s in 
the latency III BL cell line Mutu III identified >20,000 EBNA2 binding sites and >7,000 
EBNA3 binding sites, as determined using an antibody that recognizes all EBNA3 proteins 
(McClellan et al., 2013). There appeared to be a remarkable overlap between EBNA3 and 
EBNA2 binding sites, suggesting co-regulation by EBNA2 and EBNA3 proteins. Similar to 
results from Zhao et al., EBNA2 sites were enriched in DNA-recognition motifs for EBF1 and 
RBPJ, while EBNA3C sites were enriched in motifs for PU.1. Again only a small proportion 
of EBNA2 and EBNA3 binding sites were found proximal to the TSS, but are frequently 10-
50 kb away from the nearest TSS, suggesting the involvement of long-range chromatin 
interactions. McClellan and colleagues identified a binding site for EBNA2 and all EBNA3s 
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within the CTBP2 gene, which encodes one of the two homologues of CtBP, and proposed 
that EBNA3 proteins repress CTBP2 expression by preventing looping between the binding 
site and the CTBP2 promoter, while the absence of EBNA3A was sufficient to allow looping 
and correlated with increase expression of CTBP2. The role of EBNA2 at the binding site is 
not fully understand, but was proposed to weaken repression by competing with EBNA3s for 
access to the binding site, because re-ChIP experiments (ChIP with a one antibody, but 
instead of reversing the cross-links performing a re-ChIP with either the same or another 
antibody) did not detect chromatin with co-bound EBNA2 and EBNA3. In contrast, at the 
ADAM28-ADAMDEC1 locus, EBNA3A and EBNA3C were proposed to enable repressive 
chromatin looping between an intergenic EBNA3A and EBNA3C binding site and the 
promoters of ADAM28 and ADAMDEC1 (for more details see Chapter III: Gene repression 
by EBNA3C). In contrast, activating chromatin looping between enhancer elements and 
promoter has been shown during the epigenetic activation of the miR-221/miR-222 locus by 
EBNA3A and EBNA3C (Bazot et al., 2015). 
Other ChIP-Seq studies using HA and Flag-tagged EBNA3A (Schmidt et al., 2014) or 
EBNA3C (Jiang et al., 2013) identified 10,000 EBNA3A and >13,000 EBNA3C binding sites, 
again predominantly at distal regulatory elements. In contrast to EBNA2, however, only 16% 
of EBNA3A and EBNA3C binding sites overlapped with RBPJ binding sites (8-9% with joint 
EBNA2/RBPJ sites and 7-8% with RBPJ only sites), as determined by reanalysis of previous 
RBPJ ChIP-Seq (Zhao et al., 2011a). Therefore, RBPJ does not appear to be the main TF 
that tethers EBNA3 proteins to DNA, which could either support the disrupted DNA-binding 
model (Figure 1.16C) or indicate that EBNA3 proteins are mostly tethered to DNA by other 
TFs. Importantly, most EBNA3A and EBNA3C sites overlapped with ENCODE TF ChIP-Seq 
binding sites for RUNX3 (63-64%), BATF (55-65%) and IRF4 (41-44%) in LCL GM12878. 
Interestingly, highest EBNA3A signals were found at RUNX3 or BATF-IRF4 sites and 
highest EBNA3C signals at BATF-IRF4 and SPI1-IRF4 sites (Schmidt et al., 2014; Jiang et 
al., 2013). 
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Similarly, in another ChIP-Seq analysis of all EBNA3 proteins approximately 1600 
EBNA3A, 3000 EBNA3B and 3500 EBNA3C binding sites were identified (Wang et al., 
2015). Wang and colleagues also performed ChIP-Seq for RBPJ and reanalysed previous 
EBNA2 and RBPJ ChIP-Seq data (Zhao et al., 2011a). RBPJ binding was observed at 34% 
of EBNA3A, 43% of EBNA3B and 44% of EBNA3C binding sites, which is slightly higher 
than 16% in previous reports for EBNA3A and EBNA3C (Schmidt et al., 2014; Jiang et al., 
2013). Analysis of sites that display EBNA2, EBNA3 and RBPJ binding in cells with 
conditional EBNA3 proteins, showed that in the presence of functional EBNA3 proteins very 
little EBNA2 was found at these sites, whereas inactivation of EBNA3 proteins resulted in a 
switch to EBNA2 at these sites without affecting RBPJ occupancy, which supports the 
replacement model (Figure 1.16D). Consistent with the previous studies from Jiang et al. 
and Schmidt et al., EBNA3 binding sites largely overlapped with ENCODE TF ChIP-Seq 
binding sites for multiple TF (e.g. RUNX3, EBF1, PAX5, BATF, SP1 and IRF4) in LCL 
GM12878. Overexpression of IRF4 in BJAB cells, which express little IRF4, together with 
EBNA3C could increase binding of EBNA3C at some selected EBNA3C-bound sites, but 
IRF4 did not seem to affect binding of EBNA3A or EBNA3B at selected EBNA3A- or 
EBNA3B-target sites, respectively. 
In summary, at the beginning of this project, nothing was known about the genome-
wide distribution of EBNA3 proteins. It was only during the course of this project that multiple 
ChIP-Seq studies emerged on EBNA3 proteins [(McClellan et al., 2013; Schmidt et al., 2014; 
Jiang et al., 2013; Wang et al., 2015) and unpublished ChIP-Seq from our lab] in different 
cell lines either expressing un-tagged, Flag-HA-tagged or Strep-Flag-tagged EBNA3 
proteins. From these ChIP-Seq studies, it became apparent that EBNA2 and EBNA3 
proteins target predominantly distal regulatory elements and probably influence gene 
expression by modulating higher-order chromatin structures, but some gene promoters are 
also targeted directly. RBPJ is thought to be the main factor for EBNA2 recruitment as the 
majority of EBNA2 and RBPJ binding sites overlap (Zhao et al., 2011a), whereas RBPJ was 
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only seen at a minority of EBNA3 sites (Schmidt et al., 2014; Jiang et al., 2013; Wang et al., 
2015). Nevertheless, EBNA3s are still thought to compete with EBNA2 for binding to RBPJ 
and either disrupt DNA binding of RBPJ (Figure 1.16C) or replace EBNA2 (Figure 1.16D). 
However, in addition to RBPJ, other TFs such as RUNX3, BATF and IRF4 have been 
suggested to mediate DNA binding of EBNA3 proteins. Therefore, despite past and recent 
efforts in obtaining a better understanding of EBNA2 and EBNA3s in gene regulation, much 
is yet to be determined and our knowledge remains far from complete. 
1.4.3 Available recombinant EBV 
In order to study EBNA3C-mediated gene regulation, recombinant EBV were used 
during this project carrying modifications or defined mutations that are introduced in this 
section. B95-8 is the most commonly used EBV strain and in this study will be referred to as 
wild type (wt) strain. However, it is important to mention that this is a laboratory adapted 
strain that was selected for its transformation capacity of B cells in culture and has been 
passaged in marmoset lymphocytes. Compared to other EBV strains, B95-9 has a genomic 
deletion (Raab-Traub et al., 1980; Parker et al., 1990) that removed most of the EBV 
encoded miRs and one lytic origin of replication. B95-8 has been cloned into a BAC, which 
allowed the creation of recombinant EBV within E. coli (Delecluse et al., 1998). 
Figure 1.17A shows an overview of recombinant EBV used during this project. 
Recombinant knock-out (KO) EBV were created that lack each single EBNA3 individually 
(3AKO, 3BKO or 3CKO) or all three EBNA3s (E3KO) and their corresponding revertant, in 
which the deleted fragment has been re-introduced to assay for off-target secondary 
mutations that might have been introduced during the recombination and would differ from 
the wt. All KO and revertant viruses have been described (Anderton et al., 2007; White et al., 
2010). Fusion of tandem affinity purification (TAP) tags to the C-terminus of EBNA3A or 
EBNA3C introduced Flag and Strep tags that can be used to ChIP for the individual EBNA3 
(Paschos et al., 2012). Conditional EBNA3C (3CHT) contains a C-terminal fusion to a 
modified murine estrogen receptor that renders EBNA3C conditional to the presence of 4-
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hydroxytamoxifen (HT) in the culture medium (Skalska et al., 2010). In the absence of HT, 
EBNA3C is retained in the cytoplasm where it is inactive and degraded, whereas addition of 
HT to the culture medium allows the translocation of EBNA3C into the nucleus where it is 
stable and active. Furthermore, the RBPJ BM EBNA3C recombinant EBV has been created 
containing the 209AAAA and W227S (Figure 1.10B and C) mutations that almost completely 
prevent interaction between EBNA3C and RBPJ (Kalchschmidt et al., 2016). 
In order to produce infectious EBV virions (Figure 1.17B), these BACs are transfected 
into HEK293 cells and virus producer cell lines are established under hygromycin selection, 
which is encoded on the EBV BAC. Induction of the lytic cycle results in the production and 
secretion of infectious EBV recombinant virions into the supernatant, which can be used to 
infect B cells. 
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Figure 1.17: Overview of recombinant EBV available and production of infectious EBV virions. 
(A) Overview of recombinant EBV derivations from wild type B95.8 BAC. Knock-out viruses are 
deleted for either EBNA3A (∆3A), EBNA3B (∆3B), EBNA3C (∆3C) or all three EBNA3s (∆E3) and 
revertants contain reintroduction of previously deleted segments [described in (Anderton et al., 2007) 
and (White et al., 2010)]. Tandem affinitiy purification (TAP) are fused to the C-terminus of EBNA3A 
or EBNA3C and contain a Flag-2xStrep tags that can be used in ChIP [described in (Paschos et al., 
2012)]. Conditional EBNA3C contains a C-terminal fusion to modified estrogen receptor [described in 
(Skalska et al., 2010)]. RBPJ BM EBNA3C recombinant EBV has been created containing the 
209AAAA and W227S (Figure 1.10B) mutations that almost completely prevent interaction between 
EBNA3C and RBPJ [described in (Kalchschmidt et al., 2016)].(B) Recombinant EBV BACs are 
transfected in HEK293 cells and selected to establish a HEK293 producer cell line. Induction of the 
lytic cycle leads to the production and release of recombinant EBV virions into the supernatant. 
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1.4.4 Identification of EBNA3C target genes 
In order to select host genes that are potential direct targets of EBNA3C, a previous 
exon-microarray using the 3CHT conditional virus in a p16-null background was interrogated 
(Skalska et al., 2013). Due to the absence of p16 in these cells cellular proliferation does not 
decrease in the absence of functional EBNA3C, which allows direct comparison between 
cells with inactive and active EBNA3C. 
Table 1.1 and Table 1.2 list the top ten genes that are repressed or activated by 
EBNA3C. COBLL1 and AICDA are the two genes most repressed or activated by EBNA3C, 
respectively, and neither was previously reported as regulated by EBNA3C. Therefore, both 
genes were selected. However, nothing was known about the binding of EBNA3C to either 
locus and it was possible that both genes were indirect targets of EBNA3C. In contrast, 
ADAM28 and ADAMDEC1, the 2nd and 3rd most highly repressed genes by EBNA3C, were 
previously reported as regulated by EBNA3A and EBNA3C (see Section 3.1) and a study 
published shortly before the start of this project identified an EBNA3 binding site located in 
between the two adjacent ADAM28 and ADAMDEC1 genes (McClellan et al., 2012). For 
these reasons, the EBNA3C-repressed genes COBLL1, ADAM28 and ADAMDEC1 and the 
EBNA3C-activated gene AICDA were selected for investigation in this PhD project. 
Table 1.1: Top 10 genes repressed by EBNA3C 
# Gene name Genomic location * p-value Fold change 
1 COBLL1 chr2: 165,536,695 - 165,698,678 1.300E-12 -63.57 
2 ADAM28 chr8: 24,151,553 - 24,216,531 7.950E-08 -20.68 
3 ADAMDEC1 chr8: 24,241,798 - 24,263,526 1.399E-06 -17.36 
4 RP11-624C23.1 chr8: 24,158,398 - 24,769,586 8.995E-06 -13.69 
5 ANKMY2 chr7: 16,639,401 - 16,685,442 4.309E-07 -8.60 
6 TREM1 chr6: 41,242,999 - 41,254,457 4.797E-04 -6.40 
7 TSPAN13 chr7: 16,793,351 - 16,824,161 4.265E-09 -5.65 
8 PPM1L chr3: 160,473,996 - 160,788,817 1.417E-07 -4.04 
9 MUC15 chr11: 26,580,579 - 26,593,815 6.294E-05 -3.98 
10 EML5 chr14: 89,081,174 - 89,259,096 2.735E-06 -3.89 
* genomic location of RefSeq isoform 1 in case of multiple variants 
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Table 1.2: Top 10 genes induced by EBNA3C 
# Gene name Genomic location * p-value Fold change 
1 AICDA chr12: 8,754,762 - 8,765,442 2.852E-07 4.82 
2 TOX chr8: 59,717,977 - 60,031,767 2.573E-06 3.83 
3 RP4-678E16.4 chr1: 45,190,179 - 45,191,263 2.366E-04 3.41 
4 MOXD1 chr6: 132,617,194 - 132,722,673 1.553E-06 3.31 
5 GLYATL2 chr11: 58,601,540 - 58,611,997 1.003E-05 3.21 
6 ASCL1 chr12: 103,351,452 - 103,354,294 3.206E-04 3.21 
7 SLCO4C1 chr5: 101,569,692 - 101,632,253 2.223E-05 3.17 
8 HNRPLL chr2: 38,790,328 - 38,830,178 6.349E-05 3.15 
9 SPRED2 chr2: 65,537,985 - 65,659,656 2.810E-06 3.12 
10 CD1C chr1: 158,259,563 - 158,264,564 2.432E-04 3.09 
* genomic location of RefSeq isoform 1 in case of multiple variants 
 
1.5 Aims of this PhD project 
Our current understanding of the mechanisms underlying EBNA3C-mediated gene 
regulation is very limited. Therefore, the aims of this PhD project were to analyse: 
1. Mechanisms involved in EBNA3C-mediated repression of COBLL1, ADAM28 
and ADAMDEC1 
2. Mechanisms involved in EBNA3C-mediated activation of AICDA 
  
Chapter II: Materials and Methods 
 88 
2 Chapter II: Materials and Methods 
2.1 Solutions and buffers 
All solutions were prepared in Milli-Q-H2O, unless stated otherwise. 
 
Alkaline SDS 
1 % (w/v) SDS 
0.2 M  NaOH 
 
Blocking solution for western blot 
5 % (w/v) Skim milk powder (Sigma) in PBS-Tween 
 
ChIP SDS Lysis buffer (Millipore) 
50 mM  Tris, pH8.1 
10 mM  EDTA 
1 % (w/v) SDS 
 
ChIP Dilution buffer (Millipore) 
16.7 mM Tris-HCl, pH 8.1 
167 mM NaCl 
1.2 mM  EDTA 
1.1 % (v/v) Triton-X-100 
0.01 % (w/v) SDS 
 
ChIP swelling buffer 
25 mM  HEPES, pH 7.8 
1.5 mM  MgCl2 
10 mM  KCl 
0.1% (v/v) NP-40 
1 mM  DTT  (add immediately prior to use) 
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ChIP sonication buffer 
50 mM  HEPES, pH 7.8 
140 mM NaCl 
1 mM  EDTA, pH 8 
1 % (v/v) Triton X-100 
0.1 % (w/v) Sodium deoxycholate 
0.1 % (w/v) SDS 
 
ChIP low salt buffer (Millipore) 
20 mM  Tris-HCl, pH 8 
150 mM NaCl 
2 mM  EDTA, pH 8 
1 % (v/v) Triton X-100 
0.1 % (w/v) SDS 
 
ChIP high salt buffer (Millipore) 
20 mM  Tris-HCl, pH 8 
500 mM NaCl 
2 mM  EDTA, pH 8 
1 % (v/v) Triton X-100 
0.1 % (w/v) SDS 
 
ChIP LiCl buffer (Millipore) 
10 mM  Tris-HCl, pH 8 
250 mM LiCl 
1 mM  EDTA, pH 8 
1 % (v/v) NP40 
1 % (w/v) Sodium deoxycholate 
 
DNA sample loading buffer (6x) 
30% (v/v) Glycerol 
0.15% (w/v) Bromophenol blue 
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β-estradiol 
1 mM β-estradiol (1,000x) resuspended in 100% ethanol was a gift from Claudio 
Elgueta Karstegl (Paul Farrell laboratory) and was kept at 4°C in the dark. 
 
4-Hydroxytamoxifen 
4mM (10,000x) stock was prepared by resuspending 5mg of 4-hydroxytamoxifen 
(Sigma) in 3.22 ml of 100% ethanol. Aliquots were stored at -20°C in the dark. 
 
KPB (20x) 
4.6 % (w/v) KH2PO4 
24.3 % (w/v) K2HPO4 
 
LB 
1% (w/v) Bacto-tryptone 
0.5% (w/v) Yeast extract 
1% (w/v) NaCl 
Autoclave and store at room temperature. 
 
LB-Agar 
1% (w/v) Bacto-tryptone 
0.5% (w/v) Yeast extract 
1% (w/v) NaCl 
1.5% (w/v) Agar 
Autoclave and store at room temperature. 
 
PBS 
10 mM  Phosphate buffer, pH 7.4 
2.7 mM  KCl 
137 mM NaCl 
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PBS-Tween 
0.1 % Tween-20 (Sigma, UK) in 1xPBS 
 
Peptide 6 
Re-suspend 50 mg peptide 6 in 50ml OptiMEM I (Life technologies) in autoclaved 
flask under sterile conditions and leave covered with aluminium foil overnight in 
fridge, before aliquoting in sterile cryovials and storage at -80°C. 
 
PMFS 
100 mM of PMSF resuspended in isopropanol and stored at -20°C 
 
RIPA (5x) 
250 mM Tris-HCl, pH 8.0 
750 mM NaCl 
5% (v/v) NP40 
2.5% (w/v) Sodium deoxycholate 
0.5% (v/v) SDS 
Autoclave and store at room temperature. 
 
SDS-PAGE running buffer (10x) 
250 mM Tris 
1.92 M  Glycine 
1% (w/v) SDS 
 
SDS-PAGE sample loading buffer (5x) 
250mM  Tris-HCl, pH6.8 
50% (v/v)  Glycerol 
10% (w/v) SDS 
5% (v/v) β-mercaptoethanol 
0.1% (w/v) Bromophenol blue 
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SDS-PAGE transfer buffer 
10%  10x SDS-PAGE running buffer 
23.3% (v/v)  Ethanol 
 
STET 
8 % (w/v) Sucrose 
0.1 % (v/v) Triton-X-100 
50 mM  EDTA, pH 8 
50 mM  Tris, pH 8 
 
Superbroth 
1.2 % (w/v) Bactotryptone 
2.4 % (w/v) Yeast extract 
0.4 % (v/v) Glycerol 
Autoclave and store at room temperature. Add KPB before usage. 
5 % (v/v) 20x KPB (sterile filtered) 
 
10x TBE buffer 
0.89 M  Tris 
0.89 M  Boric acid 
20 mM  EDTA 
 
TE buffer 
10 mM  Tris-HCl, pH 8 
1 mM  EDTA, pH 8 
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2.2 Cell culture 
2.2.1 Cell lines and culture conditions 
All cell lines were cultured in RPMI 1640 medium (Life Technologies) supplemented 
with 10% FBS (Gibco), penicillin and streptomycin except for the following adjustments. 
Adherent HEK293 virus producers were grown in the presence of additional 2 mM L-
Glutamine (Life Technologies) and 100 µg/ml hygromycin B (Roche). Newly infected primary 
B cells were cultured in the presence of 15% FBS. LCLs with conditional EBNA3C were 
grown either in absence or presence of 400nM HT. EREB 2-5 cells with conditional EBNA2 
were cultured in the presence of 1 µM β-estradiol. All cells were incubated at 37°C and 10 % 
CO2 in a humidified incubator. Suspension cells were passaged two to three times per week 
by diluting appropriately in fresh warmed medium. Adherent cell lines (HEK293) were split 
twice weekly. For this, cells were washed once in warm PBS and incubated with 0.05% 
trypsin/EDTA (Invitrogen) at 37°C until cells detached. Fresh medium was added and cells 
were transferred into a new flask depending on the density of the parental flask. Table 2.1 
lists all cell lines used in this project.  
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Table 2.1: Cell lines used in this project 
Cell line name Cell type Description Reference 
HEK293 wtI6 HEK293 Wild type EBV producer  
Del3A-M11 30-3 HEK293 3AKO EBV producer 
(Anderton et al., 2007) 
HB9-r3A-M4 HEK293 3ARev EBV producer 
Del3B-C14 HEK293 3BKO EBV producer 
HB9-r3B-M8 HEK293 3BRev EBV producer 
Del3C-M12 30-3 HEK293 3CKO EBV producer 
HB9-r3C-M15 HEK293 3CRev EBV producer 
E3KO-C34 HEK293 E3KO EBV producer 
(White et al., 2010) 
E3Rev-C2 HEK293 E3Rev EBV producer 
LCL JK1 wtI6 LCL Wild type I6 from 1°B infection 
This study 
LCL JK1 3AKO M11 30-3 LCL 3AKO from 1°B infection 
LCL JK1 3ARev M4 LCL 3ARev from 1°B infection 
LCL JK1 3BKO C14 LCL 3BKO from 1°B infection 
LCL JK1 3BRev M8 LCL 3BRev from 1°B infection 
LCL JK1 3CKO M12 30-3 LCL 3CKO from 1°B infection 
LCL JK1 3CRev M15 LCL 3CRev from 1°B infection 
LCL D11 wt LCL Wild type in D11  
LCL D11 04 AC1 LCL TAP-tagged EBNA3C in D11 (Paschos et al., 2012) 
LCL D11 05 AC21 LCL TAP-tagged EBNA3A in D11  
LCL∆p16 3CHT A13 
never 
LCL p16
INK4A-null, EBNA3C-
conditional (Skalska et al., 2013) 
LCL∆p16 3CHT C19C2 
washed 
LCL p16
INK4A-null, EBNA3C-
conditional 
EREB 2-5 LCL Conditional EBNA2 (Kempkes et al., 1995) 
GM12878 LCL Tier 1 ENCODE  
DG75 BL EBV-negative (Ben-Bassat et al., 1977) 
DG75 RBPJ KO BL EBV-negative, lacking RBPJ (Maier et al., 2005) 
Ramos BL EBV-negative (Klein et al., 1975) 
Raji BL EBV-positive, EBNA3C-null (Epstein et al., 1966; 
Allday et al., 1993) 
Akata BL EBV-positive, latency I (Takada et al., 1991) 
Oku BL EBV-positive, Wp-restricted (Kelly et al., 2002) 
Namalwa BL EBV-positive, latency III (Klein et al., 1972) 
BJAB B cell lymphoma 
EBV-negative, initially 
described as BL, but lacking 
the cMYC:Ig translocation 
(Klein et al., 1976; Glazer and 
Summers, 1985) 
(Menezes et al., 1975) 
K562 CML EBV-negative (Lozzio and Lozzio, 1975) 
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2.2.2 Freezing and thawing cells 
For long-term storage of cells in liquid nitrogen, suspension cells were split the day 
before freezing and adherent cell lines were frozen at the time of passaging. For this, cells 
were pelleted at 1300 rpm for 4 min and 4°C (Megafuge 40R, Thermo Scientific) and re-
suspended in RPMI 1640 medium (Life Technologies) supplemented with 20 % FBS (Gibco) 
and 10 % DMSO (VWR Chemicals). Cells were transferred into sterile cryovials, placed into 
a Nalgene Mr. Frosty™ Freezing Container filled with isopropanol, stored at -80°C overnight 
before being transferred to liquid nitrogen. 
To recover cells from liquid nitrogen, cryovials were rapidly thawed in a water bath at 
37°C and slowly added into 10 ml of culture medium. Cells were pelleted, the medium 
aspirated to remove the DMSO and the cells resuspended in fresh medium. Recovered cells 
from liquid nitrogen were cultured for at least one week before the start of any experiment. 
2.2.3 Harvesting cells 
For all experiments, unless stated otherwise, on the day prior to harvesting, viable 
cell counts were performed under a light microscope using a Neubauer improved 
haemocytometer. For this, cells were diluted 1:1 with 0.4% trypan blue (Sigma) and live cells 
that do not incorporate the blue dye were counted. Suspension cells were seeded at a 
density of 3x105 cells/ml. The next day, for RNA or protein extraction, cells were pelleted at 
1300 rpm for 4 min and 4°C (Megafuge 40R, Thermo Scientific) and washed once with ice 
cold PBS. The supernatant was aspirated, cell pellets resuspended in 1 ml ice cold PBS and 
transferred into 1.5 ml tubes. Cells were centrifuged at 2000 rpm for 5 min (5424R, 
Eppendorf) and the supernatant removed to obtain dry cell pellets. Samples for protein 
extraction were immediately snap frozen on dry ice. For RNA extraction, dry cell pellets were 
lysed by vortexing in RLT buffer containing 1% (v/v) β-mercaptoethanol and snap frozen on 
dry ice. Samples were stored at -80°C until further extraction. 
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2.2.4 Time-course experiments 
2.2.4.1 EBNA3C-conditional LCL 
EBNA3C conditional LCLs (3CHT) on the p16-null background were used for multiple 
time-course experiments (Skalska et al., 2013). 
LCL∆p16 3CHT A13 never (referred to as 3CHT A13) was established in the absence 
of HT and used in an initial time-course experiment over 60 days with samples harvested for 
RNA, protein and ChIP every three days over the first 30 days and every ten days until day 
60. For this, cells were counted and diluted to 3x105 cells/ml at every time point until day 30 
and three times a week subsequently, but seeded at 3x105 cells/ml the day prior to 
harvesting. After harvesting cells on day 30, half of the +HT culture was centrifuged and the 
medium replaced by fresh medium without HT and cultured without HT until day 60 
(washed). 
Replicate time-courses using again 3CHT A13 but also LCL∆p16 3CHT C19C2 
washed (referred to as 3CHT C19) were used in time-course experiments over 30 days. 
3CHT C19 were established in the presence of HT, washed and subsequently grown without 
HT in the medium for more than three months before the experiment was started. Samples 
for RNA, protein and ChIP were harvested on day 0, 3, 6, 9, 15 and 30, but this time, cells 
were counted and split to 3x105 cells/ml one day before harvesting. 
2.2.4.2 EBNA2-conditional LCL 
EREB 2-5 cells are LCLs that were established by co-infection of umbilical cord blood 
B cells with the EBNA2-deleted P3HR1 EBV strain and a recombinant mini-EBV genome 
carrying an estrogen receptor-EBNA2 fusion protein, which renders EBNA2 conditional to 
the presence of β-estradiol in the medium (Kempkes et al., 1995). Cells were cultured in the 
presence of 1 µM β-estradiol and samples for RNA, protein and ChIP were taken. EBNA2 
was inactivated by removing β-estradiol from the media by washing the cells twice with β-
estradiol-free medium before re-suspending the cells in β-estradiol-free medium. RNA, 
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protein and ChIP samples were taken on day 1, day 2 and day 3 after removal of β-estradiol. 
EBNA2 was re-activated through re-addition of β-estradiol to the cells and additional 
samples were taken 2, 4, 8, 24 and 48 hours post re-addition. 
2.3 Validation of HEK293 EBV producing cell lines and virus production 
2.3.1 Validation of HEK293 EBV producing cell lines by episomal rescue 
Before producing recombinant EBV from HEK293 virus producing cell lines (Anderton 
et al., 2007), the identity and integrity of the recombinant EBV BACs was validated for each 
cell line. For this, recombinant EBV BACs were extracted from HEK293 virus producing cell 
lines, transformed into E. coli, extracted from single E. coli colonies, restriction enzyme 
digested and analysed by pulsed-field gel electrophoresis. 
2.3.1.1 Extraction of EBV BACs from HEK293 virus producers 
During the passaging of HEK293 virus producing cell lines, cells were washed in PBS 
and pelleted. The cell pellet was re-suspended thoroughly in 60 µl STET and cells were 
lysed by addition of 130 µl alkaline SDS while vortexing. Lysis was stopped by neutralisation 
with 110 µl 7.5 M ammonium acetate, again added while vortexing. The mixture was 
incubated on ice for 5 min and centrifuged at 13,000 rpm and 4°C for 30 min. The 
supernatant was transferred into a 1.5 ml MaXtract High Density Gel tube (Qiagen), 200 µl 
of Phenol:Chloroform:Isoamyl alcohol (25:24:1, Sigma) was added and the tube rapidly 
inverted for 30 sec. The mixture was centrifuged at 10,000 rpm for 6 min and the upper 
aqueous phase was transferred into a new MaXtract High Density Gel tube using cut-off tips 
to avoid shearing of the episomes. DNA was washed with 200 µl chloroform as described 
above and the aqueous phase was transferred into a fresh 1.5 ml tube after centrifugation. 
DNA was precipitated by addition of 670 µl of 100% ethanol and 20 min centrifugation at 
maximum speed. Precipitated DNA was washed with 200 µl of 70% ethanol and 5 min 
centrifugation at maximum speed. The DNA pellet was air-dried for 15 min, re-suspended in 
50 µl TE buffer containing 5 µg/ml RNase A and kept at 4°C. 
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2.3.1.2 Transformation of recombinant EBV BACs into E. coli 
Cut-off tips were used to add 1 µl of the extracted EBV BACs to 20 µl of Electromax 
electrocompetent DH10B E. coli (Invitrogen). Bacteria were kept on ice and electroporated 
at 1.8 kV, 25 µFD and 200 Ω using Gene pulser (BioRad). Electroporated bacteria were 
recovered in 400 µl of SOC (Invitrogen) and incubated at 37°C for one hour on an orbital 
shaker. Bacteria were plated on LB agar containing chloramphenicol and incubated 
overnight at 37°C. 
2.3.1.3 Extraction of EBV BACs from E. coli 
Single E. coli colonies were used to inoculate 1.5 ml superbroth (SB) containing 
chloramphenicol and grown at 37°C overnight on an orbital incubator. Bacteria were pelleted 
at 2,500 rpm for 5 min and room temperature and were re-suspended in 70 µl STET by 
vortexing. Bacteria were lysed with 200 µl of alkaline SDS (added while vortexing), which 
was neutralised by addition of 150 µl of 7.5 M ammonium acetate (again added while 
vortexing). Samples were incubated for 5 min on ice and centrifuged at 13,000 rpm and 4°C 
for 20 min. The supernatant was transferred into a new 1.5ml tube and DNA was 
precipitated by addition of 240 µl isopropanol and inversion of the tube. DNA was pelleted at 
10,000 rpm for 6 min and room temperature and washed in 200 µl of 70 % ethanol. The 
pelleted DNA was air-dried for 10 min and re-suspended in 50 µl TE containing 5 µg/ml 
RNase A. Re-suspended DNA was stored at 4°C until analysis by restriction enzyme 
digestion. 
2.3.1.4 Restriction enzyme digestion 
In a 15 µl reaction, 5 µl of recovered episomal DNA was digested with EcoRI 
(assessment of episome integrity) and ClaI (assessment of identity of virus producer) using 
standard New England BioLabs restriction enzyme digestion protocols. 
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2.3.1.5 Pulsed-field gel electrophoresis 
CHEF-DR II system (BioRad) was used to run pulsed-field 1 % agarose gel 
electrophoresis. Agarose was dissolved in 0.5x TBE and gels were run in 2 litres of 0.5x 
TBE. λ DNA-BstEII digest (NEB) and λ DNA-Mono cut mix (NEB) were used in a 1:1 mixture 
as DNA size ladder and heated to 50°C for 10 min before loading onto the gel. Digested 
episomes were mixed with 6x agarose gel loading buffer and run alongside the DNA size 
ladder for 13 hours and 14°C with 6V/cm and 1 sec initial sweep time and 10 sec final sweep 
time. The gels were stained with 0.5 µg/ml ethidium bromide in 0.5x TBE for 30 min with 
gentle agitation and visualised on a Gel Doc XR+ system (BioRad). 
2.3.2 Virus production 
Once the integrity of the BACs and the identity of the HEK293 virus producing cell 
lines were confirmed, infectious viral particle were produced. 
2.3.2.1 Transfection and harvest 
Virus production was induced by transfecting pCMV-EB1 and pBALF4 expression 
plasmids (from Dr Rob White) using the LID (lipofectin/integrin-targeting peptide/DNA) 
method (Hart et al., 1998). HEK293 virus producer cell lines were seeded in a 10 cm dish. 
Two days later, 9 µl Lipofectin Reagent (Invitrogen) and 480 µl Peptide 6 were mixed and 
pre-incubated for at least 5 min. pCMV-EB1 and pBALF4 plasmids (6 µg each) were 
dissolved in 1.2 ml OptiMEM I (Invitrogen) and added to the Lipofectin/Peptide 6 solution. 
This LID mixture was incubated for at least 20 min before adjusting the total volume to 5 ml 
with OptiMEM I. The medium of the seeded HEK293 virus producer cell lines was replaced 
by the 5 ml LID mix and cells were incubated with the LID mix for at least 6 hours at 37°C, 
after which the transfection mix was replaced by 10 ml of fresh medium without hygromycin 
selection and cells incubated for four days. Supernatants containing viral particles were then 
harvested through MF-Millipore 0.45 µm filters (Millex-HA, Millipore). 
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2.3.2.2 Virus titration 
The virus titre of the supernatants was determined by infection of Raji cells and 
counting GFP expressing cells [green Raji units (GRU), (Dirmeier et al., 2003)] on an 
inverted fluorescent microscope 3 days after infection and 24 hours after treatment with 
20 nM 12-O-tetradecanoylphorbol-13-acetate and 5 mM sodium butyrate. 
2.4 Isolation and infection of primary B cells 
2.4.1 Isolation of primary B cells 
Peripheral blood mononuclear cells (PBMC) were isolated from buffy coat residues 
(UK national blood transfusion service) by centrifugation over Ficoll-Paque. To isolate 
primary B cells, 109 PBMC were incubated with 500 µl CD19 microbeads (Miltenyi Biotec) 
and separated using AutoMACS Separator (Miltenyi Biotec). Purified B cells were re-
suspended at 2x106 cells/ml in RPMI/15% FBS medium and incubated at 37°C and 5% CO2. 
The next day, B cell purity was assessed using anti-CD20-APC (eBioscience) staining and 
flow cytometric analysis. 
2.4.2 Infection of primary B cells with recombinant EBV 
Three million primary B cells in 1.5 ml were infected with 0.5 ml of supernatant 
containing the following EBV viruses: wild type I6 (1.1x105 GRU), EBNA3A KO (2.7x105 
GRU), EBNA3A Rev (3.5x105 GRU), EBNA3B KO (2.0x105 GRU), EBNA3B Rev (1.4x105 
GRU), EBNA3C KO (1.1x105 GRU), EBNA3C Rev (1.9x105 GRU), EBNA3A/B/C KO 
(3.4x105 GRU), and EBNA3A/B/C Rev (3.9x105 GRU). RNA from three million uninfected 
primary B cells was taken on the day of infection and infected cells were incubated at 37°C 
and 5% CO2. For a period of 30 days, every three days 0.5 ml of cells were harvested for 
RNA extraction and replaced by fresh medium. After this, cells were, where possible, grown 
into LCL and analysed by western blotting. 
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2.5 Reverse transcription quantitative PCR (RT-qPCR) 
Total RNA was isolated either from freshly harvested cells, from frozen cell lysates in 
RLT buffer stored at -80°C or cell pellets stored at -80°C. For cells harvested during the 
course of the primary B cell infections, total RNA including miRNA was extracted using 
miRNeasy Mini Kit (Qiagen) according to the manufacturer’s protocol. Otherwise, RNA was 
extracted using RNeasy Mini Kit (Qiagen) according to the manufacturer’s protocol. Both 
extractions included the optional on column digestion of genomic DNA using RNase-free 
DNase set (Qiagen). RNA was eluted in RNase-free water (Qiagen) and extracted RNA was 
quantified using a Nanodrop Lite spectrophotometer (Thermo Scientific). 
Reverse transcription was performed on up to one microgram of RNA using 
SuperScript III first strand synthesis super mix (Invitrogen) according to the manufacturer’s 
instructions and at a cDNA synthesis temperature of 59°C. cDNA was RNase H treated and 
diluted with RNase-free water (Qiagen) to a final concentration of 5 ng/µl, assuming 
complete conversion of RNA into cDNA. 
For the quantitative PCR (qPCR) 10 ng of cDNA was used in a final reaction volume 
of 10 μl containing 5 μl Platinum SYBR Green qPCR SuperMix-UDG kit (Invitrogen) and 
200nM of RT-qPCR primers (Table 2.2). cDNA was assayed by qPCR on QuantStudio 7 
Flex (Life technologies). The qPCR programme included an initial denaturation step for 2 
min at 95°C, followed by 40 qPCR cycles with denaturation for 3 sec at 95°C and primer 
annealing and elongation for 30 sec at 60°C. Dissociation curves were used to assess the 
specificity of PCR products. Efficiency of the primer was initially assed by serial dilution of 
pooled cDNA samples. As negative qPCR controls, reverse-transcribed RNase-free water 
(Qiagen) was used with the same qPCR Master mix as the samples. Each sample was run 
in triplicates and GAPDH or GNB2L1 were used as endogenous controls. Relative gene 
expression was calculated using the 2-∆∆Ct method (Schmittgen and Livak, 2008) with      
∆∆Ct = (Ct gene of interest – Ct endogenous control)Sample A – (Ct gene of interest – Ct endogenous control)Sample B. 
Chapter II: Materials and Methods 
 102 
Table 2.2: Sequences of RT-qPCR primers 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) Reference 
ADAM28 GTTGCAGGGACAATGGCACA TGAGACGGCTGCAGGAACTG 
This study ADAMDEC1 CCTTGGTATGCCTGATGTTCCA CAGCAGGCACTTTGGTTTCTGA 
AICDA AGCCGTTCTTATTGCGAAGA TGATGAACCGGAGGAAGTTT 
ALAS1 TCCACTGCAGCAGTACACTACCA ACGGAAGCTGTGTGCCATCT (Bazot et al., 2015) 
BCL6 CTGCAGATGGAGCATGTTGT TCTTCACGAGGAGGCTTGAT (Tran et al., 2010a) 
COBLL1 CTGTTCAGCTGACAACAGATCG ACGTTGAACTCTCAGTGGTCCT This study 
GAPDH Hs_GAPDH_2_SG QuantiTect Primer Assay, QT01192646 Qiagen 
GNB2L1 GCTTGCAGTTAGCCAGGTTC GAGTGTGGCCTTCTCCTCTG (Zhang et al., 2005) 
miR155-HG GAGACGCTCCTGGCACTGC TAAACCACAGATTTCCCCTTCCTGG (van den Berg et al., 2003) 
 
2.6 Western blotting 
Protein was extracted from freshly harvested or frozen cell pellets stored at -80°C 
using 1x RIPA buffer containing 1 mM PMSF and complete protease inhibitor cocktail 
(Roche). Lysates were left on ice for 5 min and cleared by centrifugation at 14,000 rpm for 
15 min at 4°C. The supernatant was transferred into a fresh tube. The protein concentration 
was determined with the DC protein assay (Bio-Rad) and measured on a Helios 
spectrophotometer (Thermo Scientific) against bovine serum albumin as standard. 
Generally, 30 µg of total protein of each sample were mixed with SDS-PAGE sample loading 
buffer (1x final concentration) and heated to 100°C for 5 min. Gels with an appropriate 
percentage for the molecular weight of the protein to be analysed were prepared according 
to Table 2.3. Spectra™ Multicolor Broad Range Protein Ladder (Thermo Scientific) was 
used on each gel as reference for the molecular weight and protein samples were separated 
for one hour at 150V using Mini-PROTEAN® II Electrophoresis Cell (Bio-Rad) containing 
1xSDS-PAGE running buffer. Samples were transferred on Whatman nitrocellulose 
membranes (GE Healthcare) at 100V for one hour in Mini Trans-Blot Module (Bio-Rad) 
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containing SDS-PAGE transfer buffer. Membranes were blocked in SDS-PAGE blocking 
solution for at least 15 min. Primary antibodies were diluted in SDS-PAGE blocking solution 
as shown in Table 2.4 and incubated over night at 4°C with shaking. Membranes were 
washed three times for 5-10 min with PBS-Tween and incubated at room temperature for 
one hour with appropriated secondary antibodies diluted in SDS-PAGE blocking solution 
(Table 2.5). Again, membranes were washed three times for 5-10 min with PBS-Tween. 
Membranes were briefly incubated with Amersham ECL western blotting detection reagents 
(RPN2106V1 and RPN2106V2, GE Healthcare), exposed on Amersham Hyperfilm MP (GE 
Healthcare) and developed on automatic X-ray film processor JP-33 (JPI). 
 
Table 2.3: Composition of resolving and stacking gels for SDS-PAGE 
Resolving gel 7.5 % 10 % 12 % Stacking gel  
1 M Tris, pH 8.8 2.96 ml 2.96 ml 2.96 ml 1 M Tris, pH 6.8 620 µl 
30 % Acrylamide/Bis 
solution 37.5:1 1.98 ml 2.64 ml 3.3 ml 
30 % Acrylamide/Bis 
solution 37.5:1 828 µl 
ddH2O 2.96 ml 2.3 ml 1.64 ml ddH2O 3.47 µl 
10 % SDS 79.2 µl 79.2 µl 79.2 µl 10 % SDS 49.6 µl 
15 % APS 26.4 µl 26.4 µl 26.4 µl 15% APS 24.8 µl 
TEMED 5.3 µl 5.3 µl 5.3 µl TEMED 5 µl 
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Table 2.4: Primary antibodies for western blotting 
Protein 
recognised Species and type Source 
Catalogue 
number Dilution Reference 
AID Rat monoclonal eBioscience mAID-2 1:1000  
BMI1 Rabbit polyclonal Bethyl A301-694A 1:1000  
COBLL1 Rabbit polyclonal Abcam ab64465 1:2000  
EBNA2 Mouse monoclonal Abcam ab90543 1:500  
EBNA3A Sheep polyclonal Abcam ab16126 1:1000  
EBNA3B Rat monoclonal Dr. Elizabeth Kremmer 6C9 1:10 
(White et al., 
2010) 
EBNA3C Mouse monoclonal Prof. Martin Rowe  A10 1:10 (Maunders et al., 1994) 
γ-tubulin Mouse monoclonal Sigma T6557 1:8000  
HA tag Mouse monoclonal Covance MMS-101R 1:1000  
LMP1 Mouse monoclonal Dako M0897  1:500  
p16 Mouse monoclonal Prof. Gordon Peters JC8 1:10  
Rb Mouse monoclonal BD Pharmingen 554136 1:500  
Rb (phospho 
S807/811) Rabbit polyclonal Cell Signaling 9308S 1:500  
RBPJ Rat monoclonal Prof. Bettina Kempkes J7A11-161 1:100 
(Maier et al., 
2005) 
SUZ12 Goat polyclonal Santa Cruz SC46264 1:1000  
 
Table 2.5: Secondary antibodies for western blotting 
Antibody Source Catalogue number Dilution 
ECL sheep anti-mouse IgG HRP GE Healthcare NA931V 1:2000 
Polyclonal rabbit anti-sheep Ig/HRP Dako P0163 1:2000 
Polyclonal goat anti-rabbit Ig/HRP Dako P0448 1:2000 
Polyclonal rabbit anti-goat Ig/HRP Dako P0449 1:2000 
Polyclonal rabbit anti-rat Ig/HRP Dako P0450 1:2000 
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2.7 Chromatin immunoprecipitation (ChIP) 
For ChIPs, cells were split to 3x105 cells/ml the day prior to crosslinking multiples of 
15 ml (~4.5x106 cells) with 1% formaldehyde (Sigma, UK) for 10 min at either 37°C or room 
temperature. Cells were washed twice in ice-cold PBS containing 1 mM PMSF, 1 µg/ml 
aprotinin (Roche) and 1 µg/ml pepstatin A (Roche). The equivalent of 4.5x106 cells was 
pelleted in one 1.5 ml tube and snap-frozen on dry ice. Samples were stored at -80°C. Per 
ChIP chromatin of 1.5x106 cells was used, so each tube provided enough material for three 
ChIPs. 
All ChIP buffers used in this paragraph were supplemented with 1 mM PMSF, 1 
µg/ml aprotinin (Roche) and 1 µg/ml pepstatin A (Roche) immediately prior to use and 
sample were kept on ice or 4°C until the elution from the beads. For ChIPs assaying histone 
modifications and SUZ12, chromatin was extracted in 300 µl ChIP SDS Lysis buffer and was 
sheared using a Bioruptor UCD-200 sonicator (Diagenode) at the highest setting for 12.5 
min in pulses of 0.5 min (0.5 min on and 0.5 min off). Samples were then diluted 10-fold in 
ChIP Dilution buffer and 950 µl were used for each ChIP with 50 µl kept aside as input. For 
ChIPs against anti-Flag, BMI1, p300 and RBPJ, thawed cells were incubated in 1 ml 
swelling buffer under rotation for 20 min at 4°C. Nuclei were resuspended in 1 ml sonication 
buffer, left on ice for a minimum of 30 min and sonicated for one hour using a M220 focused 
sonicator (Covaris) with 75 W peak power, 26 duty cycle, 200 cycles/burst and 6°C set 
temperature. Samples were then adjusted to 3 ml using ChIP sonication buffer and 950 µl 
were used for each ChIP with 50 µl kept aside as input. Sheared chromatin from Bioruptor 
UCD-200 or M220 sonication was initially verified for size by agarose gel electrophoresis. 
Thereafter, the ChIP assay kit from Millipore (17-295) was used, essentially 
according to the manufacturer’s protocol. Protein A Agarose/Salmon Sperm DNA beads (16-
157, Millipore) were used to IP rabbit-derived antibodies, Protein G Agarose/Salmon Sperm 
DNA beads (16-201, Millipore) were used to IP mouse-derived antibodies and protein G 
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magnetic beads (9006BC, Cell signaling) were used to IP the anti-Flag antibody. QIAquick 
PCR purification kit (28106, Qiagen) was used to purify DNA fragments instead of 
phenol/chloroform extraction in the manual. DNA was assayed by qPCR on QuantStudio 7 
Flex (Life technologies) using Platinum SYBR Green qPCR SuperMix-UDG kit (11733-046, 
Life Technologies) and 200nM of ChIP primer. Input DNA was 5% of DNA used in ChIPs 
and was diluted to 2.5% prior to PCR quantification. The qPCR programme included an 
initial denaturation step for 2 min at 95°C, followed by 40 qPCR cycles with denaturation for 
3 sec at 95°C and primer annealing and elongation for 30 sec at 60°C. Dissociation curves 
were used to assess specificity of PCR products. For every experiment, standard curves of 
four 5-fold serial dilutions of a mixture of different inputs were used to determine the 
efficiency of each primer pair. For this, the undiluted first standard was set to one and the log 
of each dilution [log(1), log(1/5), log(1/25), log(1/125)] was plotted against the Ct value of 
that dilution producing a standard curve where the slope represents the efficiency of the 
primer pair (efficiency = 10(-1/slope)-1). The efficiency was always close to 100% and the range 
of the standard curve covered the Ct values obtained from input and ChIP samples. The 
DNA amount in each sample was determined by using the slope and the y-intercept of the 
standard curve. Enrichment relative to input was then calculated by dividing the DNA 
amount in the ChIP sample by the DNA amount in the corresponding input sample. Error 
bars were calculated as standard deviations from triplicate PCR reactions for both input and 
ChIP. Antibodies used are listed in Table 2.6 and sequences of ChIP primers in Table 2.7. 
Table 2.6: Antibodies used for ChIP 
Protein recognised Species and type Source Catalogue number Quantity 
Anti-Flag (DYKDDDDK) Rabbit polyclonal Cell Signaling 2368S 4 µg 
BMI1 Rabbit polyclonal Bethyl A301-694A 4 µg 
EBNA2 Mouse monoclonal Abcam ab90543 4 µg 
H3K4me3 Rabbit monoclonal Millipore 17-614 4 µg 
H3K9ac Rabbit polyclonal Millipore 17-658 4 µg 
H3K27ac Mouse monoclonal Millipore 05-1334 2 µg 
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Protein recognised Species and type Source Catalogue number Quantity 
H3K27me3 Rabbit polyclonal Millipore 07-449 4 µg 
p300-C20 Rabbit polyclonal Santa Cruz SC585X 4 µg 
RBPJ Rabbit polyclonal Abcam ab25949 4 µg 
SUZ12 Rabbit polyclonal Abcam ab12073 4 µg 
 
Table 2.7: Sequences of ChIP primers 
Primer name Sense Primer sequence (5’-3’) Reference 
ADAM28 TSS Forward CCATTGTTGCAGGACCACAG This study 
Reverse GCCTCCTCTCCAGTGAGACA 
ADAM28 control Forward ACAGGAGCATGCACTCTTCA 
(McClellan et al., 2012) Reverse GGCAATGTTCTGCTGCAA 
ADAM peak Forward CTTCATGGCTACAGACTCTTGG 
Reverse CCTATGTCTCGCTTCCTGCT 
ADAMDEC1 TSS Forward TAAGGATACTGAACAACAATCG 
This study 
Reverse GGAATGTGTGAACTGAGACT 
AICDA region I Forward GAGGAAGGCCAGTGCAATCA 
Reverse CAGGGAGGCAAGAAGACACT 
AICDA region II Forward GCTAGTTAACTTTGTTGATC 
Reverse CTACTCAGGACAGAAATGAC 
AICDA region III Forward GCTAGCCAGTCTTTGTGCCT 
Reverse ACCAGGATCAGGAGGTGTTG 
AICDA region IV Forward TGGACACCAGCTAGATTGTTCA 
Reverse TCACACTTTCACCCACACAGA 
AICDA region V Forward CCTGTTCCTCTCCTTACCGC 
Reverse ACGGAAGCCCTTGTATCTTTGA 
AICDA region VI Forward CAGCAAGTTTCCTTCTGCGA 
Reverse GCCATTTCTGACTCAGCAGC 
AICDA control Forward GTCCTGTACAGTAACTAGAGAAAA 
Reverse GCAAAGCAAGACGACAAAGGA 
COBLL1 peak Forward CTGAGTAACAAGAGCGAAAGAG 
Reverse ATCAGATGTGTTATGACTAACAGC 
COBLL1 control Forward CCCTCCAGTATACCCCAGCT 
Reverse ACCCCTTCTCTTTACTTGGCC 
COBLL1 TSS Forward GCCGCCGTCTCTACAAGGTCTA 
Reverse CTACCCAGTAAACCCCACGG 
GAPDH Forward CGCTCTCTGCTCCTCC Millipore 
Reverse TTTCTCTCCGCCCGTCCAC 
Myoglobin Forward GGAGAAAGAAGGGGAATCACA (Delbarre et al., 2010) 
Reverse GATAAATATAGCCAACGCCACA 
HES1 Forward AAGTTTCACACGAGCCGTTC (Ntziachristos et al., 2012) 
Reverse GCTGTTATCAGCACCAGCTC 
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2.8 Transient reporter assays 
2.8.1 Cloning of transient reporter vectors 
Genomic DNA was extracted from GM12878 cells according to the instructions of the 
Blood & Cell Culture DNA Midi Kit (Qiagen) and served as template in all PCR reactions. 
The promoter regions 1 kb upstream of the RefSeq gene annotation of ADAM28, 
ADAMDEC1, AICDA or COBLL1 (short transcripts) were PCR amplified with primers that 
add MluI restriction sites (Table 2.8) using Q5 High Fidelity polymerase (NEB). The amplified 
promoter regions were then cloned upstream of the luciferase gene in pGL3-basic vector 
(Promega) using the MluI restriction site (Figure 2.1A). Restriction digestion and DNA 
sequencing was used to confirm the direction of the insert. 
PCR was also used to amplify the ADAM peak (1 kb around the ADAM peak adding 
either SalI or NotI restriction sites), the COBLL1 peak (1.5 kb around the COBLL1 peak 
adding SalI restriction sites), AICDA region II (1 kb around region II adding SalI restriction 
sites), AICDA region III (1 kb around region III adding SalI restriction sites) and AICDA 
region IV (2 kb around region IV adding NotI restriction sites). ADAM peak SalI and COBLL1 
peak were cloned downstream of the luciferase gene driven by the ADAM28 or COBLL1 
promoter, respectively, using the SalI restriction site (Figure 2.1B and C). ADAM peak NotI 
was cloned upstream of the ADAMDEC1 promoter in the pGL3-ADAMDEC1 vector using 
the NotI restriction sites (Figure 2.1D). AICDA regions II and III were inserted downstream of 
the luciferase gene driven by the AICDA promoter using the SalI restriction sites (Figure 
2.1B) and AICDA region IV was cloned upstream of the AICDA promoter using the NotI 
restriction sites (Figure 2.1E). 
All vectors were screened for the correct orientation and were sequence verified by 
Sanger sequencing. Primers used to PCR amplify promoter regions and EBNA3 binding 
peaks are listed in Table 2.8. 
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Table 2.8: Sequences of primers used to clone transient reporter vectors 
Primer name Sense Primer sequence (5’-3’) 
ADAM28 promoter Forward GAATTCACGCGTGGCGCGCCGGAGGCCTCACTCTCATGGTAG 
Reverse AAGCTTACGCGTGACAGAATGAAACTCCCTGG 
ADAMDEC1 
promoter 
Forward GAATTCACGCGTGGCGCGCCGAAGGTATGGGTTTTTAGATTGGG 
Reverse AAGCTTACGCGTGGACACTGTTTGCCCCTGGTGC 
ADAM peak NotI Forward GAATTCGCGGCCGCTAAAGCCATGGGTCAGATGAGA 
Reverse GAATTCGCGGCCGCCTGGATTGATTACAAACAAAAT 
ADAM peak SalI Forward GAATTCGTCGACTAAAGCCATGGGTCAGATGAGACT 
Reverse AAGCTTGTCGACCTGGATTGATTACAAACAAA 
AICDA Reg I 
(promoter) 
Forward GAATTCACGCGTGGCGCGCCTTGATTTGAAAATCATCAAGG 
Reverse AAGAGCACGCGTGTCTTAGTCTGACAGTGCATTGGC 
AICDA Reg II Forward GAATTCGTCGACTTTAAAAGGATAATAATTTTTATGG 
Reverse AAGCTTGTCGACGTCAGACAATGTCAAATGTC 
AICDA Reg III Forward GAATTCGTCGACCAACTATGGAACAACTGAGG 
Reverse AAGCTTGTCGACAGTCTATTTAGGTATTCATG 
AICDA Reg IV Forward GAATTCGCGGCCGCAGATGTAAGGAAGTGGTCCAG 
Reverse AAGAGCGCGGCCGCGGCATTGGGAAAGAATTCCTTC 
COBLL1 promoter Forward GAATTCACGCGTGGCGCGCCTTAAAGGTCAAGTTAAAAAC 
Reverse AAGCTTACGCGTTCTCTACAAGGTCTAGCGGG 
COBLL1 peak Forward GAATTCGTCGACGGGCACAGAGAAACTTTCTGC 
Reverse AAGCTTGTCGACGGATTCACTTGAGGCTAGTATT 
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Figure 2.1: Luciferase vectors cloned during this study. 
(A) The 1kb region 5’ of the TSS of ADAM28, ADAMDEC1, AICDA or COBLL1 were cloned upstream 
of the luciferase gene (luc+) into pGL3-basic vector using MluI restriction sites. (B) The 1 kb 
sequence around the ADAM peak, AICDA region II or III was cloned downstream of luc+ into pGL3-
ADAM28 or pGL3-AICDA, as indicated. (C) The 1.5 kb sequence around the COBLL1 peak was 
cloned downstream of luc+ into pGL3-COBLL1. (D) The 1 kb sequence around the ADAM peak was 
cloned upstream of the 1kb 5’ region of ADAMDEC1. (E) The 2 kb sequence around AICDA region IV 
was cloned upstream of the 1kb 5’ region of AICDA. 
A 
pGL3-ADAM28 1kb sense
5832 bp
AmpR
luc+
1kb 5' of ADAM28 TSS
Rep_Origin_2
Rep_Origin_1
NotI
SalI
MluI (1)
MluI (4819)
pGL3-ADAM28 1kb sense+peak
6838 bp
luc+
AmpR ADAMpeak
1kb 5' of ADAM28 TSS
Rep_Origin_1
Rep_Origin_2
NotI
MluI (5753)
MluI (6767)
SalI (1924)
SalI (2930)
pGL3-peak-ADAMDEC1 1kb sense
6840 bp
luc+
AmpR
ADAM peak
1kb 5' of ADAMDEC1 TSS
Rep_Origin_1
Rep_Origin_2
SalI
MluI (5755)
MluI (6769)
NotI (4565)
NotI (5573)
pGL3-COBLL1 short 1kb sense-peak
7338 bp
luc+
AmpR
1kb 5' of COBLL1 TSS for short transcripts
COBLL1 peak
Rep_Origin_1
Rep_Origin_2
NotI
MluI (1)
MluI (6325)
SalI (1996)
SalI (3502)
B 
E D 
pGL3-reg4-AICDA 1kb sense
7840 bp
luc+
AmpR
1kb 5' of AICDA TSS
AICDA reg4
Rep_Origin_1
Rep_Origin_2
SalI
MluI (6755)
MluI (7769)
NotI (4565)
NotI (6573)
pGL3-ADAM28 
pGL3-ADAMDEC1 
pGL3-AICDA 
pGL3-COBLL1 
1kb 5’ of TSS 
pGL3-ADAM28-peak 
pGL3-AICDA-RegII 
pGL3-AICDA-RegIII 
pGL3-COBLL1-peak 
1kb 5’ of TSS 1kb 5’ of TSS 
1kb peak 
( DAM, 
Reg II or III) 
1.5kb 
COBLL1 
peak 
pGL3-ADAMDEC1-peak pGL3-AICDA-RegIV 
C 
1kb 5’ of TSS 1kb 5’ of TSS 
1kb 
ADAM 
peak 2kb 
AICDA 
RegIV 
Chapter II: Materials and Methods 
 111 
2.8.2 Cloning of RBPJ binding mutant (BM) EBNA3C into expression vector 
The shuttle vector used to create the RBPJ BM EBNA3C recombinant EBV 
(Kalchschmidt et al., 2016) created by Adam Gillman was digested with AarI and SpeI to 
extract the 716 bp fragment that carries the 209AAAA and W227S mutations. This fragment 
was then used to replace the AarI-SpeI fragment of pCDNA3-EBNA3C. For this, three-way 
ligation between the mutated 716 bp fragment together with the 2,056 bp SpeI/NotI fragment 
and 5,815 bp NotI/AarI fragment of pCDNA3-EBNA3C was performed. Transformed E. coli 
colonies were screened by restriction enzyme digestion for the presence of an additional 
NotI and SalI site introduced with the 209AAAA and W227S mutations compared to the 
parental pCDNA3-EBNA3C vector. 
2.8.3 Electroporation and transient reporter assays 
Vectors used in electroporations are listed in Table 2.9. Luciferase vectors (1 µg) 
were electroporated into DG75, DG75∆RBPJ or Raji cells together with 1 µg pSV-β-
galactosidase and varying amounts of pCDNA3-EBNA3 expression plasmids. Total amounts 
of DNA were balanced using an empty pCDNA3 expression plasmid. Electroporations were 
performed as described previously for DG75 (Hickabottom et al., 2002). The same protocol 
was used to electroporate Raji cells with the COBLL1 luciferase constructs, but a voltage of 
240V was used. All electroporations were harvested after 48h. Luciferase and β-
galactosidase assays were performed as described previously (Hickabottom et al., 2002) 
and measured on FLUOstar Omega (BMG Labtech). β-galactosidase activity was used to 
normalise luciferase activities for transfection efficiencies.  
Chapter II: Materials and Methods 
 112 
Table 2.9: Vectors used in transient reporter assays 
Vector name Description Reference 
pCDNA3-empty Empty expression vector Invitrogen 
pCDNA3-EBNA3A Expression vector for full-length EBNA3A  
pCDNA3-EBNA3B Expression vector for full-length EBNA3B  
pCDNA3-EBNA3C Expression vector for full-length EBNA3C  
pSG5-HA-EBNA3C 11-549 Expression vector for HA-tagged N-terminal part of 
EBNA3C (amino acids 11-549) 
Gillian Parker 
pSG5-HA-EBNA3C 550-992 Expression vector for HA-tagged C-terminal part of 
EBNA3C (amino acids 550-992) 
Gillian Parker 
pCDNA3-RBPJ BM EBNA3C Expression vector for EBNA3C carrying the 209AAAA 
and W227S mutations 
This study 
pSG5-EBNA2 Expression vector for full-length EBNA2  
pSV-β-galactosidase β-galactosidase expression vector  
pGL3-basic vector pGL3 luciferase vector without promoter or enhancer Promega 
pGL3-ADAM28 pGL3-basic vector 
+ 1kb promoter sequence of ADAM28 
This study 
(Figure 2.1) 
pGL3-ADAM28-peak 
pGL3-basic vector 
+ 1kb promoter sequence of ADAM28 
+ 1kb sequence around ADAM peak 
pGL3-ADAMDEC1 pGL3-basic vector 
+ 1kb promoter sequence of ADAMDEC1 
pGL3-ADAMDEC1-peak 
pGL3-basic vector 
+ 1kb promoter sequence of ADAMDEC1 
+ 1kb sequence around ADAM peak 
pGL3-COBLL1 pGL3-basic vector 
+ 1kb promoter sequence of COBLL1 
pGL3-COBLL1-peak 
pGL3-basic vector 
+ 1kb promoter sequence of COBLL1 
+ 1.5kb sequence around COBLL1 peak 
pGL3-AICDA Reg I pGL3-basic vector 
+ 1kb promoter sequence of AICDA (Reg I) 
pGL3-AICDA Reg II 
pGL3-basic vector 
+ 1kb promoter sequence of AICDA (Reg I) 
+ 1kb sequence around AICDA Reg II 
pGL3-AICDA Reg III 
pGL3-basic vector 
+ 1kb promoter sequence of AICDA (Reg I) 
+ 1kb sequence around AICDA Reg III 
pGL3-AICDA Reg IV 
pGL3-basic vector 
+ 1kb promoter sequence of AICDA (Reg I) 
+ 2kb sequence around AICDA Reg IV 
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3 Chapter III: Gene repression by EBNA3C 
3.1 Introduction 
This chapter will focus on the role of EBNA3C in the repression of host genes. Based 
on the exon microarray in EBNA3C-conditional LCL (Skalska et al., 2013), the three host 
genes most repressed by EBNA3C (Table 1.1) – COBLL1, ADAM28 and ADAMDEC1 – 
were selected as model genes in order to explore in more detail the molecular mechanisms 
and factors that are involved in EBNA3C-mediated gene repression. These three genes 
have been selected for what appeared to be a very robust repression by EBNA3C and not 
because of their biological function (see Discussion 3.4.5 for why EBV might target them). 
COBLL1 is a novel EBNA3C target gene and has not been previously described as 
regulated by EBNA3C or other latent EBV proteins. The function of the COBLL1 (Cordon-
bleu (COBL) like 1) protein is unknown. 
ADAM28 and ADAMDEC1 are known targets of both EBNA3A and EBNA3C. In 
addition to the microarray on 3CHT LCL EBNA3C (Skalska et al., 2013), they have been 
identified in microarray analyses on EBNA3A KO LCL (Hertle et al., 2009), BL31 infected 
with EBNA3A or EBNA3C KO viruses (White et al., 2010) and BJAB stably expressing 
EBNA3C (McClellan et al., 2012). They are both members of the ADAM (a disintegrin and 
metalloprotease) family of cell surface proteins (or in some cases secreted proteins) with 
proteolytic and adhesive properties. ADAM28 and ADAMDEC1 are encoded in adjacent 
genomic loci. Shortly before the beginning of this study an intergenic EBNA3 binding site 
was identified between ADAM28 and ADAMDEC1 (McClellan et al., 2012). When EBNA3C 
was expressed reduced levels of the activation-associated histone modification H3K9/14ac 
and increased levels of the repressive H3K27me3 mark were observed within ADAM28 and 
at the TSS of ADAMDEC1 (McClellan et al., 2012). During the course of this study 
repressive looping in the presence of EBNA3C was reported between the EBNA3 binding 
site and the TSSs of ADAM28 and ADAMDEC1 (McClellan et al., 2013). 
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Most of these observations were however obtained from stable transfectants of 
EBNA3C in the EBV-negative BL cell line BJAB and in the absence of other latent EBV gene 
products. Before this study, nothing was known about the changes to gene expression of 
these three genes in primary B cells early after infection with EBV. Furthermore, nothing is 
known about the molecular mechanisms, including the temporal sequence of events or the 
factors that are involved in the EBNA3C-mediated gene repression of these genes. Most of 
the results presented in this Chapter have now been published (Kalchschmidt et al., 2016). 
3.2 Results 
3.2.1 Validation of EBNA3C repressed genes in EBV-infected primary B cells 
Previously established virus producing cell lines (Anderton et al., 2007) were re-
validated before producing recombinant EBV viral particles to infect primary B cells in order 
to establish that COBLL1, ADAM28 and ADAMDEC1 are genuine targets of EBNA3C and to 
determine whether EBNA3A or EBNA3B are involved in their regulation. 
Viral episomes were rescued from EBV B95.8 wild type (wtI6), EBNA3A (3A), 
EBNA3B (3B), EBNA3C (3C), triple EBNA3A/3B/3C (E3) knock-out (KO) or revertant (Rev) 
HEK293 virus producer cell lines (overview in Figure 1.17). Episomes were digested with 
ClaI or EcoRI and analysed by pulsed-field gel electrophoresis (Figure 3.1A). All episomes 
showed the expected restriction enzyme digestion pattern (for list of all fragments see Table 
7.1), which validated the integrity of the EBV BACs and the identity of all cell lines. In 
addition, western blot analysis for the expression of EBNA3 proteins in RIPA extracts of the 
HEK293 virus producer cell lines further confirmed the identity of all cell lines (Figure 3.1B). 
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Figure 3.1: Verification of HEK293 virus producer cell lines. 
(A) Restriction enzyme digestion and pulsed-field agarose gel electrophoresis of viral episomes 
rescued from HEK293 virus producer cell lines as indicated. Episomes were rescued from EBV B95.8 
wild type I6 (wtI6), EBNA3A (3A), EBNA3B (3B), EBNA3C (3C), EBNA3A/3B/3C (E3) knock-out (KO) 
or revertant (Rev) cell lines and digested with ClaI or EcoRI. All cell lines show the expected 
restriction enzyme digestion pattern (see Table 7.1 for full list). Arrows highlight bands in the wild type 
that are specifically changed in each mutant indicated by asterisks with expected fragment sizes 
shown below each digestion. (B) Western blot analysis of the same HEK293 virus producer cell lines 
as in A. Cell lines were analysed for expression of EBNA3A, EBNA3B, EBNA3C and γ-tubulin as 
loading control. 
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Next, having validated all HEK293 virus producer cell lines, infectious viral particles 
were produced and used to infect purified primary B cells in a single experiment to establish 
that COBLL1, ADAM28 and ADAMDEC1 are genuine targets of EBNA3C and to determine 
whether EBNA3A or EBNA3B are involved in their regulation. Consistent with the fact that 
EBNA3A and EBNA3C are both important for B cell transformation, B cells infected with 
triple E3KO virus could not be cultured past day 21 as cells stopped proliferating and/or 
died. 3AKO- or 3CKO-infected cultures also struggled around this time, but cells still 
proliferated. All other infections (wt, Rev and 3BKO) did not exhibit this crisis and proliferated 
as expected to establish LCLs. 
Infection with all EBNA3A- and EBNA3C-competent viruses resulted in a reduction of 
gene expression of ADAM28 (2-3 log fold, Figure 3.2A) and ADAMDEC1 (1-2 log fold, 
Figure 3.2B) over a period of 30 days after infection. In the absence of all EBNA3s, EBNA3C 
alone and to a lesser extent EBNA3A alone, there was a failure to repress ADAM28 and 
ADAMDEC1. This makes ADAM28 and ADAMDEC1 targets of EBNA3A and EBNA3C, 
which is consistent with previous reports (Hertle et al., 2009; McClellan et al., 2012). 
For COBLL1, infection with all EBNA3C-competent viruses resulted in a robust 3-4 
log fold repression over the same period of time (Figure 3.2C). Only the triple E3KO, lacking 
all EBNA3 proteins, and the 3CKO failed to repress COBLL1 expression and maintained 
levels similar to uninfected primary B cells. This is consistent with COBLL1 being regulated 
only by EBNA3C. 
Analysis of ALAS1 (Figure 3.2D) and GNB2L1 (Figure 3.2E), two control genes that 
are not targeted by EBV proteins, did not exhibit these differences in gene expression 
between the various virus infections. 
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Figure 3.2: Repression of ADAM28, ADAMDEC1 and COBLL1 in primary B cells infected with 
recombinant EBV. 
Infection of purified primary B cells with EBV B95.8 wild type (wtI6), recombinant EBNA3A (3A), 
EBNA3B (3B), EBNA3C (3C) or triple EBNA3A/B/C (E3) knock-out (KO) or revertant (Rev) viruses. 
Over a period of 30 days post infection, RT-qPCR gene expression for ADAM28 (A), ADAMDEC1 (B), 
COBLL1 (C), ALAS1 (D) or GNB2L1 (E) was normalised to GAPDH and is shown relative to 
uninfected primary B cells. Primary B cells infected with E3KO were rather unhappy on day 21 post 
infection and could not be cultured past that time-point (†). These results are from a single 
experiment. 
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I was able to establish stable LCLs from all primary B cell infections, except for 
E3KO-infected cells. Western blot analysis of these LCLs revealed that 3AKO and 3CKO 
LCLs had low levels of retinoblastoma protein (Rb) and phosphorylated Rb (P-Rb) and in 
addition 3CKO LCL had lost expression of p16INK4a protein (Figure 3.3). This type of clonal 
selection has been observed before, more frequently however, with cells infected with 3AKO 
virus (Hertle et al., 2009; Skalska et al., 2010). More importantly and consistent with the 
gene expression results, western blot analysis of these LCL revealed that COBLL1 protein is 
only detectable in 3CKO LCL and completely undetectable in all EBNA3C-competent cell 
lines (Figure 3.3). Unfortunately, protein expression of ADAM28 and ADAMDEC1 could not 
be assessed because commercial antibodies tested did not produce convincing or 
reproducible results. 
 
Figure 3.3: Western blot analysis of LCL established from primary B cell infections. 
Western blot verification of EBNA3A (3A), EBNA3B (3B), EBNA3C (3C) knock-out (KO), revertant 
(Rev) or wild type (wtI6) LCL grown out from the primary B cell infection. LCL were analysed on day 
85 post infection for expression of EBNA3A, EBNA3B, EBNA3C, COBLL1, p16INK4A, Retinoblastoma 
protein (Rb), Phosphorylated Rb (P-Rb) and γ-tubulin as loading control. 
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3.2.2 Recapitulation of EBNA3C-mediated gene repression in EBNA3C-conditional 
LCL 
Having established that EBNA3C is the main repressor of both ADAMs and COBLL1 
in EBV-infected primary B cells, the next step was to determine whether it is possible to 
recapitulate this repression in EBNA3C-conditional (3CHT) LCLs. These cells carry 
recombinant EBV that express endogenous levels of an EBNA3C/estrogen receptor fusion 
protein, which renders EBNA3C conditional to the presence of 4-hydroxytamoxifen (HT) in 
the medium (see Section 1.4.3). 3CHT A13 is a p16-null EBNA3C-conditional LCL that has 
been established in the absence of HT and therefore inactive EBNA3C. Having seen in the 
infection of primary B cells that the full repression of both ADAMs and COBLL1 required a 
period of 30 days and to see whether the repression was reversible, the 3CHT time-course 
experiment was designed to run over a period of 60 days (Figure 3.4A). For this, cells were 
cultured for 60 days either in the absence of HT (-HT, inactive EBNA3C), presence of HT 
(+HT, active EBNA3C) or when HT was washed from the medium after 30 days and cells 
cultured for another 30 days in the absence of HT (washed, inactivated EBNA3C). 
In the absence of HT and therefore inactive EBNA3C, these cells express ADAM28, 
ADAMDEC1 and COBLL1 at similar levels to uninfected primary B cells and gene 
expression levels of all three genes were relatively stable over this 60-day period. Activation 
of EBNA3C by the addition of HT to the medium resulted in a 2-log fold repression of 
ADAM28 (Figure 3.4B) and ADAMDEC1 (Figure 3.4C) and a 3-4 log fold repression of 
COBLL1 (Figure 3.4D). However, repression was fully reversible. Inactivation of EBNA3C, 
by removing HT from the medium from day 30 onwards, resulted in full de-repression over a 
similar 30-day period. Again, these changes of gene expression could not be detected for 
the two control genes ALAS1 (Figure 3.4E) and GNB2L1 (Figure 3.4F). At the protein level, 
most of COBLL1 protein was lost three days after activation of EBNA3C and was completely 
undetectable by day 6 (Figure 3.4G). However, this was also reversible as COBLL1 protein 
reappeared 20 days after inactivation of EBNA3C. 
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Figure 3.4: Repression of ADAM28, ADAMDEC1 and COBLL1 in EBNA3C-conditional LCL. 
(A) Time-course using 3CHT A13 LCL. Cells were grown over 60 days either in absence of HT (-HT), 
presence of HT (+HT) or with HT removed after 30 days +HT (washed). (B-F) RT-qPCR gene 
expression of ADAM28 (B), ADAMDEC1 (C), COBLL1 (D), ALAS1 (E) and GNB2L1 (F) was 
normalised to GAPDH and is shown relative to day 0 –HT. The dashed line indicates the limit of 
detection for COBLL1 expression and values below this line become extremely unreliable. (G) 
Western blot analysis of COBLL1 protein levels during the time-course as indicated with γ-tubulin as 
loading control. This is a representative result of three biological replicate time-courses. 
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These changes in gene expression were a direct consequence of the HT-induced 
activation of EBNA3C, because addition of HT over a period of 30 days to the non-
conditional 3CKO LCL, established from the primary B cell infection, did not change the 
expression levels of any of the three genes (Figure 3.5). HT was however functional and 
caused the expected gene expression changes when added to 3CHT cells during the same 
experiment. 
 
Figure 3.5: HT does not repress EBNA3C-target genes in non-conditional 3CKO LCL. 
Time-courses using non-conditional 3CKO or conditional 3CHT A13 LCLs. Cells were grown over 30 
days either in absence (-HT) or presence of HT (+HT). RT-qPCR gene expression of ADAM28 (A), 
ADAMDEC1 (B) and COBLL1 (C) was normalised to GAPDH and is shown relative to 3CHT on day 
0. These results are from a single experiment. 
Furthermore, the results obtained from the 3CHT A13 time-course were highly 
reproducible, not only in the same cell line (see Section 3.2.3), but also in 3CHT C19, 
another 3CHT cell line created by an independent 3CHT recombinant virus clone on the 
p16-null background. This line was grown out in the presence of HT and washed for at least 
three months before starting the experiment (Appendix, Figure 7.1 and Figure 7.2). 
  
B C A 
1.E-02	
1.E-01	
1.E+00	
1.E+01	
0	 10	 20	 30	
Ge
ne
	e
xp
re
ss
io
n	
re
la
-v
e	
to
	3
CH
T	
-H
T	
d0
	
Time	(days)	
ADAM28	
1.E-02	
1.E-01	
1.E+00	
1.E+01	
0	 10	 20	 30	
Time	(days)	
ADAMDEC1	
3CHT	-HT	 3CHT	+HT	
3CKO	-HT	 3CKO	+HT	
1.E-04	
1.E-03	
1.E-02	
1.E-01	
1.E+00	
1.E+01	
0	 10	 20	 30	
Time	(days)	
COBLL1	
Chapter III: Gene repression by EBNA3C 
 122 
3.2.3 Comparison between primary B and EBNA3C-conditional LCL 
In order to determine the extent to which the EBNA3C-conditional 3CHT LCL 
represent changes to gene expression observed after infection of primary B cell with EBV, 
gene expression of all three genes were directly compared between the two systems (Figure 
3.6). Repression of ADAM28, ADAMDEC1 and COBLL1 expression in newly EBV-infected 
primary B cells was very similar to repression observed in the 3CHT LCL after activation of 
EBNA3C. Repression of all three genes followed highly exponential repression profiles (R2 > 
0.9) in primary B cell infections (wtI6 as representative EBV infection of primary B cells), but 
also in three independent 3CHT time courses (two replicate A13 time-courses and one C19 
time-course). The dynamic range of COBLL1 repression (more than three logs) was 
remarkable, following a highly similar exponential repression profile in newly infected primary 
B cells, but also in all three 3CHT LCL time-courses (Figure 3.6A). Repression of ADAM28 
and ADAMDEC1 was rather more variable between cell lines, it was slowest in the two 
replicate 3CHT A13 time-courses and fastest in newly infected primary B cells (Figure 3.6B 
and C). Together however, these results showed for the first time, that the EBNA3C 
conditional cell lines can be used to recapitulate efficiently EBNA3C-mediated gene 
repression observed in B cells early after infection with EBV. 
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Figure 3.6: Comparative gene expression analysis between newly EBV-infected primary B cells 
and 3CHT LCL after activation of EBNA3C. 
RT-qPCR gene expression comparison for COBLL1 (A), ADAM28 (B) and ADAMDEC1 (C) from the 
primary B cell infection with wild type (wtI6) EBV and three replicate time-courses using 3CHT A13 
and C19 after addition of HT. Gene expression was normalised to GAPDH and expressed relative to 
uninfected primary B cells for wtI6 or 3CHT –HT on day 0 for 3CHT time-courses. Exponential 
trendlines were fitted with equations and R2 values shown.  
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3.2.4 Molecular mechanism of EBNA3C-mediated gene repression 
Having confirmed that EBNA3C was the main repressor of COBLL1, ADAM28 and 
ADAMDEC1 in newly EBV-infected primary B cells and that this repression could be 
efficiently replicated in EBNA3C-conditional LCL, my aim was to use the EBNA3C-
conditional LCL system to explore some of the molecular details and to identify factors that 
were involved in this very efficient repression of gene expression by EBNA3C. 
3.2.4.1 EBNA3 binding at the COBLL1 and the ADAM28/ADAMDEC1 loci 
At the beginning of this project, it was unknown whether COBLL1 was a direct target 
of EBNA3C, because nothing was known about EBNA3C binding at the COBLL1 locus. In 
contrast, an intergenic EBNA3 binding site in between ADAM28 and ADAMDEC1 had been 
detected by ChIP-Seq using a commercial polyclonal antibody against EBNA3C that also 
precipitates EBNA3A and EBNA3B (McClellan et al., 2012). 
Anti-Flag ChIP-Seq using LCLs expressing either tandem-affinity purification tagged 
EBNA3A, EBNA3C or wild type (untagged) EBNA3s (Figure 3.7A) was performed by Dr 
Kostas Paschos in our lab (Paschos et al., manuscript in preparation). This identified a 
single intragenic EBNA3A and EBNA3C binding site, hereafter called COBLL1 peak, 
approximately 80kb downstream of the TSS of COBLL1 (Figure 3.7B). The anti-Flag ChIP-
Seq also detected binding of EBNA3A and EBNA3C at the previously identified intergenic 
EBNA3 binding site between ADAM28 and ADAMDEC1 (McClellan et al., 2012), hereafter 
called ADAM peak (Figure 3.7C). Neither of these peaks was observed in Anti-Flag ChIP-
Seq performed on wild type (wt) LCL encoding untagged EBNA3A and EBNA3C (Figure 
3.7B and C). 
The enrichment levels of EBNA3A and EBNA3C at the ADAM and COBLL1 peaks as 
determined by ChIP-Seq are shown in Figure 3.7D, which was confirmed by anti-Flag ChIP-
qPCR performed by Dr Quentin Bazot (Figure 3.7E). In both ChIP-Seq and ChIP-qPCR, 
enrichment levels of EBNA3C were higher at the COBLL1 peak than at the ADAM peak. 
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Figure 3.7: EBNA3A and EBNA3C binding at COBLL1 and ADAM28/ADAMDEC1. 
(A) Overview of recombinant EBV encoding either TAP-tagged (two Strep and one Flag tag) EBNA3A 
or EBNA3C or wild type (wt) untagged EBNA3s. Cell lines created from these individual viruses were 
used in anti-Flag ChIP-Seq or ChIP-qPCR experiments. (B) Anti-Flag ChIP-Seq on cell lines as 
indicated and shown for the COBLL1 locus using Savant genome browser. (C) As in (B) but shown 
for the ADAM28/ADAMDEC1 locus. (D) Fold enrichment of EBNA3A-TAP and EBNA3C-TAP as 
determined by ChIP-Seq at the ADAM and COBLL1 peaks. (E) Verification EBNA3 occupancy at the 
ADAM and COBLL1 peaks by anti-Flag ChIP-qPCR. Dr Kostas Paschos performed the ChIP-Seq and 
Dr Quentin Bazot the ChIP-qPCR shown here. 
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3.2.4.2 Changes of epigenetic histone marks correlate with gene expression levels 
In order to understand better the sequence of events that led to such robust 
repression of COBLL1 and the ADAM28/ADAMDEC1 locus, my aim was to employ ChIP to 
identify changes in epigenetic marks, factors involved in the regulation and potentially the 
sequence of events. For this, I designed primers across the COBLL1 and 
ADAM28/ADAMDEC1 locus. The regions around the TSS of all three genes, the EBNA3 
binding sites and some additional control sites within each locus were selected. COBLL1 is 
located on chromosome 2, has multiple transcript variants and a CpG island around the TSS 
(Figure 3.8A). ADAM28 and ADAMDEC1 are encoded on chromosome 8 and also have 
multiple transcript variants, but no distinct CpG island (Figure 3.8F). All designed ChIP-
qPCR primer pairs were assessed for amplification efficiency and specificity, determined by 
standard curves derived from serial dilutions and dissociation curves, respectively. Next, 
various antibodies recognising different epigenetic histone modifications or factors were 
assayed in ChIP experiments on 3CHT LCL grown for a prolonged time either in the 
presence or absence of HT. From these preliminary experiments, ChIP antibodies were 
selected and ChIP was performed on samples harvested throughout the 3CHT A13 time-
course. 
ChIP for the activation-associated histone marks H3K4me3, H3K9ac and H3K27ac 
showed a reduction predominantly at the TSS of all three genes after activation of EBNA3C 
(Figure 3.8B, C, D, G, H and I). Analysis of the repressive H3K27me3 mark revealed an 
increase mainly at the TSS of COBLL1 (Figure 3.8E), but at lower levels also across the 
ADAM28/ADAMDEC1 locus (Figure 3.8J). These consistent changes in epigenetic histone 
marks could not be observed at GAPDH or Myoglobin, two controls for expressed and 
repressed genes, respectively. 
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Figure 3.8: Changes in epigenetic marks at the COBLL1 and ADAM28/ADAMDEC1 loci after 
activation of EBNA3C during the 3CHT A13 time-course. 
(A) UCSC genome browser overview of COBLL1 genomic locus showing ChIP-Seq tracks for 
EBNA3A-TAP and EBNA3C-TAP, the TSS (horizontal arrow) and CpG islands. The locations of ChIP-
qPCR primer pairs at the TSS, the EBNA3-binding site and a control site (located approximately 
halfway between the TSS and the EBNA3-binding site) are indicated below the UCSC gene track. (B-
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E) ChIP for H3K4me3 (B), H3K9ac (C), H3K27ac (D), H3K27me3 (E) on samples from 3CHT A13 
time-course at locations within the COBLL1 locus, at GAPDH or myoglobin as indicated. Cells were 
grown in the absence (-HT) or presence of HT (+HT) and numbers indicate the day of harvest. ChIP 
values represent enrichment relative to input ± SD of triplicate qPCR reactions for ChIP and input of 
each sample. (F-J) As A-E but for the ADAM28/ADAMDEC1 locus. This is a representative of two 
independent biological replicates (see Appendix, Figure 7.3 and Figure 7.4). 
Very similar results were obtained from the biological replicate 3CHT C19 time-
course (Appendix, Figure 7.3 and Figure 7.4), which allowed a more detailed analysis 
between the changes in epigenetic histone marks and their effect on gene expression. For 
this, ChIP enrichment levels of epigenetic histone marks at the TSS of all three genes were 
normalised for each of the two 3CHT time-courses. Activation-associated histone marks 
were expressed relative to the first time point –HT (day 3) and repressive histone marks 
relative to the last time point +HT (day 30). Both time-courses were used to calculate mean 
values and standard deviations (SD), which revealed that at the TSS of all three genes loss 
of the activation-associated histone marks H3K9ac, H3K27ac and H3K4me3 preceded any 
increase in the repressive histone mark H3K27me3 (Figure 3.9A-C top). 
Comparison between the changes in histone marks and corresponding mRNA 
expression levels (Figure 3.9A-C bottom) of each gene over time revealed that the initial 
repression of mRNA expression correlated well with the loss of all three activation-
associated histone modifications (H3K9ac, H3K27ac and H3K4me3) and appeared to be 
independent of the appearance of the repressive H3K27me3 modification, which was mainly 
deposited after most gene expression was already repressed. 
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Figure 3.9: Correlation of changes of epigenetic marks at the TSS of ADAM28, ADAMDEC1 and 
COBLL1 with gene expression. 
ChIP-qPCR values (top) at the TSS of ADAM28 (A), ADAMDEC1 (B) and COBLL1 (C) from 3CHT 
A13 and 3CHT C19 time-courses were normalised and displayed as mean values ± SD. Activation-
associated histone marks H3K4me3, H3K9ac and H3K27ac from the first time-point –HT (day 3) were 
set to 1 and were used as equivalent for day 0. The repressive histone mark H3K27me3 levels of the 
last time point +HT (day 30) were set to 1. Mean values ± SD from both replicate time-courses are 
shown. For better visual clarity, error bars are colour-matching the corresponding histone mark and 
only upper bars are shown for activation-associated marks and lower bars for H3K27me3. mRNA 
expression data for each gene (bottom) are shown as mean values ± SD from three replicate time 
courses (3CHT A13 rep 1+2 and 3CHT C19). 
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3.2.4.3 Factor recruitment to the COBLL1 or ADAM28/ADAMDEC1 loci 
Having seen that changes to epigenetic histone modifications were concurrent for the 
EBNA3C-mediated gene repression of both ADAMs and COBLL1, my aim was to determine 
some of the factors involved in the repression. Since H3K27me3 is catalysed by PRC2 and 
polycomb complexes were previously found to be involved in the repression of BCL2L11 
(Paschos et al., 2012) and CDKN2A (Skalska et al., 2010), ChIP for PRC2 family member 
SUZ12 was performed. Consistent with the increase in H3K27me3, SUZ12 could be 
detected at the TSS of COBLL1 after activation of EBNA3C (Figure 3.10B). However, 
compared to SUZ12 levels at the TSS of COBLL1, no direct enrichment of SUZ12 could be 
detected across the ADAM locus (Figure 3.10F), despite the observed increase in 
H3K27me3 levels albeit to low levels (Figure 3.8J). In contrast and rather unexpected, ChIP 
for the PRC1 family member BMI1 (PRC1.4) revealed recruitment of BMI1 to both COBLL1 
peak and ADAM peak, but not the TSS of COBLL1, with highest BMI1 levels nine days after 
EBNA3C activation (Figure 3.10C and G). 
Finally, since EBNA3C cannot bind directly to DNA and RBPJ is the best-
characterised DNA binding factor to which all EBNA3s bind, ChIP for RBPJ was performed. 
This showed, again rather surprisingly, that RBPJ only accumulated on both the COBLL1 
and ADAM peaks, when EBNA3C was functional with highest RBPJ levels six days after 
activation of EBNA3C (Figure 3.10D and H). 
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Figure 3.10: Factor binding to the COBLL1 and ADAM28/ADAMDEC1 loci during the 3CHT A13 
time-course. 
(A) UCSC genome browser overview of COBLL1 locus showing ChIP-Seq tracks for EBNA3A-TAP 
and EBNA3C-TAP, the TSS (horizontal arrow) and CpG islands. The locations of ChIP-qPCR primer 
pairs at the TSS, the EBNA3-binding site and a control site (located approximately halfway between 
the TSS and the EBNA3-binding site) are indicated below the UCSC gene track. (B-D) ChIP for 
SUZ12 (B), BMI1 (C) and RBPJ (D) on samples from 3CHT A13 time-course at locations within the 
COBLL1 locus, at GAPDH or myoglobin as indicated. Cells were grown in the absence (-HT) or 
presence of HT (+HT) and numbers indicate the day of harvest. ChIP values represent enrichment 
relative to input ± SD of triplicate qPCR reactions for ChIP and input of each sample. (E-H) As A-D, 
but for the ADAM28/ADAMDEC1 locus. This is a representative of two independent biological 
replicates (see Appendix, Figure 7.3 and Figure 7.4). 
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The similarity to the ChIP results from the biological replicate time-course 3CHT C19 
(Appendix, Figure 7.3 and Figure 7.4) allowed a more detailed analysis of the factor binding 
using the combined results of the replicate time-courses. For this, enrichment levels for each 
factor were expressed relative to the time-point with the highest enrichment level during 
each time-course. 
This revealed that maximal SUZ12 levels were reached at the TSS of COBLL1 by 6-9 
days (Figure 3.11A), which preceded the substantial increase in H3K27me3 at this site 
occurring about 15 days after activation of EBNA3C (Figure 3.9C). High levels of SUZ12 
were maintained at the TSS of COBLL1 over a period of at least 60 days after activation of 
EBNA3C (Figure 3.10B). This was different for BMI1, in what appeared to be a more 
transient recruitment to ADAM peak and COBLL1 peak (Figure 3.11B). Maximal BMI1 levels 
were achieved about nine days after activation of EBNA3C and subsequently dropped, but 
stayed significantly higher than in cells with inactive EBNA3C. Comparing the recruitment 
profiles of SUZ12 to the TSS of COBLL1 and BMI1 to the COBLL1 peak, it appeared that 
both were recruited at similar times, but to distinct sites. 
 
Figure 3.11: Binding of SUZ12 to the TSS of COBLL1 and BMI1 and RBPJ to ADAM peak and 
COBLL1 peak after activation of EBNA3C. 
ChIP-qPCR values for SUZ12 at the TSS of COBLL1 (A), BMI1 (B) and RBPJ (C) at the ADAM peak 
and COBLL1 peak from the two biological time-courses (3CHT A13 and C19) were normalised by 
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setting the maximal enrichment level during each time-course to one and by using the first time-point 
–HT (day 3) as equivalent for day 0. Mean values ± SD from both replicate time-courses are shown. 
For better visual clarity, error bars are colour-matched to either ADAM peak (only lower bars 
displayed) or COBLL1 peak (only upper bars displayed). For BMI1, day nine of the C19 time-course 
was treated as an outlier and was not taken into account for the analysis. 
Recruitment of RBPJ again seemed to be transient to both ADAM and COBLL1 
peaks with highest enrichment levels found on day 3-6 after activation of EBNA3C and 
subsequently decreasing, but again remaining above the levels seen in cells with inactive 
EBNA3C (Figure 3.11C). Therefore, the recruitment of RBPJ seemed to precede the 
recruitment of BMI at both ADAM peak and COBLL1 peak. 
Next, because of the observation that both BMI1 and RBPJ appeared to be 
transiently recruited to both ADAM peak and COBLL1 peak, global BMI1 and RBPJ protein 
levels were assessed by western blot analysis in samples from the two biological replicate 
time-courses (Figure 3.12 and Figure 7.2). This showed that there were no consistent 
changes to the global protein levels of BMI1, SUZ12 or RBPJ that would explain the 
transient increases of BMI1 and RBPJ at the ADAM peak and the COBLL1 peak. 
 
Figure 3.12: Western blot analysis of 3CHT A13 time-course. 
Time-course using 3CHT A13 LCL. Cells were grown over 60 days either in absence of HT (-HT), 
presence of HT (+HT) or with HT removed after 30 days +HT (washed). 30 µg of RIPA extracts from 
selected samples were analysed for the expression of BMI1, SUZ12 and RBPJ by western blot along 
γ-tubulin as loading control. 
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3.2.5 Recapitulation of repression in transient reporter assays 
In order to assess whether it is possible to recapitulate the repression of all three 
genes in transient reporter assays, I cloned the promoter regions of ADAM28, ADAMDEC1 
and COBLL1 upstream of the luciferase gene in the pGL3-basic vector either in the 
presence or absence of the ADAM peak (for ADAM28 and ADAMDEC1, see Figure 3.13A 
for ADAM28) or the COBLL1 peak (Figure 3.14A). For this, the individual promoter regions 
or the EBNA3 binding peaks were PCR amplified from genomic DNA extracted from LCL 
GM12878, a tier 1 LCL used in the ENCODE project, introducing restriction enzyme 
recognition sequences for subsequent cloning into the pGL3-basic vector (see Material and 
Methods). The orientation and sequence of the inserts were verified for all luciferase vectors 
by DNA sequencing and restriction enzyme digests (see Material and Methods). 
Preliminary electroporations were performed to assay the luciferase activity of each 
vector in various cell lines. Luciferase vectors based on the promoter region of ADAM28 
resulted in very robust luciferase activity upon electroporation into the EBV-negative BL cell 
line DG75 (Ben-Bassat et al., 1977) compared to the promoter-less pGL3-basic vector. 
Luciferase activity was further enhanced by the presence of the ADAM peak DNA sequence 
(Figure 3.13B). Luciferase vectors containing the ADAMDEC1 promoter region alone did not 
result in luciferase expression and the presence of the ADAM peak resulted only in ~5-fold 
higher luciferase activities compared to the promoter-less pGL3-basic vector (data not 
shown). The reasons for this discrepancy between ADAM28 and ADAMDEC1 constructs are 
unclear. It is possible that this was caused by the cloning strategy for the promoter region 
that was based on the 1kb sequence upstream of the RefSeq gene annotation, which might 
be too far away from the actual TSS of ADAMDEC1. The luciferase expression levels were 
not high enough to study repression, which is why the ADAMDEC1 constructs were not used 
in further assays. Luciferase vectors based on the COBLL1 promoter resulted in very low 
luciferase activity in DG75 that do not express endogenous COBLL1 (data not shown). 
However, robust luciferase activity was observed in the EBV-positive, but EBNA3C-null, cell 
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line Raji (Allday et al., 1993) that express endogenous COBLL1. Again, the presence of the 
COBLL1 peak DNA sequence further enhanced luciferase activities (Figure 3.14B). 
Next, in order to determine whether the repression of ADAM28 by EBNA3A and 
EBNA3C and the repression of COBLL1 by EBNA3C could be recapitulated in the transient 
reporter assays, the dynamic range of these assays was determined by co-electroporating 
decreasing amounts of EBNA3 expression plasmids along with the luciferase vectors that 
contain the EBNA3 peak DNA sequences. This revealed that the workable range was 
between 1 ng and 1 µg of co-electroporated EBNA3 expression plasmid representing 
approximately one plasmid and 1,000 plasmids per cell, respectively (data not shown). 
For the pGL3-ADAM28-peak construct, increasing amounts of EBNA3A or EBNA3C, 
but not EBNA3B, resulted in a reduction of luciferase activity (Figure 3.13C), which is 
consistent with the results of the primary B cell infection (Figure 3.2A). This repression of 
luciferase activity was not seen for the pGL3-ADAM28 construct where only the ADAM28 
promoter is present, but not the ADAM peak (data not shown). For the pGL3-COBLL1-peak 
construct, only increasing amounts of EBNA3C, but not EBNA3A or EBNA3B, resulted in a 
reduction of luciferase activity (Figure 3.14C), which is again consistent with the primary B 
cell infections (Figure 3.2C). As for the ADAM28 constructs, without the COBLL1 peak DNA 
sequence present in the luciferase vector repression was not observed (data not shown). 
An advantage of transient reporter assays is that truncation mutants can be 
employed in order to try to determine which part of EBNA3C is necessary for the repression 
of the ADAM28 and COBLL1 constructs. Therefore, expression plasmids encoding either an 
N-terminal part of EBNA3C (amino acids 11-549) or a C-terminal part (amino acids 550-992) 
were used instead of full-length EBNA3C. These were constructed and used previously. This 
revealed that the N-terminal part of EBNA3C was able to repress both the pGL3-ADAM28-
peak (Figure 3.13D) and pGL3-COBLL1-peak (Figure 3.14D) constructs, whereas the C-
terminal part of EBNA3C failed to repress either construct (Figure 3.13E and Figure 3.14E). 
The repression of the ADAM28 construct by the N-terminal part of EBNA3C seemed to be 
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impaired compared to full-length EBNA3C, however, luciferase activities of transfections 
using lower amounts of the N-terminal expression plasmid displayed higher levels compared 
to the balanced empty vector control (Figure 3.13D). The reasons for this are unknown and 
for the COBLL1 construct no such discrepancy could be observed (Figure 3.14D). 
Therefore, it appeared that the N-terminal part of EBNA3C (amino acids 11-549) was 
sufficient to repress ADAM28 and COBLL1 luciferase constructs. 
One of the factors that bind to the N-terminal part of EBNA3C is RBPJ (see Figure 
1.10). The observation that this part of EBNA3C was required for the successful repression 
of the ADAM28 and COBLL1 reporters and the fact that RBPJ was recruited or stabilised at 
the EBNA3-binding site at both endogenous loci (Figure 3.11C), prompted a closer 
examination of the importance of RBPJ in EBNA3C-mediated repression. For this reason, 
RBPJ-null DG75 cells [SM224.9, Figure 3.13F, (Maier et al., 2005)] were used for the 
transient luciferase assays instead of RBPJ-competent DG75 used before. In the absence of 
RBPJ, both full-length EBNA3A and EBNA3C are unable to repress luciferase activities of 
the pGL3-ADAM28-peak construct (Figure 3.13G). Unfortunately, repression of COBLL1 
construct could not be analysed in these cells due to the low luciferase activity of this 
construct in DG75. 
However, during the course of this project Adam Gillman created the RBPJ binding 
mutant (BM) EBNA3C (see Introduction and Figure 1.10B and C), which I cloned into a 
pCDNA3 expression vector. This mutant EBNA3C failed to repress luciferase activity when 
co-transfected along the pGL3-ADAM28-peak construct in RBPJ-competent DG75 (Figure 
3.13H) or along the pGL3-COBLL1-peak construct in Raji cells (Figure 3.14F). This showed 
that repression of both ADAM28 and COBLL1 in transient assays is dependent on the ability 
of EBNA3C to interact with RBPJ. 
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Figure 3.13: Transient reporter assays of ADAM28 constructs – ADAM peak acts as an 
enhancer and repression by EBNA3A and EBNA3C is dependent on ADAM peak and RBPJ. 
(A) Schematic overview of luciferase vectors used in the transient reporter assays. The 1 kb promoter 
region upstream of the TSS of ADAM28 (black arrow) and 1 kb around the ADAM peak (black box) 
was cloned upstream and downstream, respectively, of the luciferase gene (grey box) in the pGL3-
basic vector. (B) Luciferase reporter assays in DG75 after electroporation of 1 µg of reporter vector as 
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indicated and expressed relative to pGL3-basic vector. (C) Luciferase reporter assays in DG75 after 
electroporation of 1 µg pGL3-ADAM28-peak and increasing amounts of EBNA3 expression plasmids 
as indicated. (D) As in C, but co-transfecting increasing amounts of expression plasmid encoding the 
N-terminal half of EBNA3C (amino acids 11-549). (E) As in C, but co-transfecting increasing amounts 
of expression plasmid encoding the C-terminal half of EBNA3C (amino acids 550-992). (F) Western 
blot analysis of RBPJ in RBPJ-null DG75 (DG75∆RBPJ) and RBPJ-competent DG75. (G) As in C, but 
in RBPJ-null DG75. (H) As in C, but co-transfecting increasing amounts of expression plasmid 
encoding the RBPJ binding mutant (BM) of EBNA3C. (C-H) Western blots for corresponding EBNA3 
proteins or γ-tubulin as loading control. The N-terminal half of EBNA3C expressed as HA-fusion 
protein was detected by anti-HA antibody. Luciferase units were normalised to β-galactosidase units 
of the same transfection and are shown as mean relative luciferase units (RLU) ± SD. 
 
Figure 3.14: Transient reporter assays of COBLL1 constructs – COBLL1 peak acts as an 
enhancer and repression by EBNA3C is dependent on COBLL1 peak and RBPJ. 
(A) Schematic overview of luciferase vectors used in the transient reporter assays. The 1 kb promoter 
region upstream of the TSS of COBLL1 (black arrow) and 1.5 kb around the COBLL1 peak (black 
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box) were cloned upstream and downstream, respectively, of the luciferase gene (grey box) in the 
pGL3-basic vector. (B) Transient luciferase reporter assays in Raji after electroporation of 1 µg of 
reporter vector as indicated and expressed relative to pGL3-basic vector. (C) Transient luciferase 
reporter assays in Raji after electroporation of 1 µg pGL3-COBLL1-peak and increasing amounts of 
EBNA3 expression plasmids as indicated. (D) As in C, but co-transfecting increasing amounts of 
expression plasmid encoding the N-terminal half of EBNA3C (amino acids 11-549). (E) As in C, but 
co-transfecting increasing amounts of expression plasmid encoding the C-terminal half of EBNA3C 
(amino acids 550-992). (F) As in C, but co-electroporating increasing amounts of RBPJ binding 
mutant (BM) of EBNA3C. (C-F) Western blots show corresponding EBNA3 protein and γ-tubulin as 
loading control. The N-terminal half of EBNA3C expressed as HA-fusion protein was detected by anti-
HA antibody. Luciferase units were normalised to β-galactosidase units of the same transfection and 
are shown as mean relative luciferase units (RLU) ± SD. 
3.2.6 Repression is dependent on interaction between RBPJ and EBNA3C 
Finally, in order to determine whether binding of EBNA3C to RBPJ was necessary for 
the repression of endogenous ADAM28 and COBLL1 – as suggested by the transient 
reporter assays – but also ADAMDEC1 in the context of infection, Adam Gillman created the 
recombinant EBV carrying the RBPJ BM EBNA3C (Figure 1.10B and Figure 1.17) and used 
this virus to infect primary B cells. RNA samples were harvested every 5 days from the time 
of infection. Consistent with the results of the transient luciferase reporter assays and the 
ChIP studies, infection with the RBPJ BM EBNA3C virus revealed that when EBNA3C 
cannot bind to RBPJ it was unable to repress ADAM28, ADAMDEC1 or COBLL1 (Figure 
3.15A-C). Regarding the expression levels of all three genes, the RBPJ BM EBNA3C virus 
behaved similar compared to EBNA3C KO virus, whereas EBNA3C revertant and wild-type 
viruses resulted in robust repression of all three genes as seen in the previous primary B cell 
infections (Figure 3.2). As before, the control gene ALAS1 did not show these differences in 
gene expression between the various virus infections (Figure 3.15D). 
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Figure 3.15: Ability of EBNA3C to bind to RBPJ is essential for the repression of ADAM28, 
ADAMDEC1 and COBLL1. 
Infection of purified primary B cells with wild type (wtA5), EBNA3C knock-out (3CKO), EBNA3C 
revertant (3CRev) or RBPJ binding mutant (BM) EBNA3C recombinant EBV. Over a period of 30 days 
post infection, RT-qPCR gene expression for ADAM28 (A), ADAMDEC1 (B), COBLL1 (C) and ALAS1 
(D) was normalised to GNB2L1 and shown relative to uninfected primary B cells. This is a single 
experiment that was performed and analysed by Adam Gillman. 
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3.3 Summary 
• In newly EBV-infected primary B cells ADAM28 & ADAMDEC1 are repressed 
by EBNA3A & EBNA3C and COBLL1 is repressed only by EBNA3C. 
• EBNA3C is the main repressor of all three genes. 
• EBNA3C-conditional LCL can be used to reliably recapitulate EBNA3C-
mediated gene repression seen in newly EBV-infected primary B cells. 
• EBNA3C-mediated gene repression follows a highly exponential repression 
profile. 
• Gene repression by EBNA3C seems to take place in two steps: 
1. Initial repression is associated with loss of activation-associated histone 
marks resulting in the loss of most mRNA transcription. 
2. Subsequent deposition of repressive histone marks by recruited 
polycomb repressive complexes maintains or further enhances 
repressed state. PRC1 and PRC2 complexes appeared to be recruited 
at the same time, but to two distinct sites at the COBLL1 locus. 
• Dynamic recruitment of RBPJ was observed to EBNA3-binding sites only 
when EBNA3C was functional. 
• Repression can be recapitulated in transient reporter assays. This also 
revealed that the DNA sequences of both EBNA3-binding peaks act as 
enhancers in the absence of EBNA3 proteins. 
• Repression, both in transient reporter assays but more importantly in newly 
EBV-infected primary B cells, is absolutely dependent on the ability of 
EBNA3C to bind to RBPJ. 
• Most of the results presented in this chapter are now published (Kalchschmidt 
et al., 2016). 
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Figure 3.16: Two-step model of EBNA3C-mediated gene repression. 
(A) Gene expression in the absence of functional EBNA3C through activation-associated histone 
marks H3K4me3, H3K9ac and H3K27ac. (B) Activation of EBNA3C results in the recruitment and/or 
stabilisation of RBPJ:EBNA3C complexes at the EBNA3C binding peak. EBNA3C potentially recruits 
H3K4me3 demethylases (KDM5A/B/C/D) and histone deacetylases (HDAC1/2) that catalyse the loss 
of activation-associated histone marks leading to rapid repression of transcription. (C) After most of 
gene expression has been already repressed, recruitment of polycomb repressive complexes 1 and 2 
(PRC1 and PRC2) and deposition of the repressive mark H3K27me3 was observed. Surprisingly, at 
least at the COBLL1 locus, recruitment of PRC1 was observed at the EBNA3C binding site, whereas 
PRC2 was recruited to the gene promoter. It is possible that both sites are involved in chromatin 
looping that would bring PRC1 and PRC2 together. 
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3.4 Discussion 
The discussion in this Chapter will only focus on issues specific for EBNA3C-
mediated gene repression. A broader discussion of the role of EBNA3C in gene regulation in 
general can be found in Chapter V: General discussion. 
Although EBNA3s were known to be transcriptional regulators and EBNA3C is 
undoubtedly the most studied of the three EBNA3s, very little was known about the precise 
molecular mechanisms by which EBNA3C regulates gene expression. Here, focusing on two 
genomic loci that are very robustly repressed by EBNA3C, some of these mechanisms could 
be identified, which might apply more broadly to EBNA3C-mediated gene repression of host, 
but possibly also viral gene expression. 
3.4.1 Recruitment of RBPJ to chromatin requires functional EBNA3C 
Most unexpected, was the dynamic recruitment and/or stabilisation of what are 
probably RBPJ/EBNA3C complexes at the EBNA3-binding sites at the 
ADAM28/ADAMDEC1 and COBLL1 loci very early after activation of EBNA3C (Figure 
3.11C). Unfortunately, ChIP directly for EBNA3C cannot be reliably performed on these 
samples, because EBNA3C is not TAP-tagged (see Chapter V: General discussion). 
This is in contrast to the paradigm that RBPJ is always stably bound at its DNA 
binding sites to repress gene expression in the absence of Notch signalling (Figure 1.16A). 
Furthermore, it is not consistent with the previously proposed models that EBNA3s prevent 
EBNA2-mediated transactivation through disruption of RBPJ binding to DNA (Figure 1.16C) 
or by replacing EBNA2, but keeping RBPJ stably bound to DNA (Figure 1.16D). No EBNA2 
occupancy was observed at the ADAM and COBLL1 peak in the absence of EBNA3C 
(Figure 7.5). 
Recent studies have revealed a more dynamic behaviour of RBPJ binding to DNA. 
Ectopic activation of Notch signalling can induce de novo binding or increased binding of 
RBPJ in Drosophila (Krejcí and Bray, 2007) and mammalian cells (Castel et al., 2013; Wang 
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et al., 2014) to activate Notch target genes. Increased binding of RBPJ was predominantly 
observed at distal enhancer sites co-occupied by NICD and resulted in increased p300 
occupancy and higher H3K27ac levels (Castel et al., 2013; Wang et al., 2014). Similarly, 
EBNA2 expression appeared to increase the occupancy of RBPJ at some EBNA2 target 
genes during EBNA2-mediated gene activation (Portal et al., 2011), which was more 
recently shown on a large number of genes (Lu et al., 2016). However, to my knowledge no 
dynamic RBPJ recruitment has been reported during gene repression. 
An extended discussion on the role of RBPJ in EBNA3C-mediated gene regulation 
can be found in Chapter 5. 
3.4.2 Two step mechanism of EBNA3C-mediated gene repression 
3.4.2.1 First step: Loss of activation-associated histone marks 
Rapid loss of activation-associated histone modifications (H3K4me3, H3K9ac and 
H3K27ac) predominantly at the TSS seemed to coincide with most of the loss of mRNA 
expression (Figure 3.16A and B). Demethylases are responsible for the removal of methyl 
groups and KDM5A/B/C/D, which belong to the Jumonji C family of demethylases that can 
remove mono-, di- or trimethylation on lysine residues, have been shown to be able to 
catalyse the removal of H3K4me3 (Iwase et al., 2007; Christensen et al., 2007; Klose et al., 
2007; Lee et al., 2007; Tahiliani et al., 2007; Kooistra and Helin, 2012). ChIP for 
KDM5A/B/C/D was not attempted due to limited ChIP material of the 3CHT time-courses 
and time constrains, but antibodies for all four proteins are commercially available and would 
need to be tested for specificity before being used in ChIP. The expectation would be that 
one or several of them are recruited to ADAM28/ADAMDEC1 and COBLL1 locus very early 
after activation of EBNA3C. 
The removal of acetyl groups on histones is catalysed by HDACs. There are 18 
human HDACs grouped into four families according to their homology (HDAC family 1-4) 
[reviewed in (Haery et al., 2015)]. EBNA3C has been shown to bind to and recruit the class 
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one HDAC family members 1 and 2 (Radkov et al., 1999; Knight et al., 2003). This makes 
both of them likely candidates for involvement in the initial repression. ChIP for HDAC1 has 
been attempted, but was not followed-up due to limited ChIP material of the 3CHT time-
courses and time constraints. Again, the expectation would be to observe recruitment very 
early after activation of EBNA3C. 
In addition, both HDAC1 and HDAC2 have been found together with KDM5A/Sin3 or 
KDM5C/NcoR/REST in multiprotein complexes (Tahiliani et al., 2007; Hayakawa et al., 
2007; Hayakawa and Nakayama, 2011). Besides HDAC1 and HDAC2, EBNA3C can bind to 
both Sin3 and NcoR (Knight et al., 2003). Therefore, it seems likely that EBNA3C recruits 
multifunctional complexes that are able to remove H3K4me3 and histone acetylation in the 
initial phase of repression. 
ChIPs for these factors might also reveal why the repression of COBLL1 is faster and 
more extensive compared to the repression of the ADAM28/ADAMDEC1 locus. A tempting 
speculation would be that higher levels of EBNA3C on the COBLL1 peak, recruit more 
demethylases and deacetylases that are responsible for a faster repression of the COBLL1 
locus compared to the ADAM28/ADAMDEC1 locus where less EBNA3C can be found. 
Another possibility is that changes in the 3D chromatin organisation (see below) required for 
gene repression are more quickly established at the COBLL1 locus compared to the 
ADAM28/ADAMDEC1 locus. 
3.4.2.2 Second step: Recruitment of polycomb proteins and deposition of repressive 
histone marks 
In a second step and what appears to be independent from the initial repression, the 
PRC1 protein BMI1 was recruited to ADAM peak and COBLL1 peak and the PRC2 protein 
SUZ12 to the TSS of COBLL1 (Figure 3.16C). Comparison to gene expression levels 
revealed that PRC2-catalysed H3K27me3 levels was unlikely to be the direct cause for 
repression, but rather involved in maintaining or extending the repressive state. It has been 
a long-standing question in polycomb-mediated repression whether H3K27me3 was a cause 
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or consequence of gene expression – the results observed here would suggest the latter. 
This is consistent with the findings of two recent studies. Hosogane and colleagues found 
that H3K27me3 levels were a consequence of changes in gene expression induced by H-
Ras expression in the mouse embryonic fibroblast cell line NIH 3T3 (Hosogane et al., 2013). 
Unfortunately, changes in activation-associated histone marks were not assessed in this 
study. Moreover, Riising et al. found that PRC2 was dispensable for the initiation of 
repression, but required for maintenance of the repressed state and that small-molecule 
inhibition of transcription could trigger recruitment of PRC2 in mouse embryonic stem cells 
(Riising et al., 2014). 
Repeated attempts were made to investigate whether PRC1-catalysed H2AK119ub 
was deposited at the ADAM28/ADAMDEC1 and COBLL1 loci, but due to concerns about 
antibody reliability and specificity this ChIP has not been performed on the A13 and C19 
time-courses. 
3.4.3 Simultaneous recruitment of PRC1 and PRC2 proteins to two distinct loci 
Another surprising finding from the ChIP analysis was that BMI1, probably acting as 
part of PRC1, was found at the ADAM peak and COBLL1 peak, whereas SUZ12, as part of 
PRC2, was found at the TSS of COBLL1. At the ADAM28/ADAMDEC1 locus, no direct 
SUZ12 recruitment could be detected although H3K27me3 levels increased at this locus, 
albeit at much lower levels compared to the COBLL1 locus. It is possible that SUZ12 binding 
was therefore below the detection limit or that recruitment of SUZ12 to a discrete site was 
missed by the choice of primers. This is however unlikely, because previous studies 
identified that 95% of SUZ12 binding sites localised within 1kb of TSS and that 40% were 
within 1kb of CpG islands, which by themselves could recruit PRC2, leading to the 
deposition of H3K27me3 (Lee et al., 2006; Tanay et al., 2007; Ku et al., 2008; Mendenhall et 
al., 2010). All TSSs were included in the ChIP analysis and only COBLL1 has a CpG island 
around its TSS, which might explain the direct recruitment of SUZ12 and the much higher 
levels of H3K27me3 at COBLL1 relative to the ADAM28/ADAMDEC1 locus. 
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Unfortunately, this meant that COBLL1 was the only locus, where both recruitment of 
PRC1 proteins and PRC2 proteins could be observed. In contrast to the classical and more 
recent models of polycomb recruitment (see Introduction), PRC1 and PRC2 complexes 
appeared to be recruited simultaneously, but to different genomic loci. Higher order 
chromosome structures can be mediated by polycomb complexes (Lanzuolo et al., 2007; 
Tiwari et al., 2008a; b) [reviewed in (Cheutin and Cavalli, 2014)], so perhaps repression of 
COBLL1 involves chromatin looping between the COBLL1 peak and the TSS of COBLL1, 
which would bring BMI1 (PRC1) and SUZ12 (PRC2) together (Figure 3.16C). Previously 
chromosome conformation capture has been successfully used to show repressive loop 
formation between the ADAM peak and the TSS of ADAM28 and ADAMDEC1 when 
EBNA3C was expressed (McClellan et al., 2013). Attempts were made to employ the same 
technique to analyse the higher-order chromosome structure of the COBLL1 locus together 
with the ADAM locus as a positive control. Unfortunately, this did not lead to reproducible 
results. The reasons for this are not known and time constrains did not allow further 
investigation. However, one possible indication of repressive loop formation between the 
COBLL1 peak and the TSS of COBLL1 or the ADAM peak and the TSSs of ADAM28 and 
ADAMDEC1 might be that low levels of BMI1 and RBPJ enrichment could be detected on 
the TSS of all three genes (Figure 3.10C, D, G and H). It is possible that this resulted from a 
close spatial proximity between the EBNA3C binding peak and the TSSs when the cells 
were cross-linked. 
Furthermore, it is currently unclear whether polycomb proteins are part of a default 
repressive mechanism that is activated at these two genomic loci once activation-associated 
histone marks are removed, or whether they are directly recruited. This and the role of RBPJ 
in gene regulation mediated by EBNA3C will be discussed in Chapter 5. 
3.4.4 Comparisons with EBNA3A-mediated repression 
Recently, a similar two-step mechanism of gene repression has been reported for the 
EBNA3A-mediated repression of CXCL9 and CXCL10 (Harth-Hertle et al., 2013). In the 
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absence of EBNA3A, EBNA2 binds to an intergenic regulatory element and CXCL9 and 
CXCL10 are expressed. Doxycycline-induced overexpression of EBNA3A in EBNA3A KO 
LCL displaced EBNA2 from the regulatory element resulting in initial de-activation marked by 
loss of activation-induced histone marks and only subsequently an increase in H3K27me3. 
This is very similar to the EBNA3C-mediated repression of ADAM28, ADAMDEC1 and 
COBLL1, however, no EBNA2 occupancy and no change in EBNA2 levels could be detected 
on the ADAM peak or COBLL1 peak during the 3CHT A13 time course or in 3CHT cells 
grown either in absence or presence of HT for prolonged period of time (Figure 7.5). The 
results of the luciferase assays show clearly that the DNA sequences of the ADAM peak and 
COBLL1 peak act as enhancer elements, so in the absence of EBNA3C this might be 
enough to activate these two loci. Interestingly, EBNA3C seems to target these enhancer 
elements and somehow converts them into repressive elements. From the luciferase assays 
it became clear that the ADAM peak or the COBLL1 peak have to be present in the 
luciferase vectors for repression to take place. 
3.4.5 Biological role of ADAM28, ADAMDEC1 and COBLL1 – why are they repressed 
by EBV? 
Besides the molecular mechanisms of EBNA3C-mediated repression, another 
question is the biological relevance of the repression of ADAM28, ADAMDEC1 and COBLL1 
for EBV. A closer look at their biological functions might help to explain this. 
ADAM28 and ADAMDEC1 are members of the ADAM family of membrane-bound or 
secreted proteases. Members of this family share a conserved multidomain structure 
comprised of pro, metalloproteinase, disintegrin, cysteine-rich, epidermal growth factor 
(EGF)-like, transmembrane and cytoplasmic domains [reviewed in (Edwards et al., 2008; 
Klein and Bischoff, 2011)]. The pro-domain inhibits the activity of the metalloproteinase 
domain, ensures correct protein folding and is generally cleaved during the transit through 
the Golgi secretory system. The metalloprotease domain is responsible for the proteolytic 
activity, but not all ADAM family members contain active metalloprotease domains. The 
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disintegrin domain can mediate protein-protein interaction or cell-cell adhesion through 
interaction with, for example, integrins. The cysteine-rich domain is rather variable between 
the different members of the ADAM family and faces towards the catalytic site of the 
metalloproteinase domain, where it is thought to mediate binding to substrates, but also 
influences desintegrin-integrin interactions. The biological function of the EGF domain is 
unclear. The cytoplasmic domain of membrane-bound ADAMs is highly variable and is 
involved in further regulation of ADAM activity and localisation through interaction with 
intracellular proteins and/or posttranscriptional modifications. With these multiple domains – 
through regulation of proteolysis, signalling, migration and cell adhesion – ADAM proteins 
have various roles in human physiology, such as egg-sperm interaction [reviewed in (Cho, 
2012)], ectodomain shedding of cytokines or growth factors [reviewed in (Reiss and Saftig, 
2009; Taylor et al., 2014)] or regulated intramembrane proteolysis, e.g. during Notch 
signalling where extracellular S2 proteolysis of Notch by ADAM10 or ADAM17 induces the 
intracellular S3 cleavage [reviewed in (Christian, 2012)]. Deregulation of ADAM expression 
can result in various diseases, including cancer [reviewed in (Murphy, 2008; Rocks et al., 
2008; Mochizuki and Okada, 2007)]. 
ADAM28 (also known as MDC-L, eMDCII and TECADAM) is highly expressed on B 
lymphocytes (Roberts et al., 1999; McGinn et al., 2011) and is able to bind to α4β1, α4β7, α9β1 
integrins (Bridges, 2001; Bridges et al., 2003; 2005; McGinn et al., 2011) and P-selectin 
glycoprotein ligand 1 (Shimoda et al., 2007). Furthermore, ADAM28 has a membrane-bound 
and a secreted isoform (Roberts et al., 1999), both of which are catalytically active (Howard 
et al., 2001) and able to cleave CD23 (Fourie, 2003), insulin-like growth factor binding 
protein 3 (Mochizuki et al., 2004), connective tissue growth factor (Mochizuki et al., 2010), 
von Willebrand factor (Mochizuki et al., 2012), tumour necrosis factor α (Jowett et al., 2012) 
and CD200 (Twito et al., 2013). Probably as a result of its above listed functions, ADAM28 
over expression has been reported in multiple human cancers, e.g. in breast carcinoma 
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(Mitsui et al., 2006), non-small cell lung carcinoma (Ohtsuka et al., 2006; Kuroda et al., 
2010; Lv et al., 2012) or acute B cell lymphoblastic leukemia (Zhang et al., 2015). 
Compared to the other ADAM family proteins, ADAMDEC1 (ADAM-like, decysin 1) 
has a non-canonical metalloprotease domain, only contains half of the disintegrin domain 
and lacks the cysteine-rich region, the EGF-motif, the transmembrane domain and the 
cytoplasmic tail (Bates et al., 2002). Due to the lack of the transmembrane domain, 
ADAMDEC1 is strictly secreted. The non-canonical metalloprotease domain is catalytically 
active and able to cleave α2-macroglobulin, casein and carboxymethylated transferrin (Lund 
et al., 2013; 2015). The physiological role of ADAMDEC1 is unknown. Reduced expression 
of ADAMDEC1 was detected during tumour progression of colorectal cancer (Macartney-
Coxson et al., 2008) and in a poor prognosis subgroup of gastric adenocarcinoma (Pasini et 
al., 2014). Increased expression has been reported within unstable regions of atherosclerotic 
plaques (Papaspyridonos et al., 2006), in sarcoidosis lung tissues (Crouser et al., 2009) and 
in craniopharyngioma cells (Xu et al., 2012a). A recent study found high levels of 
ADAMDEC1 expression in kidney transplants that were rejected by T cell-mediated 
mechanisms compared to other mechanisms, e.g. antibody-mediated rejection (Venner et 
al., 2014). 
The repression of ADAM28 and ADAMDEC1 by EBNA3A and EBNA3C is likely to be 
part of an immune modification strategy, involving reduced shedding of cytokines and 
chemokines and reduced cell-to-cell interaction between the EBV infected B cells and 
immune cells. This would be important during in vivo infections. Currently, nothing is known 
about the in vivo role of EBNA3A or EBNA3C. As a part of this PhD project, infectious 
EBNA3A, EBNA3C and triple EBNA3 KO and Rev viruses were produced at a large scale, to 
determine their role in a humanised mouse model of EBV infection [reviewed in (Münz, 
2015)] in collaboration with Donal McHugh and Dr Christian Münz. Preliminary results, 
revealed substantially reduced viral loads in animals infected with EBNA3A and EBNA3C 
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KO viruses compared to wild type or revertant viruses. However, further work is ongoing to 
determine the activation of immune cells during these infections. 
COBLL1 (COBL-like 1, formerly also called KIAA0977   protein) is conserved in 
vertebrates and its N-terminus shares 37% sequence homology with the actin-nucleation 
factor Cordon-bleu (COBL) (Mori et al., 2001; Carroll et al., 2003; Ahuja et al., 2007) 
[reviewed in (Kessels et al., 2011)]. The gene function of COBLL1 remains unknown. 
However, more recently abberant COBLL1 expression has been repeatedly reported 
in various cancers and loss of COBLL1 expression was often associated with disease 
progression and a poor prognosis. Frame-shift mutations in COBLL1 have been identified in 
24% of colorectal cancers (Mori et al., 2001). Multiple studies also identified COBLL1 as 
prognostic a biomarker that was down-regulated in CLL with a non-mutated IgH variable 
region, which is the subgroup that is linked with poor prognosis. In contrast higher COBLL1 
expression was found in CLL with mutated IgH variable region, associated with a more 
favourable outcome (Haslinger et al., 2004; Abruzzo et al., 2007; Mansouri et al., 2012; 
Ronchetti et al., 2013). Interestingly, mutations in the functional domain of ADAM28 were 
also reported in some of these CLL patients (Mansouri et al., 2012). In DLBCL (Tompkins et 
al., 2013) and malignant pleural mesothelioma (Gordon et al., 2003; 2005; 2009) lower 
COBLL1 expression was again associated with a less favourable outcome. In prostate 
cancer, however, COBLL1 expression was increased in tumours (Singh et al., 2002; Wang 
and Gotoh, 2009) and in proximal gastric cancers COBLL1 expressing tumours were 
associated with disease progression and poor prognosis (Wang et al., 2013). 
Beside cancer studies, the COBLL1 locus has been associated with alcohol addiction 
(Dick et al., 2010), type 2 diabetes (Manning et al., 2012; Albrechtsen et al., 2013; Randall et 
al., 2013; Mancina et al., 2013; Desmarchelier et al., 2014; Kraja et al., 2014), thickness of 
the left Heschl’s gyrus (Cai et al., 2014) and periodontitis (Sima et al., 2015). In a 
biochemical study, COBLL1 was identified by mass spectrometry to interact with nardilysin 
that binds to H3K4me2 and plays a role in transcriptional regulation through association with 
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NCoR/SMRT complex and HDAC3 (Li et al., 2012). However, this interaction has still to be 
confirmed. In conclusion, the biological function of COBLL1 protein is unknown and it 
remains unclear why EBV via EBNA3C so robustly represses COBLL1 expression. 
3.4.6 Remarks 
It is worth noting that the 4th most highly repressed gene by EBNA3C (RP11-
624C23.1, see Table 1.1) is a long non-coding RNA with four isoforms of different lengths 
that run on the negative strand across the ADAM28/ADAMDEC1 locus (Figure 7.9). Analysis 
of microarray data (http://www.epstein-barrvirus.org.uk) is consistent with the whole locus 
being co-ordinately regulated by EBNA3A and EBNA3C. 
Furthermore, EBNA2 up regulates ADAMDEC1 (Lucchesi et al., 2008), but not 
ADAM28, probably through binding to an enhancer element proximal to the TSS of 
ADAMDEC1 (Figure 7.9). However, EBNA3A- and EBNA3C-mediated repression of the 
entire ADAM28/ADAMDEC1 locus dominates over induction of ADAMDEC1 by EBNA2. 
3.4.7 Conclusion 
The findings presented here are a first step into a better understanding of how 
EBNA3C represses cellular and perhaps also viral genes. However, further studies including 
additional EBNA3C-repressed genes are needed in order to determine whether the findings 
presented here apply to all EBNA3C repressed genes and to fully understand the molecular 
mechanisms. 
The role of EBNA3C in gene regulation in general including the recruitment of RBPJ 
and the kinetics of the regulation will be further discussed in Chapter V: General discussion. 
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4 Chapter IV: Gene activation by EBNA3C 
4.1 Introduction 
Having analysed EBNA3C-mediated gene repression in the previous chapter, this 
chapter will now focus on EBNA3C-mediated gene activation. Therefore, AICDA, the gene 
encoding AID, was selected based on the previous Affymetrix exon microarray study using 
EBNA3C-conditional LCL [Table 1.2 and (Skalska et al., 2013)]. This gene will serve as 
model gene to better understand molecular mechanisms involved in EBNA3C-mediated 
induction of gene expression. As discussed in the introduction AID expression is controlled 
on multiple levels (Figure 1.6). Various studies have reported that EBV-infected B cells 
express AID [e.g. (Gil et al., 2007; Epeldegui et al., 2007)], but currently only LMP1 and 
EBNA2 have been identified to deregulate AID expression. Over-expression of LMP1 alone 
induced AID expression in LMP1-conditional BJAB cells resulting in CSR, which could be 
prevented by inhibiting NFκB signalling (He et al., 2003). More recently, it was suggested 
that LMP1 activates AID through NFκB signalling and binding of the TF early growth 
response 1 (EGR-1) to the AID promoter (Kim et al., 2013). EBNA2 on the other hand has 
been reported to repress expression of AID in three different EBNA2-conditional cell lines, 
EREB 2-5 cells, BL41 and BJAB cells (Tobollik et al., 2006). The repression of AID by 
EBNA2 had very similar kinetics compared to the repression of IgM by EBNA2, but no 
mechanism for the repression has been reported or proposed. EBNA3C has not been 
previously linked to the regulation of AID expression. 
4.2 Results 
4.2.1 Validation of AICDA as an EBNA3C-activated gene in primary B cells infected 
with EBV 
First of all, in order to validate that AICDA is up regulated by EBNA3C and to 
determine whether EBNA3A or EBNA3B are involved in the regulation, AICDA mRNA 
expression was analysed in primary B cells infected with wild type, knock-out (3AKO, 3BKO, 
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3CKO or E3KO) or revertant (3ARev, 3BRev, 3CRev, E3Rev) viruses (Figure 4.1A). This 
revealed that all EBNA3C-competent viruses induced AICDA expression over a 30-day 
period. Only infections with viruses lacking EBNA3C (3CKO or E3KO) failed to induce 
AICDA expression. In GC B cells, BCL6 positively regulates AID expression through 
repression of miR-155 (Basso et al., 2012). The EBNA3C-mediated induction of AICDA was 
however independent of the expression of BCL6, which was highly repressed by all 
recombinant viruses (Figure 4.1B). Potentially due to the lack of repression by BCL6, 
expression of miR-155HG, a long-precursor transcript that contains miR-155, increased after 
infection with all EBV recombinant viruses (Figure 4.1C). Although 3CKO-infected cells 
displayed the highest levels of miR155-HG, the level was only marginally higher compared 
with the other recombinant virus infections and therefore it is unlikely that miR-155 
contributes to the low expression levels of AICDA in 3CKO-infected cells. 
 
Figure 4.1: Induction of AICDA by EBNA3C in primary B cells infected with recombinant EBV. 
Infection of purified primary B cells with wild type (wtI6), recombinant EBNA3A (3A), EBNA3B (3B), 
EBNA3C (3C) or triple EBNA3A/B/C (E3) knock-out (KO) or revertant (Rev) viruses. Over a period of 
30 days post infection, RT-qPCR gene expression for AICDA (A), BCL6 (B) and miR-155-HG (C) was 
normalised to GAPDH and is shown relative to uninfected primary B cells. Primary B cells infected 
with E3KO could not be cultured past that time-point (†). These results are from a single experiment. 
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4.2.2 Recapitulation of EBNA3C-mediated gene activation of AICDA in EBNA3C-
conditional LCL 
Having seen that AICDA is a genuine target of EBNA3C in newly EBV-infected B 
cells, the p16-null 3CHT LCL were again used in order to determine whether it is possible to 
recapitulate the induction of AICDA by EBNA3C in these cells. The 3CHT A13 time-course 
showed increased AICDA mRNA levels after activation of EBNA3C with maximal expression 
levels being attained about 30 days after the addition of HT (Figure 4.2A). This induction 
was reversible, removal of HT from the culture medium resulted in a decrease of AICDA 
expression back to levels similar to those seen in cells with inactive EBNA3C. The regulation 
of AID could also be observed at the protein level as revealed by western blotting with two 
independent antibodies (e.g. Figure 4.2B). 
When compared to other cells, 3CHT LCL with inactive EBNA3C expressed AID at 
levels very similar to purified primary B cells, whereas 3CHT LCL with active EBNA3C 
expressed AID at levels similar to several other B95.8 EBV transformed LCLs (Figure 4.2C 
and D). Some LCL appeared to express very high levels of AID and it is worth mentioning 
that LCL GM12878, a LCL used as tier 1 cell line in ENCODE, was one of these. BL derived 
cell lines (Ramos, Akata, Oku and Namalwa), irrespective of EBV status expressed high 
levels of AID consistent with them having a GC origin. The two EBNA3C expressing BL lines 
Oku (Wp restricted) and Namalwa (latency III) express higher levels than Ramos (EBV 
negative) and Akata (latency I), that do not express EBNA3C. BJAB, a EBV-negative B cell 
lymphoma derived cell line that is not thought to be GC-derived (Klein et al., 1976; Glazer 
and Summers, 1985), and K562 derived from a patient with chronic myelogenous leukemia 
(Lozzio and Lozzio, 1975), expressed low or undetectable levels of AID, respectively. 
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Figure 4.2: Induction of AICDA during the 3CHT A13 time-course and comparison across 
various cell lines. 
(A) Time-course using EBNA3C-conditional LCL 3CHT A13. Cells were grown over 60 days either in 
absence of HT (-HT), presence of HT (+HT) or with HT removed after 30 days +HT (washed). RT-
qPCR gene expression for AICDA was normalised to GAPDH and is shown relative to -HT on day 0. 
(B) AID and γ-tubulin protein expression in selected samples of the 3CHT A13 time-course shown in 
A. (C) RT-qPCR AID mRNA expression in 3CHT LCLs, three in house B95.8 EBV transformed LCL, 
LCL GM12878, Ramos (EBV-negative BL), Akata (EBV-positive BL, latency 1), Oku (EBV-positive, 
latency 3), Namalwa (EBV-positive BL, latency 3), BJAB (EBV-negative B cell lymphoma) and K562 
(EBV-negative erythromyeloblastoid leukemia) was normalised to GAPDH and shown relative to 
primary B cells. Results are shown as mean ± SD of three technical replicates. (D) AID and γ-tubulin 
protein expression in samples shown in C. 
The induction of AID was a direct consequence of the HT-induced activation of 
EBNA3C, because addition of HT to non-conditional 3CKO LCL established from the 
primary B cell infection did not result in activation of AID (Figure 4.3). HT was functional and 
caused induction of AID in EBNA3C-conditional 3CHT LCL over the same experiment. 
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Figure 4.3: HT does not induce AID in non-conditional 3CKO LCL. 
Time-courses using non-conditional 3CKO LCL or conditional 3CHT A13 LCL. Cells were grown over 
30 days either in the presence or absence of HT. Gene expression of AID was normalised to GAPDH 
and is shown relative to day 0 for 3CHT or 3CKO. This result is from a single experiment. 
4.2.3 Comparison between primary B and EBNA3C-conditional LCL 
Direct comparisons of AICDA gene expression in newly EBV-infected primary B cells 
with 3CHT LCLs after activation of EBNA3C revealed very similar kinetics and extent (Figure 
4.4). Similar to the EBNA3C-repressed genes (see Section 3.2.3), EBNA3C-mediated 
induction of AICDA appeared to follow a highly exponential regulation profile (R2 > 0.95) 
over a time period of 30 days when functional EBNA3C was present. Therefore, 3CHT LCL 
can be also used to recapitulate efficiently EBNA3C-mediated gene activation. 
 
Figure 4.4: Comparison of AICDA induction between newly infected primary B cells and 3CHT 
LCL after activation of EBNA3C. 
Comparison of AICDA expression between wild type (wtI6) EBV infected primary B cells and three 
replicate time-courses in 3CHT A13 and C19 after addition of HT. Gene expression was normalised to 
GAPDH and expressed relative to uninfected primary B cells for wtI6 or 3CHT –HT on day 0 for 3CHT 
time-courses. Exponential trendlines were fitted and equations and R2 values are shown. 
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4.2.4 Molecular mechanism of EBNA3C-mediated gene activation 
4.2.4.1 EBNA3C-binding at regulatory regions of AICDA 
The regulation of AICDA in B cells is tightly controlled and regulated on multiple 
layers to prevent expression outside a GC environment (see Figure 1.6). From the results of 
the primary B cell infection, it appeared that EBNA3C did not regulate AICDA expression on 
a post-transcriptional level via miR155 (Figure 4.1C) or indirectly via the major GC 
transcription factor BCL6 – so it is not just inducing the cells to become GC-like (Figure 
4.1B). In order to determine whether EBNA3C regulates the AICDA locus directly (Figure 
4.5A), the ChIP-Seq on EBNA3C-TAP or wild type LCL performed by Dr Kostas Paschos 
was interrogated (Figure 4.5B). EBNA3C occupancy could be detected in four of the 
previously identified regulatory regions that control expression of AICDA. Importantly, all 
regulatory regions indisputably identified as enhancers, namely region II, region IV, region V 
and region VI, showed binding of EBNA3C in the order of magnitude region VI>IV>II>V 
(Figure 4.5B and C). The result of the ChIP-Seq could be confirmed by ChIP-qPCR using 
EBNA3C-TAP LCL and untagged wt LCL, showing a similar order of EBNA3C occupancy at 
the individual regulatory regions (Figure 4.5D). In addition to this, there might be some 
occupancy of EBNA3C at the putative enhancer region III, although for reasons that are 
unclear, the background signal appeared to be remarkably higher at this site compared to 
the other regulatory regions (Figure 4.5D). However, no signal has been detected at this site 
in the ChIP-Seq (Figure 4.5B and C). 
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Figure 4.5: EBNA3C binding at the AICDA locus. 
(A) Schematic overview of previously characterised regulatory regions that control transcriptional 
levels of AID expression (see Introduction). (B) Anti-Flag ChIP-Seq on EBNA3C-TAP (Flag and Strep) 
or untagged (wt) LCL displayed at the AICDA locus using Savant genome browser. The asterisk 
marks a site of identical reads also observed in the input sample (not shown), which is not identified 
as a genuine ChIP-Seq peak by the Model-based analysis of ChIP-Seq (MACS) algorithm. Dr Kostas 
Paschos performed the ChIP-Seqs. (C) Calculated fold enrichment of EBNA3C-TAP at indicated 
regulatory regions of AICDA as determined by ChIP-Seq. (D) Verification of EBNA3C occupancy by 
anti-Flag ChIP-qPCR in EBNA3C-TAP and wt LCL. ChIP values represent enrichment relative to input 
± SD of triplicate qPCR reactions for ChIP and input of each sample. This is a representative of two 
independent biological replicates. 
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4.2.4.2 Changes of epigenetic histone marks control expression levels 
In order to understand better how AICDA is up regulated by EBNA3C after having 
detected EBNA3C binding at most regulatory elements of AICDA and having established 
that 3CHT LCL can be used to recapitulate efficiently gene expression changes of AICDA, 
ChIPs for activation-associated epigenetic histone marks H3K4me3, H3K9ac and H3K27ac 
were performed on the 3CHT A13 time course (Figure 4.6B-D). This revealed that when 
expression of AICDA was induced by EBNA3C there were higher levels of H3K4me3 around 
the promoter region of AICDA (region I), but also at region II ~1.5 kb downstream of the TSS 
(Figure 4.6B). In addition, H3K9ac and H3K27ac increased at these two regions, but also at 
region V, one of the upstream enhancers ~32 kb upstream of the TSS (Figure 4.6C and D). 
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Figure 4.6: Changes in epigenetic marks across the AICDA locus during the 3CHT A13 time-
course. 
(A) UCSC genome browser overview of the AICDA genomic locus showing ChIP-Seq tracks for 
EBNA3C-TAP with occupancy highlighted in blue. DNA sequence conservation to murine AICDA 
locus is shown in green and previously identified regulatory regions I, II, III, IV, V and VI are 
highlighted by black vertical arrows, which also indicate locations for primers used in ChIP-qPCR (C 
indicates a control region). The horizontal arrow indicates the TSS of AICDA. (B-D) ChIP for 
H3K4me3 (B), H3K9ac (C) and H3K27ac (D) on samples from the 3CHT A13 time-course at locations 
across the AICDA locus, at GAPDH or myoglobin as indicated. Cells were grown in the absence (-HT) 
or presence of HT (+HT) and numbers indicate the day of harvest. ChIP values represent enrichment 
relative to input ± SD of triplicate qPCR reactions for ChIP and input of each sample. This is a 
representative of two independent biological replicates (see Appendix Figure 7.6). 
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Similar results were observed in the biological replicate time-course 3CHT C19 
(Appendix, Figure 7.6A-C). Therefore, normalised histone marks H3K4me3 and H3K9ac at 
region I from both replicate time-courses could be averaged and compared with AICDA 
mRNA expression. H3K4me3 and H3K9ac increased at the TSS from day 15 onwards 
(Figure 4.7A), which correlates well with AICDA gene expression (Figure 4.7B). 
 
Figure 4.7: Correlation between changes of histone marks H3K4me3 and H3K9ac at the TSS of 
AICDA and gene expression. 
(A) ChIP-qPCR values at the TSS of AICDA (region I) from the 3CHT A13 and 3CHT C19 time-
courses were normalised by setting H3K4me3 and H3K9ac levels from the last time-point +HT (day 
30) to 1 and levels from the first time-point –HT (day3) were used as equivalent for day 0. Mean 
values ± SD from both replicate time-courses are shown. For better visual clarity, error bars are 
colour-matching the corresponding histone mark and only upper bars are shown for H3K9ac and 
lower bars for H3K4me3. (B) RT-qPCR gene expression for AICDA from three replicate time courses 
(3CHT A13 rep 1+2 and 3CHT C19) was normalised to GAPDH and is shown as mean values ± SD. 
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4.2.4.3 Factor recruitment to the AICDA locus 
Having seen an increase in activation-associated histone marks when AICDA was 
activated by EBNA3C, I focused on identifying recruited factors that catalysed these 
changes. Historically, PRC1 was linked to gene repression, but more recently PRC1 
complexes have been found at actively expressed genes (see Introduction) and EBNA3C 
appears to induce its recruitment (see previous Chapter and General Discussion). 
Therefore, ChIP for BMI1 was performed on the 3CHT A13 time-course, which showed an 
increase in BMI1 occupancy when AICDA was up regulated by functional EBNA3C (Figure 
4.8B). Increased BMI1 levels were seen mainly at region IV and VI, but, to a lesser extent, 
also at region II and region V – all of which are regions where EBNA3C was detected. 
Furthermore, ChIP for histone acetyltransferease p300 – one of the few 
transcriptional co-activators with which EBNA3C has been reported to interact in GST-pull 
down experiments (Subramanian et al., 2002) – revealed that there was a transient 
recruitment of p300 mainly to regions IV and VI, again only when EBNA3C was functional 
(Figure 4.8C). 
Since EBNA3C cannot bind directly to DNA, again ChIP for the DNA binding factor 
RBPJ was performed (Figure 4.8D). This showed that RBPJ occupancy transiently 
increased at all regions where EBNA3C was found and the levels of recruited RBPJ 
correlated well with the levels of EBNA3C detected by ChIP-Seq (region VI>IV>II>V). 
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Figure 4.8: Factor binding to the AICDA locus during the 3CHT A13 time-course. 
(A) UCSC genome browser overview of the AICDA genomic locus showing ChIP-Seq tracks for 
EBNA3C-TAP with occupancy highlighted in blue. DNA sequence conservation to murine AICDA 
locus is shown in green and previously identified regulatory regions I, II, III, IV, V and VI are 
highlighted by black vertical arrows, which also indicate locations for primers used in ChIP-qPCR (C 
indicates a control region). The horizontal arrow indicates the TSS of AICDA. (B-D) ChIP for BMI1 
(B), p300 (C) and RBPJ (D) on samples from the 3CHT A13 time-course at locations across the 
AICDA locus, at GAPDH or myoglobin as indicated. Cells were grown in the absence (-HT) or 
presence of HT (+HT) and numbers indicate the day of harvest. ChIP values represent enrichment 
relative to input ± SD of triplicate qPCR reactions for ChIP and input of each sample. 
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Similar ChIP results were observed in the 3CHT C19 time-course (Appendix Figure 
7.6D-F), which again allowed a more detailed analysis of the recruited factors to AICDA 
regions IV and VI using the combined results of the 3CHT A13 and C19 time-courses 
(Figure 4.9). This analysis revealed that maximal BMI1 levels could be detected about 9 
days after activation of EBNA3C, however, again these levels were not maintained and 
subsequently decreased to levels similar or marginally higher than in cells with inactive 
EBNA3C (Figure 4.9A). Acetyltransferase p300 showed maximal levels around day 15 after 
activation of EBNA3C, but here levels seem to remain higher compared to cells with inactive 
EBNA3C (Figure 4.9B). RBPJ occupancy sharply peaked 3-6 days after activation and 
quickly decreased to levels similar to those in cells with inactive EBNA3C (Figure 4.9C). 
 
Figure 4.9: Binding of BMI1, p300 and RBPJ to AICDA region IV and VI after activation of 
EBNA3C. 
ChIP-qPCR values for BMI1 (A), p300 (B) and RBPJ (C) at AICDA region IV and VI from the two 
biological time-courses (3CHT A13 and C19) were normalised by setting the maximal enrichment 
level during each time-course to one and by using the first time-point –HT (day 3) as equivalent for 
day 0. Mean values ± SD from both replicate time-courses are shown. For better visual clarity, error 
bars are colour-matched and only lower bars are displayed for region IV and upper bars for region IV. 
For BMI1, day nine of the C19 time-course was treated as an outlier and was not taken into account 
for the analysis. 
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4.2.5 Induction of AICDA is dependent on interaction between RBPJ and EBNA3C 
In order to determine whether the interaction between EBNA3C and RBPJ is essential for 
the EBNA3C-mediated up regulation of AICDA, Adam Gillman analysed primary B cells 
infected with the RBPJ BM EBNA3C virus (see Figure 1.10B, Figure 1.17 and previous 
Chapter) for expression of AICDA (Figure 4.10). This revealed that EBNA3C failed to induce 
expression of AICDA when it cannot bind to RBPJ, which was similar to infection with 
EBNA3C KO virus. However, all recombinant viruses where EBNA3C could interact with 
RBPJ (wtA5 and 3CRev) showed induction of AICDA comparable to the previous primary B 
cell infections (Figure 4.1). 
 
Figure 4.10: Ability of EBNA3C to bind to RBPJ is essential for the activation of AICDA. 
Infection of purified primary B cells with wild type (wtA5), EBNA3C knock-out (3CKO), EBNA3C 
revertant (3CRev) or RBPJ binding mutant (BM) EBNA3C recombinant EBV. Over a period of 30 days 
post infection, RT-qPCR gene expression for AICDA was normalised to GNB2L1 and shown relative 
to uninfected primary B cells. This is a single experiment that was performed and analysed by Adam 
Gillman. 
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4.2.6 EBNA2 represses and LMP1 induces expression of AID 
The regulation of AICDA by EBV is very complex and appears to involve factors other 
than EBNA3C. Previously, it has been reported that LMP1 and to a lesser extent LMP2A can 
also induce expression of AICDA (He et al., 2003), whereas EBNA2 has been reported to 
repress expression of AICDA (Tobollik et al., 2006). 
In order to confirm that AID is regulated by EBNA2, a time-course experiment in 
EBNA2-conditional EREB 2-5 cells was performed based on the previous study from 
Tobollik and colleagues. EREB 2-5 cells are infected with EBV strain P3HR1 that is 
truncated for EBNALP and deleted for EBNA2, but contain a stable expression plasmid 
encoding an EBNA2-estrogen receptor fusion protein that renders EBNA2-conditional to the 
presence of β-estradiol in the culture medium (Kempkes et al., 1995). Withdrawal of β-
estradiol from the medium inactivates EBNA2 and cell proliferation ceases, because EBNA2 
is essential to maintain B cell proliferation. A time-course experiment in these cells 
confirmed that inactivation of EBNA2 led to an increase in AID mRNA and protein 
expression (Figure 4.11A and B). This increase in AID is not caused by LMP1, because 
LMP1 protein levels quickly decrease in the absence of EBNA2. Re-activation of EBNA2 
resulted in a very rapid repression of AID at the mRNA level and remarkably slower at the 
protein level. A minor re-induction was observed at 8 and 24 hours, which was potentially 
caused by the EBNA2-induced transiently high levels of LMP1 (Figure 4.11A and B). These 
results are very similar to reports from Tobollik and colleagues with the exception that the 
LMP1-mediated induction of AID, probably through increased NFκB signalling, was less 
pronounced. This confirms that EBNA2 is a potent repressor of AID expression, whereas 
LMP1 seems to be only a weak activator of AID expression. 
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Figure 4.11: Repression of AID by EBNA2 in EREB 2-5 cells. 
(A) EBNA2-conditional time-course using EREB 2-5 cells. Before the start of the time-course cells 
were always cultured in the presence of β-estradiol (est), which was removed on day 0 and cells were 
cultured for 3 days in the absence of β-estradiol (-est) before re-addition of β-estradiol (+est). RT-
qPCR gene expression of AICDA was normalised to GAPDH and is shown relative to day 0. (B) 
Western blot analysis for AID, LMP1 and γ-tubulin in the same samples as in A. 
This prompted me to analyse protein levels of EBNA2 and LMP1 in samples of the 
two 3CHT time-courses. Levels of EBNA3 proteins did not consistently change during either 
time-course, however a decrease in EBNA2 and LMP1 protein levels was observed in 
samples with functional EBNA3C (+HT) during the A13 (Figure 4.12A) and the C19 (Figure 
7.2) time-courses, which was more pronounced in the A13 than in the C19 time-course. 
This raised the question whether the induction of AID was directly caused by 
EBNA3C or merely a consequence reduced EBNA2-mediated repression of AID. The very 
rapid repression of AID by EBNA2 within 4 hours after re-activation of EBNA2 suggested a 
direct regulation and analysis of ChIP-Seq data for EBNA2 in Mutu III cells (McClellan et al., 
2013) revealed EBNA2 occupancy at AICDA regulatory regions III, IV, V and VI (Figure 
4.12B). EBNA3C is found at the same upstream enhancers (IV, V and VI) and it is possible 
that both compete for access to these sites probably through competitive binding to RBPJ, 
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which was detected during the 3CHT time-courses (Figure 4.8D and Figure 7.6F) and also in 
ChIP-Seq analysis in IB4 LCL (Zhao et al., 2011a). 
In order to determine whether the induction of AICDA by EBNA3C was merely a 
consequence of lower global EBNA2 levels leading to reduced local EBNA2 occupancy at 
the regulatory sites of AID, EBNA2 ChIP was performed on samples of the 3CHT A13 and 
C19 time-courses. This revealed very marginal reduction or no changes to EBNA2 levels at 
the regulatory regions of AICDA in samples with functional EBNA3C compared to samples 
with inactive EBNA3C (Figure 4.12D and Figure 7.6G). EBNA2 binding at the promoter 
region of HES1 (Sakai et al., 1998), a well-characterised EBNA2-regulated gene, was used 
as positive control, which appeared to be quite variable between samples, but no consistent 
change in samples with functional EBNA3C compared to samples with inactive EBNA3C 
could be detected. Therefore, it does not appear that high levels of EBNA2 are actively 
repressing expression of AID in the absence of functional EBNA3C, which is consistent with 
a basal rate of AICDA transcription comparable to primary B cells. 
The fact that EBNA2 represses and EBNA3C activates the expression of AID is 
surprising, because usually EBNA2 recruits co-activators, whereas EBNA3C recruits co-
repressors (see Introduction). This will be discussed in the Discussion section of this and the 
next Chapter. 
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Figure 4.12: Global EBNA2, EBNA3 and LMP1 protein levels and occupancy of EBNA2 at the 
AICDA locus during the 3CHT A13 time-course. 
(A) Western blot analysis on samples of the 3CHT A13 time-course for EBNA3A, EBNA3B, EBNA3C, 
EBNA2, LMP1 and γ-tubulin. (B) UCSC genome browser overview of AICDA locus as in Figure 4.6A, 
but also showing ChIP-Seq data for RBPJ in IB4 LCL (Zhao et al., 2011a) and EBNA2 in Mutu III 
(McClellan et al., 2013). EBNA2 binding sites at AICDA regulatory regions are highlighted in red. (C) 
ChIP for EBNA2 on samples from 3CHT A13 time-course at locations across the AICDA locus, at 
GAPDH or HES1 as indicated. Cells were grown in the absence (-HT) or presence of HT (+HT) and 
numbers indicate the day of harvest. ChIP values represent enrichment relative to input ± SD of 
triplicate qPCR reactions for ChIP and input of each sample. 
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4.2.7 Transient reporter assays in an attempt to recapitulate regulation of AICDA by 
EBNA3C and EBNA2 
In order to determine whether the regulation of AICDA by EBNA3C and EBNA2 can 
be recapitulated in transient reporter assays, all the regulatory elements of AICDA that were 
identified at that time, namely region I, II, III and IV [region V and VI were only reported later 
in (Kieffer-Kwon et al., 2013)], were PCR amplified from genomic DNA extracted from LCL 
GM12878 introducing restriction enzyme recognition sequences for subsequent cloning into 
the pGL3-basic vector (see Material and Methods and Figure 4.13A). 
Electroporation of these luciferase vectors into DG75 cells revealed a basal promoter 
activity of region I, a subtle repressive capacity of region II and enhancer activities of region 
III and IV (Figure 4.13B). To my knowledge, this is the first time that human regulatory 
regions of AICDA were used in transient reporter assays. However, these results are similar 
to reports from transient luciferase assays using the corresponding murine regulatory 
sequences of mouse Aicda. Mouse region I was reported to increase luciferase activity 
between 5-15 fold above pGL3-basic vector (Yadav et al., 2006; Park et al., 2009; Tran et 
al., 2010b), which was slightly repressed by the presence of region II (Park et al., 2009; Tran 
et al., 2010b) or increased by the presence of region IV (Tran et al., 2010b). In contrast, 
mouse region III did not affect luciferase activity in these transient assays (Tran et al., 
2010b), but was shown to be necessary for Aicda expression in a BAC transgenic mouse 
model (Crouch et al., 2007). The results from human region III suggest a positive effect on 
luciferase activity (Figure 4.13B). 
Having established that human AICDA regulatory regions have a similar effect on 
luciferase activity as those from mouse Aicda, my next aim was to determine their role in the 
regulation by EBNA3C and EBNA2. Therefore, increasing amounts of EBNA3C or EBNA2 
expression plasmids were transfected together with luciferase vectors containing region I 
and in addition either region II (Figure 4.13C), region III (Figure 4.13D) or region IV (Figure 
4.13E). Unfortunately, no consistent effect on luciferase activity could be observed for region 
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II and IV. For region III, large amounts of EBNA3C seemed to have a repressive effect, 
which was unexpected and very likely due to levels of expression outside the physiologic 
range (5,000-10,000 expression plasmids per cell in the transfection). From these results it 
also seems that EBNA2 might activate region III, which again contradicts the expectation 
and the technical variation between individual experiments was rather large (Figure 4.13D). 
For reasons that remain unclear, it was not possible to recapitulate regulation of AICDA by 
EBNA3C or EBNA2 in transient reporter assays using sub-genomic fragments. This strategy 
was therefore not pursued further. 
 
Figure 4.13: Attempt to recapitulate regulation of AICDA in transient reporter assays. 
(A) Overview of luciferase vectors. The 1 kb promoter region of AICDA (region I, black arrow) and 1 
kb around the AICDA regulatory regions II and III or 2 kb for region IV (black boxes) were cloned 
upstream or downstream of the luciferase gene (grey box). (B) Transient luciferase reporter assays in 
DG75 cells after electroporation of 1 µg of reporter vector as indicated and expressed relative to the 
promoter-less basic vector. (C-E) Transient luciferase reporter assays in DG75 after electroporation of 
1 µg luciferase vector – Reg II (C), Reg III (D) or Reg IV (E) – and increasing amounts of EBNA3C or 
EBNA2 expression plasmids as indicated. Luciferase units were normalised to β-galactosidase units 
of the same transfection and are shown as mean relative luciferase units (RLU) ± SD.  
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4.3 Summary 
• EBNA3C is essential for the up regulation of AICDA in newly EBV-infected 
primary B cells. 
• EBNA3C-conditional LCL can be used to reliably recapitulate EBNA3C-
mediated induction of AICDA seen in newly EBV-infected primary B cells. 
• EBNA3C directly targets all regulatory regions of AICDA that have been 
previously identified as enhancers. 
• Activation-associated epigenetic marks are deposited across the AICDA locus 
when EBNA3C is functional probably through recruitment of acetyltransferase 
p300. The role of recruited BMI1 is unclear, but raises interesting questions 
concerning PRC1 in gene activation. 
• Ability of EBNA3C to bind to RBPJ is absolutely essential for the induction of 
AICDA. 
• Other EBV proteins are involved in the regulation of AICDA: 
• EBNA2 represses AID, possibly by targeting most of the regulatory 
regions of AICDA that are also targeted by EBNA3C. 
• LMP1 up regulates AID, possibly through NFκB signalling. 
• Regulation by EBNA3C or EBNA2 could not be recapitulated in transient 
reporter assays. 
• Most of the results presented in this Chapter have been submitted to JEM for 
publication and are currently under peer review. 
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Figure 4.14: Model of gene activation by EBNA3C at AID genomic locus. 
(A) In the absence of functional EBNA3C, AICDA is expressed at basal levels comparable to primary 
B cells. EBNA2 has been detected to bind to regulatory regions III, IV, V and VI and has the potential 
to negatively affect AICDA transcription. (B) Presence of functional EBNA3C, leads to the 
recruitment/stabilisation of what are probably RBPJ:EBNA3C complexes at regulatory regions II, IV, V 
and VI (occupancy levels in the following order: VI>IV>II>V). Acetyltransferase p300 and the PRC1 
subunit BMI1 are recruited to region IV and VI and an increase in activation-associated histone marks 
can be detected at region I and region V. Chromatin looping between the upstream enhancers and 
the promoter probably supports high transcription levels of AID. 
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4.4 Discussion 
The discussion of this Chapter will only focus on issues specific for EBNA3C-
mediated gene activation. A broader discussion of issues regarding the role of EBNA3C in 
gene regulation can be found in Chapter 5. 
At the onset of this study, compared with EBNA3C-mediated gene repression, near to 
nothing was known about the role of EBNA3C in gene activation. Here, focusing on the gene 
most robustly induced by EBNA3C as revealed in an exon microarray screen, some insights 
could be obtained. Infection of primary B cells with recombinant EBV showed clearly that 
EBNA3C is essential for the induction of AID expression. AID activity is controlled on 
multiple levels (see Figure 1.6), but it appeared that EBNA3C only acts at the transcriptional 
level. It specifically targets most of the DNA regulatory elements that have been previously 
identified to control expression of AID, most importantly all previously identified enhancer 
elements that together form the AID super-enhancer are targeted by EBNA3C. Activation of 
EBNA3C function resulted in the deposition of activation-associated histone modifications 
mainly around the TSS of AICDA. The levels of these histone marks correlated well with AID 
mRNA expression. 
4.4.1 Dynamic recruitment of RBPJ during EBNA3C-mediated induction of AICDA 
Again, most surprising was the dynamic recruitment and/or stabilisation of what are 
probably RBPJ/EBNA3C complexes at the EBNA3-binding sites in the enhancer regions of 
AID after activation of conditional EBNA3C by the activating ligand HT. The observation that 
EBNA3C activates and EBNA2 represses the AID locus, possibly through competitive 
binding to RBPJ, is also very surprising (Figure 4.14). This turns the traditional models of 
EBNA2- and EBNA3C-mediated gene regulation on their head (Figure 1.16C and Figure 
1.16D), because typically EBNA2 is considered as potent transactivator and EBNA3C as 
strong repressor when anchored to DNA. Although EBNA2 and EBNA3C have been linked 
to gene repression and activation, respectively (see Introduction), to my knowledge 
Chapter IV: Gene activation by EBNA3C 
 176 
repression by EBNA2 and activation by EBNA3C have not been previously reported for the 
same gene. Dynamic recruitment of RBPJ in gene activation has been reported during 
Notch signalling (in both Drosophila and mammals) and also in response to EBNA2 (see 
Section 3.4.1), but to my knowledge this is the first time it has been observed for EBNA3C-
mediated gene activation. 
Previous studies found that the EBNA3C-mediated gene activation of the viral LMP1 
promoter (in transient reporter assays) was independent of RBPJ, but required PU.1/SPI1 
binding sites (Zhao and Sample, 2000; Lin et al., 2002). Here, however, binding of EBNA3C 
to RBPJ appears to be essential for the activation of AICDA, as determined by infection of 
primary B cells with the RBPJ BM EBNA3C virus (Figure 4.10). It is possible that EBNA2 
inhibits activation of AID by competing with EBNA3C for binding to RBPJ, however, 
mechanisms independent of RBPJ might also be involved (see Section 4.4.3). 
A more extended discussion on the role of RBPJ in EBNA3C-mediated gene 
regulation can be found in Chapter 5. 
4.4.2 Role of BMI1 (PRC1) and p300 in EBNA3C-mediated gene activation 
Another surprise was the transient recruitment of BMI1 to the regulatory sites of 
AICDA with levels correlating with EBNA3C-occupancy (VI>IV>II>V), because BMI1 as part 
of PRC1 was traditionally associated with gene repression and silencing. However, both 
PRC1 and PRC2 complexes have been recently associated with gene activation (see 
Section 1.3.3.2.1). No recruitment of the PRC2-family member SUZ12 could be detected 
during the 3CHT A13 and C19 time-courses at sites across the AICDA locus (Figure 7.7). It 
is unclear what role BMI1 plays at the AICDA locus, but it has been reported at actively 
expressed genes (Frangini et al., 2013). 
Frangini and colleagues found that PRC1 (Ring1B, Bmi1 and Cbx7) and Aurora B 
could be co-immunoprecipitated and co-occupied many active promoters in resting murine B 
and T cells. Knock-out of either Ring1B or Aurora kinase B resulted in reduced transcription 
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of these genes and decreased cell viability. Aurora kinase B was found to phosphorylate 
H3S28, inhibit PRC1-catalysed ubiquitination of H2AK119 and recruit deubiquitinase USP16 
at these promoters (Frangini et al., 2013). Interestingly, EBNA3C has been shown to directly 
interact with Aurora kinase B by co-immunoprecipitation and GST pull downs, which mapped 
the interaction to the N-terminal residues 90-160 of EBNA3C (Jha et al., 2013). As PRC1 
proteins and EBNA3C can independently bind to Aurora kinase B, it is therefore possible 
that an activating EBNA3C-PRC1-Aurora kinase B complex is recruited to the AICDA locus. 
ChIP for Aurora kinase B has been attempted, but not pursued, because Aurora kinase B is 
globally recruited to condensed chromatin during mitosis, which would make data 
interpretation very difficult in LCL that continuously proliferate. ChIP to assess 
phosphorylation levels of H3S28 across the 3CHT A13 and C19 time course was not 
performed because activated B cells display this mark only on mitotic chromosomes 
(Sabbattini et al., 2014). 
Some PRC1 complexes have been found to interact with autism susceptibility gene 2 
(AUTS2) protein that activated gene expression through recruitment of p300 to promoter 
regions controlling neural gene expression during the development of the mouse central 
nervous system (Gao et al., 2014). However, it is important to mention that the AUTS2 
containing PRC1 complexes were limited to PRC1.3 and PRC1.5, but have not been 
described for canonical or non-canonical PRC1.4 that contain BMI1 (see Figure 1.14). 
Interrogation of the 3CHT exon-microarray indicated that AUTS2 is expressed in LCL and it 
is possible that other PRC1 complexes, which can interact with AUTS2, helped with the 
recruitment of p300, but this has not been investigated. 
Amounts of the acetyltransferase p300 predominantly increased at AICDA regulatory 
regions IV and VI, the two sites with highest levels of EBNA3C. However, no direct increase 
in H3K9 and H3K27 acetylation was detected at these two sites, but at regulatory regions I, 
II and V, which are sites up to 20kb away from where p300 was detected. Analysis of 
publically available HiC data from LCL GM12878 cells [Figure 4.15A, (Rao et al., 2014)], 
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which highly express AID mRNA and protein and constitutively express EBNA3C (Figure 4.2 
C and D), suggested that all upstream AICDA regulatory regions (IV, V and VI) are in 
contact with the AICDA promoter region (Figure 4.15B). Similarly, in cytokine activated 
murine B cells that express high levels of AID, all upstream Aicda regulatory regions (IV, V 
and VI) were found to be associated in long-range interactions with the promoter region 
determined by chromatin interaction analysis by paired-end tag sequencing (ChIA-PET) of 
polymerase II (Kieffer-Kwon et al., 2013). Furthermore, it has been suggested that PRC1 
complexes together with CTCF are involved in the formation of higher order chromatin 
structures that are essential for gene activation (Schaaf et al., 2013; Kondo et al., 2014). 
Therefore, it is likely that PRC1 proteins are recruited in order to either directly help in 
the recruitment of transactivators like p300 and Aurora kinase B and/or to provide support in 
the formation of the higher order chromatin structure that facilitates EBNA3C-mediated 
recruited p300 to acetylate regulatory regions that are located up to 20kb away from its main 
binding sites (Figure 4.14). 
 
Figure 4.15: Higher order chromatin structure of the AICDA locus in LCL GM12878. 
(A) Hi-C map GM12878 in situ MboI combined (4.9B) at 1kb resolution was displayed using Juicebox 
[http://www.aidenlab.org/juicebox/, (Rao et al., 2014)]. The observed number (balance normalised) of 
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contacts between a pair of loci is represented by the intensity of each pixel. AICDA and MFAP5 gene 
locations, H3K27ac in LCL GM12878, a topological associating domain (blue box) and locations of 
AID regulatory regions I, II, IV, V and VI are indicated. (B) Schematic overview of higher order 
chromatin structure of the AICDA locus in LCL GM12878 with chromatin looping indicated by black 
arrows between the promoter region of AICDA and upstream enhancer elements IV, V and VI. 
The importance of the correct higher order chromatin structure is also one possible 
explanation why EBNA3C-mediated activation and EBNA2-mediated repression of AICDA 
could not be recapitulated in transient luciferase reporter assays, when regulatory regions II, 
III and IV were taken out of their context and cloned individually into pGL3-basic vector 
containing the AICDA basal promoter (region I). To circumvent this problem, luciferase 
reporter BACs could be constructed that drive the expression of a luciferase gene cloned in 
place of the first intron of AICDA and otherwise contain either the entire AICDA locus or are 
deleted for individual regulatory regions. 
4.4.3 Regulation of AICDA by EBNA2 and LMP1 
The results of the EBNA2-conditional time-course using EREB 2-5 cells clearly 
confirmed EBNA2 as a negative regulator of AID expression (Tobollik et al., 2006) and 
LMP1 as a moderate inducer of AID expression (He et al., 2003). It is surprising, that in the 
regulation of AID, EBNA2, that is traditionally seen as a strong transactivator, is acting as a 
very potent repressor. In contrast, EBNA3C, that is more readily associated with repression, 
is essential for gene activation. It is important to mention that AID expression can be induced 
by β-estradiol via binding of estrogen receptors to the AID promoter (Pauklin et al., 2009). 
However this is not a concern for this study, because addition of β-estradiol to EBNA2-
conditional EREB2-5 cells results in a potent repression of AID expression and was reported 
not to affect AID expression in non-conditional EBNA2 cell lines (Tobollik et al., 2006). 
Furthermore, addition of HT, an estrogen antagonist, to 3CHT LCL results in the induction of 
AID and addition to non-conditional 3CKO LCL did not activate AID expression (Figure 4.3). 
The induction of AID expression in EREB 2-5 cells after inactivation of EBNA2 is 
probably a cumulative effect of lost repression by inactivated EBNA2 and maintained 
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activation by EBNA3C. Expression of EBNA3C is dependent on active EBNA2, but due to 
the relative long half-life of EBNA3C protein (Touitou et al., 2005), active EBNA3C is 
probably still present after EBNA2 has been inactivated. Unfortunately, EREB 2-5 cells 
express type II EBNA3C that cannot be detected by the anti-EBNA3C A10 antibody in 
western blots (Maunders et al., 1994). Interrogation of EBNA2 ChIP-Seq indicated that 
EBNA2 and EBNA3C seem to target mostly the same regulatory elements. Analysis of 
ChIP-Seq for RBPJ in IB4 LCL (Zhao et al., 2011a) revealed that RBPJ occupancy is 
highest at regulatory regions IV, VI and V, which is similar to the RBPJ ChIP results from the 
3CHT A13 and C19 time-course. Therefore, it seemed likely that EBNA2 and EBNA3C 
compete for binding to RBPJ to obtain access to the upstream regulatory regions of AICDA 
(Figure 4.14). However, ChIP for EBNA2 on samples of the 3CHT A13 and C19 time-
courses did not reveal changes in EBNA2 occupancy at these sites that would support a 
competitive binding model of EBNA2 and EBNA3C to these sites. Furthermore, repression 
of IgM and BCL6 by EBNA2 has been reported to be only partially dependent on RBPJ, as 
repression still occurs after activation of EBNA2 in RBPJ-null DG75 (Maier et al., 2005; 
Boccellato et al., 2007). Therefore, beside competing with EBNA3C for binding to RBPJ, 
other mechanisms may be involved in EBNA2-mediated gene repression of AID. However, 
the up regulation of AID in newly EBV-infected B cells indicates that EBNA3C-mediated 
induction dominates over EBNA2-mediated repression of AID. 
The effect of LMP1 on the expression of AID was rather moderate and it did not seem 
to play a role in the initial up regulation of AID after inactivation of EBNA2, because LMP1 
protein levels decreased rapidly and were barely detectable while AID levels still increased. 
Even the high levels of LMP1 after re-activation of EBNA2 only resulted in a relative 
moderate transient increase in AID mRNA levels, which was however in contrast to the more 
pronounced effect of LMP1 at these time-points observed by Tobollik and colleagues. LMP1 
was shown to up regulate AID expression via NFκB and EGR-1 signalling (Kim et al., 2013). 
NFκB binding sites have been reported within AICDA regulatory regions I (Dedeoglu et al., 
Chapter IV: Gene activation by EBNA3C 
 181 
2004; Gourzi et al., 2007; Park et al., 2009; Tran et al., 2010b), region II (Yadav et al., 2006; 
Tran et al., 2010b) and region IV (Tran et al., 2010b). Interrogation of ChIP-Seq for NFκB 
subunits RelA, RelB, cRel, p50 and p52 in GM12878 (Zhao et al., 2014) revealed occupancy 
of all five NFκB subunits predominantly at region IV, but also at region II, V and VI (Figure 
4.16). In order to investigate whether changes in NFκB signalling during the 3CHT A13 and 
C19 time-courses were involved in the up regulation of AID expression, ChIP for RelA was 
attempted. This produced very low enrichment levels at all AICDA regulatory sites, however 
the ChIP did not seem to work, because no enrichment of RelA could be detected at the 
promoter region of EBI3, a LMP1/NFκB-regulated gene chosen as a positive control (data 
not shown). Furthermore, no increase, but rather a decrease in LMP1 expression was 
observed during the 3CHT A13 and C19 time-courses (Figure 3.12 and Figure 7.2). 
Assuming unaltered LMP1/NFκB signalling in cells with active and inactive EBNA3C, this 
suggests that LMP1 does not play a major role in the induction of AID. However, in order to 
determine whether LMP1 has to be present for the EBNA3C-mediated induction of AID and 
to assess the extent of LMP1 in the regulation, primary B cells would have to be infected 
with LMP1 KO virus. This however is complicated by the fact that LMP1 is important for B 
cell transformation by EBV. LMP1 KO LCL can be established, but only in the presence of 
feeder cells and with a low efficiency (Dirmeier et al., 2003). 
 
Figure 4.16: NFκB binding at AICDA locus in GM12878. 
UCSC genome browser overview of AICDA genomic locus showing ChIP-Seq data for NFκB subunits 
RelA, RelB, cRel, p50 and p52 in GM12878 (Zhao et al., 2014). Positions of the AICDA regulatory 
regions (I-VI) are indicated below the ChIP-Seq tracks. 
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In summary, the precise interplay between EBNA3C and EBNA2 in the regulation of 
AICDA remains to be determined. The results presented here suggest that both nuclear 
proteins are directly involved in the regulation and might compete with each other for binding 
to RBPJ. Infection of primary B cells with EBV and the 3CHT conditional system showed that 
the presence of functional EBNA3C is absolutely essential for the activation of AID and 
further depends on the ability of EBNA3C to bind to RBPJ, indicating that EBNA3C-mediated 
induction dominates over EBNA2-mediated repression of AID. LMP1, probably through 
NFκB signalling, seems to play only a minor role in the induction of AID. 
4.4.4 Why does EBV activate AID expression and what at are the consequences for 
the EBV-infected B cells? 
In addition to providing insight into the molecular mechanisms by which EBV 
deregulates AID expression, this study raises very interesting questions about why EBV 
activates AID expression in newly infected B cells, what consequences this has for EBV-
infected B cells and why it might favour EBV. 
Expression of AID at high levels is generally limited to GC B cells (see Section 
1.1.5.3) and expression of EBNA3C in vivo is thought to be limited to EBV-infected B blasts 
prior to their entry into GCs (Figure 4.17A). Therefore, EBNA3C expression has the potential 
to induce AID in pre-GC EBV-infected B blasts resulting in AID expression for a longer time 
and possibly at higher levels. Although LMP1 and LMP2A were believed to provide the 
necessary pro-survival signals for EBV-infected B cells to survive the GC reaction, it has 
been found that EBV-infected B cells still undergo CSR (Babcock et al., 1998; Joseph et al., 
2000a) and SHM with a pattern that is similar to antigen-selected memory B cells (Souza et 
al., 2005). Therefore, EBV-infected B cells appear to participate in the normal B cell 
selection process in GCs and it is possible that increased levels of AID might provide them 
with a higher probability of surviving the GC reaction. This would be consistent with the 
observation that EBV positive memory B cells are more likely to have undergone CSR and 
to contain a higher number of SHM compared to EBV negative memory B cells (Souza et al., 
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2007). Although the induction of AID by EBNA3C in vitro was relatively slow (see Section 
5.1.1 for an extended discussion on the kinetics of EBNA3C-mediated gene regulation) this 
might be sufficient to favour EBV-infected B cells by expressing AID before they enter GCs 
and therefore over a longer time-frame and maybe at higher levels. It is also possible that 
the induction is more rapid in vivo. 
This does however not explain why EBNA2 has the ability to counter-act EBNA3C-
mediated induction of AID. It is possible that EBNA2 is required to fine-tune AID expression. 
EBNA2 expression has to cease in order to allow EBV-infected B blasts to express BCL6, to 
enter GCs and to differentiate. This will also result in the loss of EBNA3C expression, but 
AID expression probably remains high due to signals from Tfh cells in the GC environment. 
Repression of AID by EBNA2 might be a viral fail-safe mechanism that prevents overly high 
levels of EBNA3C-induced AID, which could potentially be disadvantageous for the host and 
virus (see below), when EBV-infected cells fail to switch off EBNA2 and therefore cannot 
transit through the GC to become memory B cells (Figure 4.17B). 
Interestingly, recently EBV infected B cells were discovered in the marginal zone 
surrounding GCs and these had the phenotype of non-class switched memory B cells (IgD+ 
and CD27+). In addition, they expressed the EBV latency III programme and showed signs 
of extensive proliferation [Figure 4.17B, (Thorley-Lawson, 2015)]. These cells seem to have 
failed to switch off EBNA2 and could therefore not enter a GC, but it remains be confirmed 
that they are BCL6-negative and AID-positive. If they are AID-positive, EBNA2 might ensure 
that AID expression levels are restricted by counter-acting the EBNA3C-mediated activation 
of AID. Latency III expressing B blasts are effectively targeted by CTLs (see Section 1.2.5.4) 
so it remains to be determined how common these marginal zone EBV-infected B blasts are, 
how long they survive and whether they are important in the EBV life cycle. 
These cells could be the in vivo counterparts of LCLs established by infection of 
naïve B cells with EBV in culture, which remain BCL6-, become CD27+, express AID and 
undergo SHM [(Siemer et al., 2008) and this study], but not CSR without external T cell 
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stimuli and therefore remain IgD+ (Heath et al., 2012). It has been suggested that EBV 
infection per se could be sufficient to reach the memory B cell compartment without the need 
for cells to transit GCs [Figure 4.17B, (Heath et al., 2012)]. However, this remains to be 
confirmed in vivo and currently an adequate explanation of how EBV would switch directly 
from latency III in proliferating B blasts to latency 0 in resting memory B cells is lacking 
(Thorley-Lawson, 2015). 
 
Figure 4.17: Are there different routes to EBV latency and what is the role of AID? 
(A) Classical germinal centre (GC) model of persistence (see Figure 1.7 for details). Latency III 
expressing EBV-infected B blasts potentially start expressing AID and to undergo somatic 
hypermution (SHM) as a result of EBNA3C expression, but are unable to enter GCs due to the 
repression of BCL6 by EBNA2. Switch from latency III to latency II allows B blasts to enter GC and to 
undergo class switch recombination (CSR). CD27+ memory B cells emerge from GC reaction and 
enable persistent infection. (B) Prolonged proliferation of latency III expressing EBV-infected B blasts 
could be possible in the marginal zone surrounding GCs. These cells would originate from cells that 
fail to repress EBNA2 and might represent the in vivo counterpart of LCL (AID+, BCL6-, SHM+, CSR- 
and CD27+). They represent targets for cytotoxic T lymphocytes (CTL) as they express latency III. It 
might be possible that the memory B cell compartment is reached via GC-independent pathways. 
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A major unanswered question is what effect does AID have on EBV-infected B cells. 
Previous in vitro studies have detected ongoing SHM in the IgH V(D)J region of an 
established LCL derived from a rheumatoid arthritis patient (Gil et al., 2007; Chezar et al., 
2008; Laskov et al., 2011), but in newly EBV-infected naïve B cells only around 30-35% of 
the developing clones exhibited IgH V(D)J SHM (Siemer et al., 2008; Heath et al., 2012). 
Heath and colleagues reported that in 5 of 6 limiting dilution experiments, EBV-infected 
naïve B cells that contained signs of SHM became either the dominant or significant sub-
dominant clone and hypothesised that these might have obtained a growth advantage 
through off-target SHM at non-Ig (Heath et al., 2012). Epeldegui et al. reported that infection 
of B cells with EBV resulted in mutations at BCL6 and TP53 that accumulated over time in 
the culture suggestive of ongoing SHM caused by AID (Epeldegui et al., 2007). However, by 
the time that AID reaches full-activity in LCLs, expression of BCL6 is highly repressed [see 
Figure 4.1 and (Gil et al., 2007; Siemer et al., 2008)] and it is therefore very unlikely that 
BCL6 is an off-target locus for AID activity in LCL. Consistent with this, Heath and 
colleagues failed to detect significant levels of mutations at the BCL6 locus in EBV-infected 
naïve B cells compared to CD27+ memory B cells (Heath et al., 2012). Therefore the 
observations from Epeldegui and colleagues are most likely explained by pre-existing 
mutations at the BCL6 locus in some of the EBV-infected B cells that potentially became 
more dominant over time in the culture. B cell populations infected with EBV-infection remain 
polyclonal for around four weeks post infection, but thereafter they quickly become more 
clonal and usually approach monoclonality by 8-12 weeks post infection (Ryan et al., 2006; 
Heath et al., 2012). It is currently unclear what drives this clonal development of a LCL 
culture, but it has to be considered when performing mutational analysis. 
In order to determine whether the high levels of EBNA3C-induced AID was functional 
in the 3CHT LCL, SHM at the IgH V(D)J region was analysed in samples of the 3CHT A13 
time-course in collaboration with Dr Rachael Bashford-Rogers and Prof Paul Kellam. For 
this, RNA from samples from the 3CHT A13 time-course was converted into cDNA and used 
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as template to PCR amplify the IgH V(D)J region. The PCR products were subjected to DNA 
deep-sequencing and Dr Bashford-Rogers performed the bioinformatics analysis. The clonal 
distribution within each sample was determined using the fact that each B cell clone has a 
uniquely recombined IgH V(D)J region, which act as molecular barcode. This revealed that 
at the start of the 3CHT time-course four major clones composed >90% of the cell 
population, which thereafter developed similarly in samples with active or active EBNA3C 
over the 60 day time-course (Figure 7.8A). All four major clones were subjected to V(D)J 
sequence analysis, which revealed that from day 30 onwards there were significantly more 
mutated V(D)J sequences in samples with active EBNA3C compared to samples with 
inactive EBNA3C (Figure 7.8B). This correlated with the time when maximal expression 
levels of AID were observed (Figure 4.2). 
Having found that EBNA3C-activated AID is functionally active in 3CHT LCL, we 
initiated a collaboration with Dr Peter Campbell aimed at determining AID-induced mutations 
at non-Ig loci across the whole human genome. Selected samples of the 3CHT A13 time-
course were subjected to HiSeq X Ten whole-genome sequencing (Illumina) with 30x 
coverage. Unfortunately, the analysis of this is still ongoing, because due to changes in the 
clonal composition of the LCL culture over the course of the time-course (Figure 7.8A) it is 
challenging to differentiate between genuine de novo mutations (AID-dependent and –
independent) and pre-existing mutations that start appearing because of an expansion in 
clone size. However, preliminary results indicate that EBNA3C-activated AID also introduced 
mutations at non-Ig loci that appear as kataegis, localised clusters of hypermutations (Nik-
Zainal et al., 2012; Alexandrov et al., 2013). Single-cell sorting of 3CHT cells to establish a 
clonal 3CHT culture that could be sequenced before and after AID is activated by EBNA3C 
could circumvent this problem, however LCLs do not generally grow at low cell densities. BL 
cell lines do not exhibit this limitation allowing this approach to be employed to determine 
AID off-targets in the human BL cell line Ramos (Qian et al., 2014). Additional 
overexpression of AID and inhibition of UNG was also used in order to increase the 
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detection rate of AID-induced mutations. AID off-target mutations were observed in kataegic 
clusters at loci that showed characteristic marks of super-enhancers, e.g. IgH, cMYC and 
BCL6 (Qian et al., 2014). Therefore, it is likely that EBNA3C-induced AID can also introduce 
mutations at non-Ig loci, which might directly affect the growth and/or survival rate of the 
EBV-infected B cell and hence – in vivo – potentiate the risk of B cell lymphomagenesis (see 
Section 1.2.5). 
Further analysis that remains to be performed on the existing whole genome 
sequencing data is to determine the mutational impact of AID on EBV episomes. 
Interestingly, members of the APOBEC family of cytidine deaminases, to which AID belongs, 
have been frequently described as cellular restriction factors that confer innate immunity 
against viruses, such as HIV, human T lymphotropic virus 1 (HTLV-1), hepatitis B and C 
viruses (HBV and HCV), human papilloma virus (HPV) and Kaposi’s sarcoma associated 
herpes virus (KSHV) [reviewed in (Moris et al., 2014; Harris and Dudley, 2015)]. For 
example it has been reported that infection of B cells with the gamma-herpesvirus KSHV 
resulted in increase AID levels and the overexpression of AID reduced lytic reactivation and 
therefore production of infectious viral particles (Bekerman et al., 2013). Interestingly, two 
KSHV-encoded miR were identified capable of binding in the 3’UTR of AID and reducing AID 
protein levels. In this light it appears surprising that EBV specifically upregulates AID 
expression unless the benefits (see above) outweigh the associated risks for EBV. 
4.4.5 Conclusion 
The findings presented in this Chapter provide novel insights into how EBNA3C 
activates gene expression at a particularly complex locus. EBNA3C targets most of the 
regulatory elements of AID and induces AID expression and this depends on the ability of 
EBNA3C to bind to RBPJ. It could be confirmed that EBNA2 represses AID expression and 
so is tempting to speculate that EBV via EBNA3C might activate AID expression in order to 
increase its chances of accessing the memory B cell compartment to establish a persistent 
infection. The risk this poses to both the cell and viral genomes is possibly controlled by the 
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repressive activity of EBNA2 limiting AID expression levels. However, much work is still 
required to determine the reasons and consequences of AID induction by EBV in vitro, but 
more importantly in vivo. 
AICDA is a very interesting gene to study because of the complexity of its regulation. 
However, further studies, preferentially on genes that are regulated by EBNA3C alone are 
needed in order to determine whether the findings presented here apply more generally to 
EBNA3C activated genes and to better understand the precise molecular mechanisms 
underlying EBNA3C-mediated gene activation. 
  
Chapter V: General discussion of gene repression and activation by EBNA3C 
 189 
5 Chapter V: General discussion of gene repression and activation by 
EBNA3C 
The analysis of ADAM28, ADAMDEC1 and COBLL1 as EBNA3C repressed genes 
and AICDA as an induced gene by EBNA3C revealed similarities and differences in 
EBNA3C-mediated gene regulation mechanisms that will be further discussed here. 
It was remarkable to observe such dramatic changes in gene expression, e.g. at least 
one log fold up regulation of AICDA and 3-4 log fold repression of COBLL1, occurring 
simultaneously within the same virus infected cell population and probably within the same 
cell. Unfortunately, techniques employed here only describe changes at a population level 
and do not allow one to comment on gene expression changes in single cells. Attempts to 
analyse protein expression at a single cell level, e.g. by flow cytometry or 
immunofluorescence did not produce reliable results probably due to lack of antibody 
sensitivity or specificity in these techniques. As an alternative, RNA abundance could have 
been assessed directly by RNA flow cytometry, which is likely to exhibit a greater specificity 
and sensitivity, in order to allow conclusions on whether gene expression changes uniformly 
in all cells or only in a small subset of cells within the culture. Currently, I see no reasons 
why there should be a significant difference in the response to EBNA3C between individual 
cells within the culture, but this remains to be determined. Nevertheless, interesting 
observations were made, but it is important to remember that these are derived from a 
population of cells over many population doubling times. 
Comparative gene expression analysis of EBNA3C repressed (Figure 3.6) and 
activated (Figure 4.4) genes between EBV-infected primary B cell and the EBNA3C-
conditional time-courses after activation of EBNA3C revealed that the 3CHT system could 
be efficiently used to recapitulate both repressive and activating changes in gene expression 
seen early after infection of primary B cell with EBV. This is the first time that this has been 
shown, which is important, because it validates the full functionality of the 3CHT fusion 
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proteins and their utility as a model system to study EBNA3C-mediated gene regulation. No 
changes in gene expression of EBNA3C target genes were observed after addition of HT to 
non-conditional 3CKO LCL proving that changes in gene expression in 3CHT LCL are a 
direct consequence of EBNA3C activation (Figure 3.5 and Figure 4.3). 
5.1 Similarities between EBNA3C-mediated repression and activation 
5.1.1 Kinetics of EBNA3C-mediated gene regulation 
It is striking that a relatively long period of 30-60 days post infection or activation of 
EBNA3C by HT was required for full repression/activation of EBNA3C target genes and 
equally long for full de-repression/de-activation after inactivation of EBNA3C (Figure 3.4 and 
Figure 4.2). It is however not the first time that this has been observed. Previous studies on 
EBNA3-mediated gene repression, e.g. CDKN2A (Skalska et al., 2010; 2013), BCL2L11 
(Paschos et al., 2012) and CXCL9/10 (Harth-Hertle et al., 2013), or gene activation, e.g. 
AICDA (Gil et al., 2007; Heath et al., 2012), also reported time-scales of up to four weeks or 
sometimes even longer for full activation or repression. 
It is possible that it takes that long for EBNA3C associated complexes, to fully 
establish or remove epigenetic histone marks through recruitment of auxiliary factors – 
particularly as it was found that changes in activation-associated histone marks correlated 
very well with the levels of gene expression. However, taking into account the proliferation 
rate of LCL with a doubling time of approximately 24-48 hours, this probably means that 
most cells undergo up to 30 cell divisions by the time complete repression or activation is 
achieved. DNA replication and mitosis are both processes that disrupt the chromatin 
structure locally and globally, respectively. Most TFs dissociate from mitotic chromatin that is 
up to 50-fold more condensed compared to interphase chromatin [reviewed in (Belmont, 
2006)] and the disintegration of the nuclear envelope results in a major change to the 
nuclear architecture. Interphase nuclear organisation has to be re-established in the two 
post-mitotic daughter cells. Epigenetic bookmarking has been proposed to help re-
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establishing gene expression profiles in post-mitotic cells [reviewed in (Zaidi et al., 2010)]. 
For this, certain epigenetic histone modifications such as H3K4me2/me3 and H3K27me3 are 
maintained during mitosis [reviewed in (Wang and Higgins, 2013)] and while most TF 
dissociate from mitotic chromatin, some (e.g. RUNX factors) are retained during mitosis 
[reviewed in (Kadauke and Blobel, 2013)]. Intriguingly, RBPJ has recently been found to 
remain stably associated with chromatin during mitosis and to interact with CTCF (Lake et 
al., 2014). Since on chromatin EBNA3C appears to be associated with RBPJ, this might 
ensure coordination of EBNA3C-mediated gene regulation over many cell divisions. 
Although 30 generations appear remarkably long, it is possible that EBNA3C-mediated gene 
regulation is somehow linked to the proliferation rate of the cells (see below). Currently, 
however, the reasons why EBNA3C-induced changes in gene expression occur over such 
long periods of time remain unknown, especially when compared for example to EBNA2-
mediated repression of AID, which only required four hours for a 30-fold change in AICDA 
expression (Figure 4.12A). ChIP analysis on samples of the EREB 2-5 time-course are 
required to better understand these differences in kinetics between EBNA2- and EBNA3C-
mediated gene regulation. 
As surprising as the long time-frame required to achieve maximal regulation is the 
fact that all EBNA3C-regulated genes displayed very similar and highly exponential 
regulatory profiles (R2>0.98) in newly EBV-infected primary B cells and also after activation 
of conditional EBNA3C in the 3CHT system (Figure 5.1A). The only difference between the 
individual genes beside the direction of the regulation (repressed vs activated) is how fast 
the changes occur for each gene. Consistent with the idea that the ADAM locus is co-
ordinately repressed by EBNA3C both ADAM28 and ADAMDEC1 display almost identical 
regulation profiles. Intriguingly, an almost identical exponential behaviour in the opposite 
direction was observed for de-repression/de-activation after inactivation of EBNA3C (Figure 
5.1B-E). The reasons for this are currently unknown. 
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Figure 5.1: Gene expression analysis of EBNA3C-regulated host genes. 
(A) Gene expression data for AICDA, ADAM28, ADAMDEC1 and COBLL1 from primary B cell 
infection with wtI6 EBV and three replicate 3CHT time-courses after activation of EBNA3C (A13 
Rep1+2 and C19) are displayed as mean values ± SD. Exponential trendlines were fitted up to day 30 
y	=	0.75e0.10x	
R²	=	0.96	
y	=	137.93e-0.08x	
R²	=	0.88	
1.0E-01	
1.0E+00	
1.0E+01	
1.0E+02	
0	 10	 20	 30	 40	 50	 60	
Time	(days)	
AICDA	
-HT	 +HT	 washed	
y	=	0.44e-0.38x	
R²	=	0.95	
y	=	0.00e0.51x	
R²	=	1.00	
1.E-06	
1.E-05	
1.E-04	
1.E-03	
1.E-02	
1.E-01	
1.E+00	
1.E+01	
0	 10	 20	 30	 40	 50	 60	
Ge
ne
	e
xp
re
ss
io
n	
re
la
7v
e	
to
	–
HT
	d
0	
Time	(days)	
COBLL1	
-HT	 +HT	 washed	
y	=	0.75e-0.10x	
R²	=	0.97	
y	=	0.00e0.11x	
R²	=	0.90	
1.E-02	
1.E-01	
1.E+00	
1.E+01	
0	 10	 20	 30	 40	 50	 60	
ADAMDEC1	
y	=	0.70e-0.07x	
R²	=	0.94	
y	=	0.00e0.10x	
R²	=	0.96	
1.E-02	
1.E-01	
1.E+00	
1.E+01	
0	 10	 20	 30	 40	 50	 60	Ge
ne
	e
xp
re
ss
io
n	
re
la
7v
e	
to
	–
HT
	d
0	
ADAM28	
AICDA	
y	=	0.88e0.10x	
R²	=	0.99	
ADAM28	
y	=	0.78e-0.09x	
R²	=	0.98	
COBLL1	
y	=	0.94e-0.42x	
R²	=	1.00	
ADAMDEC1	
y	=	1.07e-0.16x	
R²	=	0.98	
1.E-05	
1.E-04	
1.E-03	
1.E-02	
1.E-01	
1.E+00	
1.E+01	
1.E+02	
0	 5	 10	 15	 20	 25	 30	
Ge
ne
	e
xp
re
ss
io
n	
re
la
7v
e	
to
	d
0	
Time	(days)	
AICDA	 ADAM28	 ADAMDEC1	 COBLL1	
B C 
A 
D E 
Chapter V: General discussion of gene repression and activation by EBNA3C 
 193 
for AICDA and ADAM28 and up to day 15 for ADAMDEC1 and COBLL1, because repression is either 
achieved by this time (ADAMDEC1) or slowed down after this time-point (COBLL1). (B-E) Gene 
expression data for ADAM28 (A), ADAMDEC1 (B), COBLL1 (C) and AICDA (D) over the 3CHT A13 
time-course of cells grown in the absence (-HT), presence (+HT) of HT or in cells with HT removed at 
day 30 (washed). Exponential trendlines were fitted over the period of 30 days for +HT and washed 
conditions (trendline for washed COBLL1 expression is only fitted for the first 20 days after removal of 
HT). Equations and R2 values are shown for each trendline. 
Because both primary B cells and LCLs were kept mostly in the exponential growth 
phase during these time-courses together with the observed exponential regulation profile, it 
would be interesting to analyse whether there is a link between gene regulation by EBNA3C 
and cellular proliferation and whether an altered proliferation rate has an effect on its 
kinetics. For example, it would be possible to alter the proliferation rate of 3CHT LCL either 
through changes in cell culture conditions (e.g. different temperature) or through a fine-tuned 
ectopic regulation of cMYC expression. Increased expression levels of cMYC in LCL were 
shown to increase the percentage of cells in S-phase from 33% to 47% and hence resulted 
in a higher overall growth rate (Cutrona et al., 1995) without affecting the expression levels 
of latent EBV gene products (Hotchin et al., 1990). In contrast, inhibition of cMYC 
expression, either by chemical inhibition or by expression of a dominant-negative cMYC 
mutant, resulted in growth arrest of LCL (Faumont et al., 2009). Fine-regulation of the cMYC 
inhibition might only decreased the proliferation rate without inducing growth arrest. 
Unfortunately, cMYC regulates many genes and its deregulation has widespread affects on 
gene transcription. 
5.1.2 Recruitment of RBPJ is dependent on presence of EBNA3C 
Originally, RBPJ was thought to be stably associated with sequence-specific binding 
sites on DNA (Figure 1.16A) to silence gene expression by recruiting corepressors, which 
can be replaced by activators upon binding of NICD or EBNA2 (Figure 1.16B). Dynamic 
changes to RBPJ binding have been previously described for both NICD and EBNA2 (see 
Section 3.4.1), but this is the first time this has been observed for EBNA3C in gene 
repression and activation. 
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Low level RBPJ occupancy was observed in the absence of functional EBNA3C at all 
analysed EBNA3C-binding sites, which increased dramatically upon activation of EBNA3C 
suggesting that functional EBNA3C can promote the accumulation of high levels of RBPJ to 
specific sites on chromatin (Figure 3.10D+H and Figure 4.8D). It is important to mention that, 
although lower levels of RBPJ were detected at the EBNA3C-binding sites in the absence of 
functional EBNA3C, these levels were higher than at control sites on each of the three loci. 
This might be important for the initial recruitment of EBNA3C. It is then possible that the 
interaction between EBNA3C and RBPJ increases the binding to and/or stabilises 
EBNA3C/RBPJ complexes on regulatory elements that control expression of EBNA3C target 
genes, which might then serve as assembly platform for multi-protein complexes, comprised 
of additional repressors or transactivators (see also 5.3.1). 
Consistent with this, the ChIP analysis on the 3CHT A13 and C19 time-courses for all 
three genomic loci revealed that RBPJ was the first factor to increase at the EBNA3C 
binding sites (Figure 5.2A). This was subsequently followed by an increase in BMI1 
occupancy at these sites (Figure 5.2B). The role of BMI1 in repression (Chapter 3.4) and 
activation (Chapter 4.4) has been discussed previously. Interestingly, no difference in the 
recruitment profile of RBPJ and BMI1 could be detected between EBNA3C-repressed or 
activated genes. Surprisingly, it appeared that the occupancy of RBPJ and BMI1 at the 
EBNA3C-binding sites decreased over time. Either high levels of these factors are only 
needed to initiate EBNA3C-mediated gene regulation or it is conceivable that the assembly 
of a multi-protein complexes can mask the epitope detected by the antibodies used in the 
ChIP experiments, which would prevent detection at later time-points and look like reduced 
binding. 
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Figure 5.2: Binding of RBPJ and BMI1 to EBNA3C repressed and activated genes. 
ChIP-qPCR values for RBPJ (A) and BMI1 (B) at ADAM peak, COBLL1 peak, AICDA regions IV and 
VI from the two biological time-courses (3CHT A13 and C19) were normalised by setting the maximal 
enrichment level during each time-course to one and by using the first time-point –HT (day 3) as 
representative value for day 0. Mean values ± SD from both replicate time-courses are shown. For 
BMI1, day nine of the C19 time-course was treated as an outlier and was not taken into account for 
the analysis. 
Interestingly, DNA sequence analysis using publically available transcription factor 
binding prediction software [PROMO (Messeguer et al., 2002; Farré et al., 2003) and Patch 
1.0 (BIOBASE)] did not reveal strictly canonical RBPJ binding sites at the EBNA3C peaks at 
ADAM28/ADAMDEC1, COBLL1 or AICDA. Using a less stringent interpretation several 
possible sites at each EBNA3C peak were identified, but it was not possible to determine 
whether any of these was responsible for recruiting RBPJ. Recent ChIP-Seq analysis of 
EBNA3C also reported that DNA sites occupied by EBNA3C were not specifically enriched 
in RBPJ recognition motifs (Wang et al., 2015). It is also possible that binding of EBNA3C to 
RBPJ changed the DNA binding preference of RBPJ or that other TF are involved in the 
recruitment (see Section 5.3.1). 
The phenotypic importance of the interaction between EBNA3C and RBPJ first 
became apparent in transient reporter assays using RBPJ BM EBNA3C and RBPJ knock-
out cells to recapitulate the repression of ADAM28 and COBLL1, but more importantly also 
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in the context of viral infection – the RBPJ BM EBNA3C virus failed to repress ADAM28, 
ADAMDEC1 and COBLL1 or to up regulate AICDA. It is possible that the mutations 
introduced in the RBPJ BM EBNA3C alter the interaction with other yet to be described 
factor(s) required for EBNA3C-mediated gene regulation, but even wild type EBNA3C did 
not successfully repress ADAM28 luciferase constructs in the RBPJ-null DG75 cells, clearly 
indicating that the presence of RBPJ is essential for EBNA3C-mediated gene regulation. 
In contrast to previous studies (Lee et al., 2009; Maruo et al., 2009; Calderwood et 
al., 2011), the RBPJ BM EBNA3C virus was able to establish a stable LCL indicating that the 
interaction between EBNA3C and RBPJ is not absolutely required for B cell transformation. 
Further studies are required to investigate the importance of the interaction between 
EBNA3C and RBPJ. 
5.2 Differences between EBNA3C-mediated repression and activation 
Surprisingly few differences were detected between EBNA3C-mediated gene 
repression and activation. The most prominent were observed changes to epigenetic histone 
marks that differed between EBNA3C induced repression or activation. For the repressed 
genes ADAM28, ADAMDEC1 and COBLL1, activation-associated histone marks quickly 
disappeared – predominantly at the TSS of each gene – while for induced AICDA these 
marks appeared, again predominantly around the TSS, but also at a distal enhancer 
element. There was a good correlation between activation-associated marks and levels of 
gene expression (Figure 3.9 and Figure 4.7). Increased levels of the repressive histone 
modification H3K27me3 were observed at all EBNA3C-repressed loci and PRC2 at the 
COBLL1 locus, neither of which were observed at the activated AICDA locus. In contrast, 
acetlytransferase p300 was detected at some of the regulatory regions of AICDA, but not 
consistently at the repressed ADAM28/ADAMDEC1 and COBLL1 loci. More work is needed 
to understand how the mechanisms underlying EBNA3C-mediated gene repression and 
activation differ and why EBNA3C reproducibly acts as a very potent repressor on some 
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genes, but as a transactivator on others in the same timeframe and in the same population 
of cells (see Section 5.3.4). This leads to some important questions that remain 
unanswered. 
5.3 Open questions 
5.3.1 How is EBNA3C recruited to chromatin and which factors are important? 
The observations that RBPJ levels increased shortly after activation of EBNA3C at all 
EBNA3C binding sites at the ADAM, COBLL1 and AICDA loci and the fact that EBNA3C 
failed to regulate all three loci when it was unable to bind to RBPJ, suggest that RBPJ is an 
essential factor for the recruitment of EBNA3C. Unfortunately, in my hands, direct ChIP for 
EBNA3C during the 3CHT A13 and C19 time-courses did not yield reproducible results 
using a commercial polyclonal antibody against EBNA3C that also precipitates EBNA3A and 
EBNA3B (McClellan et al., 2013). The reasons for this are unknown, but it is worth 
mentioning that when the EBNA3 ChIP seemed to work, it essentially produced the same 
result as ChIP for RBPJ, again supporting the idea that both are required to form stable 
complexes at the EBNA3 peaks. In order to bypass this, ChIP was attempted using an 
antibody against the modified estrogen-receptor that is fused to EBNA3C in the 3CHT LCL, 
but this resulted in very poor enrichment relative to input (data not shown) preventing its use 
on samples of the 3CHT time-courses. In order to reliably ChIP for EBNA3C during these 
time-courses, the conditional EBNA3C on the p16-null background would also need to be 
TAP-tagged, but this virus and cell line are not yet available and it might not be possible to 
construct them because it is not known how the combined tags would affect the function and 
stability of EBNA3C. 
In addition to RBPJ, it is likely that other transcription factors are involved in targeting 
EBNA3C to DNA. Previous ChIP-Seq studies reported that EBNA3 binding sites coincided 
with ENCODE ChIP-Seq binding sites of multiple transcription factors in LCL GM12878, e.g. 
RUNX3, BATF, IRF4, BCL11A and PAX5 (McClellan et al., 2013; Jiang et al., 2013; Schmidt 
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et al., 2014; Wang et al., 2015), while only 16% (Jiang et al., 2013) or 44% (Wang et al., 
2015) of EBNA3C binding sites were reported to be co-bound by RBPJ (see Section 1.4.2). 
All of these transcription factors appear to occupy the EBNA3C binding sites at 
ADAM28/ADAMDEC1, COBLL1 and AICDA in LCL GM12878, in which EBNA3C is present 
and all genes are robustly regulated by EBNA3C (Figure 7.9B, Figure 7.10B and Figure 
7.11B). IRF4, in particular, is thought to be involved in the recruitment of EBNA3C (Jiang et 
al., 2013) and overexpression of IRF4 resulted in increased EBNA3C occupancy at 
EBNA3C-binding sites (Wang et al., 2015). Preliminary results from Dr Kostas Paschos in 
our lab indicate that shRNA-mediated knock down of IRF4 in EBNA3C-TAP LCL reduces 
EBNA3C occupancy at the COBLL1 peak and AICDA regulatory regions II and IV compared 
to the non-targeting control shRNA. Therefore, it is likely that IRF4 could act as a co-factor to 
help directing EBNA3C/RBPJ to these target sites. 
5.3.2 Why does EBNA3A bind to the COBLL1 peak and the regulatory regions of 
AICDA although it is not involved in their regulation? 
The ChIP-Seq on EBNA3A-TAP LCL detected binding of EBNA3A to the COBLL1 
peak (Figure 3.8A) and most of the regulatory regions of AICDA (Figure 7.11B), which has 
been verified by ChIP-qPCR (see Figure 3.7 for EBNA3A at the COBLL1 peak). It is 
currently unclear why EBNA3A can be detected at these two genes although the infection of 
primary B cell with 3AKO virus showed that EBNA3A was not required for in the repression 
of COBLL1 (Figure 3.2C) or the up regulation of AICDA (Figure 4.1A). Furthermore, in LCL 
with conditional EBNA3A, no changes to the expression levels of COBLL1 or AICDA could 
be detected upon activation or inactivation of EBNA3A (Dr Quentin Bazot, personal 
communication). 
It is unlikely that the occupancy of EBNA3A at these two genes is caused by an 
artefact of the TAP-tagged LCL cell lines, because a recently published ChIP-seq 
experiment using anti-HA antibody in EBNA3A-Flag-HA LCL (Schmidt et al., 2014) also 
detected EBNA3A on the COBLL1 peak (Figure 7.10A) and AICDA regulatory regions II, IV, 
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VI and possibly V (Figure 7.11A). One possible explanation of why EBNA3A is found at 
these two genes, although it does not have an apparent biological role, could be due to its 
ability to bind to EBNA3C (Calderwood et al., 2007; Paschos et al., 2012; McClellan et al., 
2013). This could also explain why EBNA3C binding can be detected together with EBNA3A 
at the regulatory regions of genes that are only regulated by EBNA3A (Dr Quentin Bazot, 
personal communication). Consistent with this, ChIP-Seq analysis of our TAP-tagged 
EBNA3 cell lines revealed that 83% of EBNA3A binding sites are co-occupied by EBNA3C 
and 37% of EBNA3C sites also display binding of EBNA3A (Dr Kostas Pachos, personal 
communication). This is even higher compared to previous studies reporting that 26% 
(Wang et al., 2015) or 50% (Schmidt et al., 2014) of EBNA3A binding sites are co-occupied 
by EBNA3C. Although the numbers vary between studies, all suggest extensive overlap 
between EBNA3A and EBNA3C targeting. 
However, it remains to be determined whether EBNA3A and EBNA3C bind to these 
regulatory sites at the same time and in the same cell. Because ChIP results are averaged 
binding events observed in many cells, it is possible that a site is only bound by EBNA3A in 
some cells, but by EBNA3C in others. In order to determine whether both bind at the same 
time, re-ChIP has to be performed on EBNA3A and EBNA3C carrying different epitope-tags. 
Unfortunately, no recombinant EBV is currently available that carries differentially epitope 
tagged EBNA3A and EBNA3C. To circumvent this, it would be possible to overexpress HA-
tagged EBNA3A in EBNA3C-TAP LCL or vice versa, but this might disrupt normal targeting 
of EBNA3 proteins to their natural binding sites. Novel insights into the targeting of EBNA3A 
and EBNA3C is likely to result from newly created (by Dr Quentin Bazot) EBV recombinants 
that carry TAP-tagged EBNA3A and conditional EBNA3C allowing one to analyse EBNA3A 
targeting to the COBLL1 peak and the regulatory regions of AICDA in the absence or 
presence of EBNA3C. 
Taking into account the low transcript number (Davies et al., 2010) and low protein 
abundance of EBNA3A and EBNA3C per individual cell, it is very surprising and hard to 
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believe that these proteins are accidentally targeted to sites where they do not have any 
biological role. Additionally, although both EBNA3A and EBNA3C are involved in the 
repression of the ADAM28/ADAMDEC1 locus, it remains unclear why EBNA3A plays only a 
subsidiary role relative to EBNA3C (Figure 3.2A and B). Further studies are needed to 
understand better the interplay between the different EBNA3s. 
5.3.3 How are PRC1 and PRC2 proteins recruited? 
The role of polycomb proteins in EBNA3C-mediated gene repression (3.4.2.2) and 
activation (4.4.2) was discussed previously. Beside their mechanistic role in gene regulation, 
it remains unclear how they are targeted to EBNA3C-regulated genes. 
5.3.3.1 Default mechanism 
The recruitment of polycomb proteins might be a default mechanism of these genes 
when they are repressed or activated. It is conceivable that removal of activation-associated 
histone modifications on ADAM28, ADAMDEC1 and COBLL1 is enough to attract polycomb 
proteins. If this is the case, preventing the removal of histone acetylation by addition of 
HDAC inhibitors during a 3CHT time-course might be enough to ensure that ADAM28, 
ADAMDEC1 and COBLL1 are not repressed by EBNA3C and polycomb proteins are not 
recruited even in the presence of EBNA3C. Unfortunately, LCLs tolerate HDAC inhibitors 
very poorly, even over relatively short time-courses of 1-2 days (Paschos et al., 2009). 
Alternatively, small molecule inhibition of transcription, similar to Riising et al. 2014, could be 
used in 3CHT LCL with inactive EBNA3C to determine whether EBNA3C-independent 
inhibition of ADAM28, ADAMDEC1 and COBLL1 transcription is sufficient to recruit 
polycomb proteins. On the other hand, IL4 and CD40L activation of primary B cells 
combined with ChIP analysis could be used to determine whether EBNA3C-independent up 
regulation of AICDA involves the recruitment of BMI1 to the regulatory regions of AICDA. 
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5.3.3.2 Direct recruitment 
Another possibility is that polycomb proteins were directly recruited either by 
EBNA3C or another factor in an EBNA3C-associated complex. One initial aim of this PhD 
project was to characterise and map the interaction between SUZ12 and EBNA3C. 
Unpublished results from our lab indicated that EBNA3C could be co-immunoprecipitated 
with SUZ12 in EBV-infected BL31 cells and LCL, and also in GST-SUZ12 pull-down 
experiments (Sara Temelso, 2012, Master’s thesis, Imperial College London). However, the 
GST-SUZ12 fusion protein purified from bacteria was not very pure and was badly 
degraded. Therefore, I established different production and purification strategies, optimised 
with help from Dr Goedele Maertens. Unfortunately, it turned out that the production and 
purification of full length SUZ12 was technically very challenging. SUZ12 was found to be 
either highly unstable or subjected to protein degradation in bacteria especially at increased 
temperatures. The best result was obtained when SUZ12 was produced from an IPTG-
inducible pET28a-His-SUMO-SUZ12-TAP vector in Rosetta II at room temperature and 
harvested two hours after induction. The purification strategy involved a four-step process 
(His-tag purification using HIS-Select, Strep-tag purification using StrepTactin, ionic 
exchange chromatography using HiTrap SP FF and size exclusion chromatography using a 
SD200 column). Unfortunately, Strep-tag pull-down experiments using the purified SUZ12-
TAP fusion protein and in vitro translated EBNA3C could not reproduce a strong interaction 
with EBNA3C relative to the beads alone. This avenue of investigation was therefore 
dropped. 
Moreover, subsequently the ChIP results on the 3CHT A13 and C19 time-courses 
showed that EBNA3C and SUZ12 did not bind at the same site, with EBNA3C at the 
COBLL1 peak and SUZ12 at the TSS of COBLL1, and that SUZ12 was not directly detected 
at the ADAM28/ADAMDEC1 locus. Therefore it is unlikely that SUZ12 is directly recruited by 
EBNA3C, even so it is possible that both sites loop in the presence of EBNA3C (see 3.4.3). 
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It now seems more likely that EBNA3C can recruit BMI1. The ChIP results on the 
3CHT A13 and C19 time-courses showed that BMI1 was recruited wherever EBNA3C bound 
(the ADAM peak, the COBLL1 peak and the AICDA regulatory regions II, VI, V and VI). 
Recruitment levels of BMI1 correlated well with the expected occupancy of EBNA3C at each 
site. This was further supported by recent ChIP-Seq for BMI1 and SUZ12 in LCLs used for 
the EBNA3C-TAP ChIP-Seq, which revealed that 47% of EBNA3C sites overlap with BMI1 
sites, but only 1% with SUZ12 sites (Dr Kostas Paschos, personal communication). 
Furthermore, using proximity-ligation techniques coupled to immunofluorescence it could be 
shown that EBNA3C localises in close proximity to BMI1 (Gillian Parker, personal 
communication). 
In addition, it has been shown that murine Bmi1 can be recruited to chromatin by 
direct interaction with the TF Runx1 (Yu et al., 2012). RUNX1 together with RUNX2 and 
RUNX3 are family members of tissue-specific core DNA binding transcription factors, which 
share a high level of protein homology. In LCLs EBNA2 upregulates RUNX3 (Spender et al., 
2002; Gunnell et al., 2016), which in turn represses RUNX1 (Brady et al., 2009). 
Interestingly, 64-80% of EBNA3C binding sites have been found to be co-occupied by 
RUNX3 [(Jiang et al., 2013; Wang et al., 2015) and Dr Kostas Paschos, personal 
communication]. Furthermore, a strong overlap between binding sites for RUNX and RBPJ 
was reported in T-lymphoblastic leukemia cells, in which 90% dynamic RBPJ binding sites 
were found at distal enhancers with strong RUNX binding and characteristics of super-
enhancers (Wang et al., 2011; 2014). Although concerns about the specificity of the RBPJ 
antibody used in these studies were raised as it also detects REST beside RBPJ (Castel et 
al., 2013), it is nevertheless possible that BMI1 is recruited by a large multiprotein complex 
composed of RUNX:EBNA3C:RBPJ, in which RUNX and RBPJ could mediate DNA binding 
and potentially also ensure mitotic bookmarking, while EBNA3C is perhaps required to 
stabilise the whole complex. 
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5.3.4 What determines whether a locus is repressed or activated by EBNA3C? 
5.3.4.1 Distinct forms of repressive or activating EBNA3C complexes 
It is conceivable that different forms of EBNA3C proteins exist, e.g. through different 
post-transcriptional modifications (PTM) on EBNA3C that determine the interaction with 
associated co-factors. Thus one form could be responsible for recruiting co-repressors 
whereas another for recruiting transactivators. Biochemical and mass spectrometric analysis 
could be employed to detect different PTMs. Furthermore, in order to determine whether 
activating forms or repressive forms of EBNA3C are preferentially targeted to induced or 
repressed genes, respectively, end-targeting proteomics of isolated chromatin fragments 
(ePICh) could be attempted (Déjardin and Kingston, 2009; Ide and Déjardin, 2015). This 
technique allows the identification of proteins by mass spectrometry that are bound at a 
distinct chromatin site. Currently it is limited to abundant loci (>100 copies per cell), therefore 
large BAC constructs containing loci targeted by EBNA3C could be used to provide up to 
several hundred BAC copies per cell (Bian and Belmont, 2010). By using BAC constructs 
containing EBNA3C repressed or induced genes, respectively, it might be possible to detect 
different forms of EBNA3C together with potentially novel interacting factors. The question 
that would remain, however, is how activating or repressive forms of EBNA3C are 
specifically recruited to induced or repressed genes, respectively. 
5.3.4.2 Sequence of the EBNA3-binding site 
It is possible, that all necessary information required for EBNA3C to activate or 
repress a specific locus is encoded by the DNA sequence at the EBNA3C binding site. To 
test this, the regulatory elements, to which EBNA3C is tethered, could be exchanged 
between repressed and activated genes using genome-editing techniques, e.g. 
CRISPR/CAS9 [reviewed in (Hsu et al., 2014; Doudna and Charpentier, 2014; Wiles et al., 
2015)]. This could be used for example to exchange the DNA region around the COBLL1 
peak with that around AICDA region IV. If the DNA sequence alone is important, this should 
result in COBLL1 being activated and AICDA being repressed (or not induced) after 
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activation of EBNA3C, in which case the DNA sequences of the EBNA3C binding sites will 
have to be analysed more precisely in order to detect what confers this information. 
5.3.4.3 Locus specific features or factors 
If the DNA sequence of the EBNA3C binding site does not contain regulatory 
information, there might be additional locus-specific features or factors in that particular 
genomic context, which are required to provide the regulatory information. Analysis of the 
higher order chromatin structure(s) or its localization within the nucleus when EBNA3C is 
active or inactive could provide important information regarding the effect of the locus. 
Again, genome editing techniques could be used to alter sites at the locus that are likely to 
change the 3D conformation (e.g. CTCF sites) and consequently maybe its location in 
nuclear space in order to assess the effect of the changed locus on EBNA3C-mediated gene 
regulation. 
It is likely that not a single, but rather a combination of all three above listed 
possibilities act together in order to control EBNA3C-mediated gene regulation. 
5.4 Final conclusions 
The findings made during the course of this project provide important information on 
the EBNA3C-mediated regulation of three repressed genes and one activated gene. First of 
all, it was important to verify that all four genes were genuine targets of EBNA3C by infecting 
primary B cells with recombinant EBV and to identify that EBNA3C-conditional LCLs can be 
used to recapitulate reliably EBNA3C-mediated changes in gene expression observed early 
after infection of primary B cells with EBV. This was shown for the first time and revealed the 
full functionality of the 3CHT system, which will be also important for future studies on 
EBNA3C-mediated gene regulation. 
ChIP analysis has revealed similarities and differences between EBNA3C-mediated 
gene repression and activation occurring simultaneously in the same cell population and has 
provided novel insights into the temporal sequence of events and the dynamics of factor 
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recruitment. For EBNA3C-mediated gene repression a two-step mechanism was observed, 
in which activation-associated histone marks were removed, resulting in the extensive loss 
of gene expression, before repressive marks were deposited by simultaneous, but spatially 
distinct recruitment of PRC1 (BMI1) and PRC2 (SUZ12). For EBNA3C-mediated gene 
activation, increases in activation-associated histone marks were detected that correlated 
well with recruited histone acetyltransferase p300 and PRC1 (BMI1) and increased levels of 
gene expression. Most surprisingly and common to both EBNA3C-mediated gene repression 
and activation was the dynamic recruitment and/or stabilisation of RBPJ/EBNA3C 
complexes on chromatin only in the presence of active EBNA3C. The functional importance 
of the interaction between EBNA3C and RBPJ became apparent in transient reporter assays 
and was confirmed in primary B cell infection using an EBV recombinant encoding a RBPJ 
binding mutant EBNA3C that failed to regulate all four genes. 
Further studies are needed in order to elucidate the exact molecular mechanisms 
underlying EBNA3C-mediated gene regulation, to determine whether the findings presented 
here apply to all genes regulated by EBNA3C and to discover factors that determine whether 
a locus is repressed or activated by EBNA3C. Extensive analysis is also required to identify 
the role that EBNA3C-regulated genes play for EBV biology (e.g. in vivo role of ADAM28 
and ADAMDEC1 repression and AID activation) and to determine the biological 
consequences for the EBV-infected B cells (e.g. activation of AID). 
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7 Appendix 
Table 7.1: Overview of restriction enzyme digestion fragments for recombinant EBV BACs 
used in this study. 
Fragments are sorted by size and differences to wild type EBV BAC (wtI6) are highlighted in bold. For 
ClaI digestions, Dam methylation sites were analysed to determine the size of fragments. 
 
ClaI	digestion	
	
wtI6:	pHB9,	9	ClaI	sites	
ClaI	 Dam	methylation	 Fragment	 Size	in	bp	
1	 No	 1-5	 65,585	
2	 Yes	 9-1	 61,533	
3	 Yes	 8-9	 21,039	
4	 Yes	 5-6	 15,107	
5	 No	 6-8	 3,491	
6	 No	
7	 Yes	
8	 No	
9	 No	
3AKO:	pB9-/-E3A(+12.5),	10	ClaI	sites	
ClaI	 Dam	methylation	 Fragment	 Size	in	bp	
1	 No	 10-1	 61,533	
2	 Yes	 3-6	 38,489	
3	 No	 1-3	 24,461	
4	 Yes	 9-10	 21,039	
5	 Yes	 6-7	 15,107	
6	 No	 7-9	 3,491	
7	 No	
8	 Yes	
9	 No	
10	 No	
3BKO:	pB9-/-E3B(+2.2),	9	ClaI	sites	
ClaI	 Dam	methylation	 Fragment	 Size	in	bp	
1	 No	 1-5	 62,796	
2	 Yes	 9-1	 61,533	
3	 Yes	 8-9	 21,039	
4	 Yes	 5-6	 15,107	
5	 No	 6-8	 3,491	
6	 No	
7	 Yes	
8	 No	
9	 No	
3CKO:	pB9-/-E3C(+3.1),	9	ClaI	sites	
ClaI	 Dam	methylation	 Fragment	 Size	in	bp	
1	 No	 9-1	 61,533	
2	 Yes	 4-5	 32,442	
3	 Yes	 1-4	 30,985	
4	 Yes	 8-9	 21,039	
5	 No	 5-6	 15,107	
6	 No	 6-8	 3,491	
7	 Yes	
8	 No	
9	 No	
E3KO:	pHB9JY6+3C.3A,	8	ClaI	sites	
ClaI	 Dam	methylation	 Fragment	 Size	in	bp	
1	 No	 8-1	 61,533	
2	 Yes	 3-4	 32,442	
3	 No	 1-3	 24,461	
4	 No	 7-8	 21,039	
5	 No	 4-5	 15,107	
6	 Yes	 5-7	 3,491	
7	 No	
8	 No	
	
	
EcoRI	digestion	
	
wtI6:	pHB9,	18	EcoRI	sites	
Fragment	 Size	in	bp	 Fragment	 Size	in	bp	
1	 46,444	 10	 6,218	
2	 30,077	 11	 5,466	
3	 12,430	 12	 4,161	
4	 11,905	 13	 3,152	
5	 10,503	 14	 2,077	
6	 8,501	 15	 1,259	
7	 8,413	 16	 1,107	
8	 7,139	 17	 945	
9	 6,324	 18	 634	
3AKO:	pB9-/-E3A(+12.5),	17	EcoRI	sites	
Fragment	 Size	in	bp	 Fragment	 Size	in	bp	
1	 46,444	 10	 6,218	
2	 30,077	 11	 5,466	
3	 12,430	 12	 4,161	
4	 11,905	 13	 3,152	
5	 10,503	 14	 1,259	
6	 8,501	 15	 945	
7	 8,413	 16	 634	
8	 7,139	 17	 549	
9	 6,324	 	 	
	 	 	 	
3BKO:	pB9-/-E3B(+2.2),	18	EcoRI	sites	
Fragment	 Size	in	bp	 Fragment	 Size	in	bp	
1	 46,444	 10	 6,218	
2	 27,288	 11	 5,466	
3	 12,430	 12	 4,161	
4	 11,905	 13	 3,152	
5	 10,503	 14	 2,077	
6	 8,501	 15	 1,259	
7	 8,413	 16	 1,107	
8	 7,139	 17	 945	
9	 6,324	 18	 634	
3CKO:	pB9-/-E3C(+3.1),	18	EcoRI	sites	
Fragment	 Size	in	bp	 Fragment	 Size	in	bp	
1	 46,444	 10	 6,218	
2	 27,919	 11	 5,466	
3	 12,430	 12	 4,161	
4	 11,905	 13	 3,152	
5	 10,503	 14	 2,077	
6	 8,501	 15	 1,259	
7	 8,413	 16	 1,107	
8	 7,139	 17	 945	
9	 6,324	 18	 634	
E3KO:	pHB9JY6+3C.3A,	16	EcoRI	sites	
Fragment	 Size	in	bp	 Fragment	 Size	in	bp	
1	 46,444	 10	 6,218	
2	 24,579	 11	 5,466	
3	 12,430	 12	 4,161	
4	 11,905	 13	 3,152	
5	 10,503	 14	 1,259	
6	 8,501	 15	 945	
7	 8,413	 16	 634	
8	 7,139	 	 	
9	 6,324	 	 	
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Figure 7.1: Gene expression analysis in the 3CHT C19 time-course. 
Time-course using 3CHT C19 LCL. Cells were grown over 30 days either in absence of HT (-HT) or 
presence of HT (+HT). Gene expression of ADAM28 (A), ADAMDEC1 (B), COBLL1 (C), AICDA (D) 
and ALAS1 (E) was normalised to GAPDH and is shown relative to day 0 –HT. 	 	
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Figure 7.2: Western blot analysis of the 3CHT C19 time-course. 
Time-course using 3CHT C19 LCL. Cells were grown over 60 days either in absence of HT (-HT) or 
presence of HT (+HT). 30 µg of RIPA extracts from selected samples were western blotted for the 
expression of AID, COBLL1, EBNA3A, EBNA3B, EBNA3C, EBNA2, LMP1, BMI1, SUZ12, RBPJ and 
γ-tubulin as loading control. NS indicates a non-specific band detected by the anti-COBLL1 antibody. 	 	
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Figure 7.3: ChIP analysis of the COBLL1 locus during the 3CHT C19 time-course.	
(A-G) ChIP for H3K9ac (A), H3K27ac (B), H3K4me3 (C), H3K27me3 (D), SUZ12 (E), BMI1 (F) and 
RBPJ (G) on samples from the 3CHT C19 time-course at locations within the COBLL1 locus (see 
Figure 3.8), at GAPDH or myoglobin as indicated. Cells were grown in the absence (-HT) or presence 
of HT (+HT) and numbers indicate the day of harvest. ChIP values represent enrichment relative to 
input ± SD of triplicate qPCR reactions for ChIP and input of each sample.  
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Figure 7.4: ChIP analysis of the ADAM28-ADAMDEC1 locus during the 3CHT C19 time-course.	
(A-F) ChIP for H3K9ac (A), H3K27ac (B), H3K4me3 (C), H3K27me3 (D), BMI1 (E) and RBPJ (F) on 
samples from the 3CHT C19 time-course at locations across the ADAM28-ADAMDEC1 locus (see 
Figure 3.8), at GAPDH or myoglobin as indicated. Cells were grown in the absence (-HT) or presence 
of HT (+HT) and numbers indicate the day of harvest. ChIP values represent enrichment relative to 
input ± SD of triplicate qPCR reactions for ChIP and input of each sample. 
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Figure 7.5: No changes to EBNA2 occupancy at ADAM peak and COBLL1 peak during the 
3CHT A13 time-course. 
ChIP using antibodies against EBNA2 or non-specific IgG control on samples from the 3CHT A13 
time-course at ADAM peak or COBLL1 peak. Cells were grown in the absence (-HT) or presence of 
HT (+HT) and numbers indicate the day of harvest. ChIP values represent enrichment relative to input 
± SD of triplicate qPCR reactions for ChIP and input of each sample. 
3 30 60 3 6 9 15 30 60
0.0
0.1
0.2
0.3
0.4
En
ric
hm
en
t r
el
at
iv
e 
to
 in
pu
t
ADAM peak
EBNA2
IgG
-HT +HT
3 30 60 3 6 9 15 30 60
0.00
0.02
0.04
0.06
0.08
0.10
En
ric
hm
en
t r
el
at
iv
e 
to
 in
pu
t
COBLL1 peak
EBNA2
IgG
-HT +HT
Appendix 
 256 
 
3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30
0.00
0.05
0.10
0.15
0.20
3
6
En
ric
hm
en
t r
el
at
iv
e 
to
 in
pu
t
3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30
0.00
0.05
0.10
0.15
0.20
0.25
0.30
1
2
En
ric
hm
en
t r
el
at
iv
e 
to
 in
pu
t
3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30
0.0
0.1
0.2
0.3
En
ric
hm
en
t r
el
at
iv
e 
to
 in
pu
t
-HT +HT
H3K4me3
H3K9ac
H3K27ac
BMI1
p300
RBPJ
III II I IV V VI GAPDH MyoG
3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30
0.00
0.02
0.04
0.06
En
ric
hm
en
t r
el
at
iv
e 
to
 in
pu
t
3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30
0.00
0.01
0.02
0.03
0.04
En
ric
hm
en
t r
el
at
iv
e 
to
 in
pu
t
3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30
0.00
0.05
0.10
0.15
En
ric
hm
en
t r
el
at
iv
e 
to
 in
pu
t
EBNA2
3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30 3 6 9 15 30
0.00
0.02
0.04
0.06
0.08
En
ric
hm
en
t r
el
at
iv
e 
to
 in
pu
t HES1
B 
C 
A 
E 
F 
D 
G
Appendix 
 257 
Figure 7.6:	ChIP analysis of the AICDA locus during the 3CHT C19 time-course.	
(A-G) ChIP for H3K4me3 (A), H3K9ac (B), H3K27ac (C), BMI1 (D), p300 (E), RBPJ (F) and EBNA2 
(G) on samples from the 3CHT C19 time-course at locations across the AICDA locus (see Figure 4.6), 
at GAPDH, myoglobin or HES1 as indicated. Cells were grown in the absence (-HT) or presence of 
HT (+HT) and numbers indicate the day of harvest. ChIP values represent enrichment relative to input 
± SD of triplicate qPCR reactions for ChIP and input of each sample. 
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Figure 7.7: Occupancy of SUZ12 across the AICDA locus during the 3CHT A13 time-course. 
ChIP for SUZ12 on samples from the 3CHT A13 time-course at locations across the AICDA locus 
(see Figure 4.6), at GAPDH, or the TSS of COBLL1 as indicated. Cells were grown in the absence (-
HT) or presence of HT (+HT) and numbers indicate the day of harvest. ChIP values represent 
enrichment relative to input ± SD of triplicate qPCR reactions for ChIP and input of each sample. 
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Figure 7.8: SHM and clonal development during 3CHT A13 time-course. 
(A) Network diagrams of B cell clones according to their rearranged V(D)J IgH sequence in samples 
of the 3CHT A13 time-course show the clonal development of the four major clones (shown in red, 
blue, green, orange) along minor clones (shown in grey) from the starting population at day 0 of the 
time-course and after 60 days of culture with inactive (-HT) or active (+HT) EBNA3C. Each vertex 
represents a unique sequence, where relative vertex size is proportional to the number of identical 
reads. Edges join vertices that differ by single nucleotide differences and clusters are collections of 
related, connected vertices. (B) Boxplots showing the fold increase in the number of mutated V(D)J 
sequences) after 15, 30 and 60 days of culture with inactive (-HT) or active (+HT) EBNA3C for the 
four largest clones (shown in same colours in A). This is calculated as a cumulative change in the 
number of mutated V(D)J sequences at each time-point relative to the starting population at day 0. P-
values were determined by paired t-test. Dr Rachael Bashford-Rogers performed the analysis and 
prepared the figures. 
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Figure 7.9: EBNA3A and EBNA3C binding sites on ADAM28/ADAMDEC1 locus are co-occupied 
by multiple transcription factors. 
(A) UCSC genome browser overview of ADAM28/ADAMDEC1 genomic locus showing ChIP-seq 
tracks for RBPJ (Zhao et al., 2011a), EBNA3A-HA (Schmidt et al., 2014) and EBNA3C-HA (Jiang et 
al., 2013) aligned to hg18. Occupancy levels are merely to indicate the position and are not to scale. 
(B) Hg19 view of same genomic locus as in (A) showing ChIP-seq tracks for EBNA2 (McClellan et al., 
2013), EBNA3 (McClellan et al., 2013), EBNA3A-TAP, EBNA3C-TAP, the TSSs of ADAM28 and 
ADAMDEC1 (horizontal arrows) on the positive strand (left to right), long non-coding RNA RP11-
624C23.1 on the negative strand (right to left), ENCODE ChIP-seq tracks for H3K4me3 and H3K27ac 
in CD20+ primary B cells (black) or LCL GM12878 (red) and ENCODE ChIP-seq peaks for various 
transcription factors in GM12878 LCL. The EBNA3A and EBNA3C binding site is highlighted by 
inclusion in a dashed box. 
Appendix 
 262 
 
Scale
chr2:
Txn Factor ChIP
Rhesus
Mouse
Dog
Elephant
Opossum
Platypus
Chicken
Lizard
X_tropicalis
Stickleback
SNPs (130)
50 kb hg18
165,260,000 165,270,000 165,280,000 165,290,000 165,300,000 165,310,000 165,320,000 165,330,000 165,340,000 165,350,000 165,360,000 165,370,000 165,380,000 165,390,000 165,400,000 165,410,000
COBLL1
COBLL1
COBLL1
COBLL1
COBLL1
KIAA0977
COBLL1
COBLL1
COBLL1
COBLL1
COBLL1
SNORA70F LOC101929633
   EBNA3A-HA_Rep2
1247.32 -
-0.884049 _
   EBNA3A-HA_Rep1
   EBNA3C-HA_Rep1
Layered H3K4Me1
Layered H3K4Me3
Mammal Cons
3 -
-0.5 _
Scale
chr2:
Txn Factor ChIP
Rhesus
Mouse
Dog
Elephant
Opossum
Platypus
Chicken
Lizard
X_tropicalis
Stickleback
SNPs (130)
50 kb hg18
165,260,000 165,270,000 165,280,000 165,290,000 165,300,000 165,310,000 165,320,000 165,330,000 165,340,000 165,350,000 165,360,000 165,370,000 165,380,000 165,390,000 165,400,000 165,410,000
COBLL1
COBLL1
COBLL1
COBLL1
COBLL1
KIAA0977
COBLL1
COBLL1
COBLL1
COBLL1
COBLL1
SNORA70F LOC101929633
   EBNA3A-HA_Rep2
1247.32 -
-0.884049 _
   EBNA3A-HA_Rep1
   EBNA3C-HA_Rep1
Layered H3K4Me1
Layered H3K4Me3
Mammal Cons
3 -
-0.5 _
Scale
Txn Factor ChIP
Rhesus
Mouse
Dog
Elephant
Opossum
Platypus
Chicken
Lizard
X_tropicalis
Stickleback
SNPs (130)
50 kb hg18
COBLL1
COBLL1
COBLL1
COBLL1
COBLL1
KIAA0977
COBLL1
COBLL1
COBLL1
COBLL1
COBLL1
SNORA70F LOC101929633
   EBNA3A-HA_Rep2
1247.32 -
-0.884049 _
   EBNA3A-HA_Rep1
   EBNA3C-HA_Rep1
Layered H3K4Me1
Layered H3K4Me3
Mammal Cons
3 -
-0.5 _
Scalechr2:
Txn Factor ChIP
RhesusMouseDogElephantOpossumPlatypChickenLiz rdX_tr p liStickleb ckN s (130)
50 kb hg18165,260,000 165,270,000 165,280,000 165,290,000 165,300,000 165,310,000 165,320,000 165,330,000 165,340,000 165,350,000 165,360,000 165,370,000 165,380,000 165,390,000 165,400,000 165,410,000
OBLL1
KIAA0977
COBLL1
LL1
S ORA70F LOC101929633
   EBNA3A-HA_Rep2
   EBNA3A-HA_RepCLayered H3K4Me13
Mammal Co s 3 --0.5 _
Scale
chr2:
EBNA2 McClellan et al.
EBNA3 McClellan et al.
EBNA3A-TAP
EBNA3C-TAP
GM12878 ATF2
GM12878 ATF3
GM12878 BATF
GM12878 BCL11A
GM12878 BCL3
GM12878 BCLAF1
GM12878 BHLHE40
GM12878 BRCA1
GM12878 CEBPB
GM12878 CHD1
GM12878 CHD2
GM12878 CTCF b
GM12878 CTCF s
GM12878 CTCF t
GM12878 CTCF w
GM12878 E2F4
GM12878 EBF1 h
GM12878 EBF1 s
GM12878 EGR1
GM12878 ELF1
GM12878 ELK1
GM12878 EP300 h
GM12878 EP300 s
GM12878 EP300 s2
GM12878 ETS1
GM12878 EZH2
GM12878 FOS
GM12878 FOXM1
GM12878 GABPA
GM12878 IKZF1
GM12878 IRF4
GM12878 JUND
GM12878 MAX
GM12878 MAZ
GM12878 MEF2A
GM12878 MEF2C
GM12878 MTA3
GM12878 MXI1
GM12878 MYC
GM12878 NFATC1
GM12878 NFE2
GM12878 NFIC
GM12878 NFYA
GM12878 NFYB
GM12878 NR2C2
GM12878 NRF1
GM12878 PAX5 h
GM12878 PAX5 h2
GM12878 PBX3
GM12878 PML
GM12878 POLR2A h
GM12878 POLR2A h2
GM12878 POLR2A s
GM12878 POLR2A s2
GM12878 POLR2A t
GM12878 POLR2A y
GM12878 POLR3G
GM12878 POU2F2
GM12878 RAD21 h
GM12878 RAD21 s
GM12878 RCOR1
GM12878+TNFa RELA
GM12878 REST
GM12878 RFX5
GM12878 RUNX3
GM12878 RXRA
GM12878 SIN3A
GM12878 SIX5
GM12878 SMC3
GM12878 SP1
GM12878 SPI1
GM12878 SRF
GM12878 STAT1
GM12878 STAT3
GM12878 STAT5A
GM12878 TAF1
GM12878 TBL1XR1
GM12878 TBP
GM12878 TCF12
GM12878 TCF3
GM12878 USF1
GM12878 USF2
GM12878 WRNIP1
GM12878 YY1 h
GM12878 YY1 c
GM12878 ZBTB33
GM12878 ZEB1
GM12878 ZNF143
GM12878 ZNF274
GM12878 ZZZ3
Txn Factor ChIP
50 kb hg19
165,550,000 165,560,000 165,570,000 165,580,000 165,590,000 165,600,000 165,610,000 165,620,000 165,630,000 165,640,000 165,650,000 165,660,000 165,670,000 165,680,000 165,690,000 165,700,000
 
 
 
 
UCSC Genes (RefSeq, GenBank, CCDS, Rfam, tRNAs & Comparative Genomics)
CD20+ (RO 01794) H3K4me3 Histone Mod ChIP-seq Raw Sig 3 from ENCODE/UW
GM12878 H3K4me3 Histone Mod ChIP-seq Raw Sig 1 from ENCODE/UW
CD20+ RO01794 H3K27ac Histone Mods by ChIP-seq Signal from ENCODE/Broad
GM12878 H3K27ac Histone Mods by ChIP-seq Signal from ENCODE/Broad
Transcription Factor ChIP-seq Uniform Peaks from ENCODE/Analysis
Transcription Factor ChIP-seq (161 factors) from ENCODE with Factorbook Motifs
GM12878 H3K4me3 Histone Mod ChIP-seq Raw Sig 2 from ENCODE/UW
GM12878 H3K27me3 Histone Mod ChIP-seq Raw Sig 1 from ENCODE/UW
GM12878 H3K27me3 Histone Mod ChIP-seq Raw Sig 2 from ENCODE/UW
GM12878 H3K36me3 Histone Mod ChIP-seq Raw Sig 1 from ENCODE/UW
GM12878 H3K36me3 Histone Mod ChIP-seq Raw Sig 2 from ENCODE/UW
GM12878 Input Histone Mod ChIP-seq Raw Sig 1 from ENCODE/UW
GM12878 CTCF Histone Mods by ChIP-seq Signal from ENCODE/Broad
GM12878 EZH2 (39875) Histone Mods by ChIP-seq Signal from ENCODE/Broad
GM12878 H2A.Z Histone Mods by ChIP-seq Signal from ENCODE/Broad
GM12878 H3K4me1 Histone Mods by ChIP-seq Signal from ENCODE/Broad
GM12878 H3K4me2 Histone Mods by ChIP-seq Signal from ENCODE/Broad
GM12878 H3K4me3 Histone Mods by ChIP-seq Signal from ENCODE/Broad
GM12878 H3K9ac Histone Mods by ChIP-seq Signal from ENCODE/Broad
GM12878 H3K9me3 Histone Mods by ChIP-seq Signal from ENCODE/Broad
GM12878 H3K27me3 Histone Mods by ChIP-seq Signal from ENCODE/Broad
GM12878 H3K36me3 Histone Mods by ChIP-seq Signal from ENCODE/Broad
GM12878 H3K79me2 Histone Mods by ChIP-seq Signal from ENCODE/Broad
GM12878 H4K20me1 Histone Mods by ChIP-seq Signal from ENCODE/Broad
GM12878 Input Histone Mods by ChIP-seq Signal from ENCODE/Broad
CD20+ CTCF Histone Mods by ChIP-seq Signal from ENCODE/Broad
CD20+ H2A.Z Histone Mods by ChIP-seq Signal from ENCODE/Broad
CD20+ H3K4me2 Histone Mods by ChIP-seq Signal from ENCODE/Broad
CD20+ Control Histone Mods by ChIP-seq Signal from ENCODE/Broad
CD20+ RO01794 EZH2 (39875) Histone Mods by ChIP-seq Signal from ENCODE/Broad
CD20+ RO01794 H4K20me1 Histone Mods by ChIP-seq Signal from ENCODE/Broad
CD20+ (RO 01794) Input Histone Mod ChIP-seq Raw Sig 1 from ENCODE/UW
COBLL1
COBLL1
COBLL1
COBLL1
COBLL1
COBLL1
SNORA70F COBLL1
COBLL1
20+94 H3K4M3 Sg 3
325 _
1 _
GM78 H3K4M3 Sg 1
325 _
1 _
CD20+ H3K27ac
250 _
1 _
GM12878 H3K27ac
250 _
1 _
GM78 H3K4M3 Sg 2
100 _
1 _
GM78 H3K27M3 Sg 1
100 _
1 _
GM78 H3K27M3 Sg 2
100 _
1 _
GM78 H3K36M3 Sg 1
100 _
1 _
GM78 H3K36M3 Sg 2
100 _
1 _
GM78 In Sg 1
100 _
1 _
GM12878 CTCF
50 _
1 _
GM12878 EZH2
50 _
1 _
GM12878 H2A.Z
50 _
1 _
GM12878 H3K4m1
50 _
1 _
GM12878 H3K4m2
50 _
1 _
GM12878 H3K4m3
50 _
1 _
GM12878 H3K9ac
50 _
1 _
GM12878 H3K9m3
50 _
1 _
GM12878 H3K27m3
50 _
1 _
GM12878 H3K36m3
50 _
1 _
GM12878 H3K79m2
50 _
1 _
GM12878 H4K20m1
50 _
1 _
GM12878 Input
50 _
1 _
CD20+ CTCF
50 _
1 _
CD20+ H2A.Z
50 _
1 _
CD20+ H3K4m2
50 _
1 _
CD20+ Control
50 _
1 _
CD20+ EZH2
50 _
1 _
CD20+ H4K20m1
50 _
1 _
20+94 In Sg 1
100 _
1 _
COBLL1	peak	
A	
EBNA3C-HA 
EBNA3A-HA 
Scale
chr2:
Txn Factor ChIP
Rhesus
Mouse
Dog
Elephant
Opossum
Platypus
Chicken
Lizard
X_tropicalis
Stickleback
SNPs (130)
50 kb hg18
165,260,000 165,270,000 165,280,000 165,290,000 165,300,000 165,310,000 165,320,000 165,330,000 165,340,000 165,350,000 165,360,000 165,370,000 165,380,000 165,390,000 165,400,000 165,410,000
COBLL1
COBLL1
COBLL1
COBLL1
COBLL1
KIAA0977
COBLL1
COBLL1
COBLL1
COBLL1
COBLL1
SNORA70F LOC101929633
   EBNA3A-HA_Rep2
   EBNA3C-HA_Rep2
   EBNA3A-HA_Rep1
   EBNA3C-HA_Rep1
Layered H3K4Me1
Layered H3K4Me3
Mammal Cons
3 -
-0.5 _
RBPJ 
B	
Appendix 
 263 
Figure 7.10: EBNA3A and EBNA3C binding sites on COBLL1 locus are co-occupied by multiple 
transcription factors. 
(A) UCSC genome browser overview of COBLL1 genomic locus showing ChIP-seq tracks for RBPJ 
(Zhao et al., 2011a), EBNA3A-HA (Schmidt et al., 2014) and EBNA3C-HA (Jiang et al., 2013) aligned 
to hg18. Occupancy levels are merely to indicate the position and are not to scale. (B) Hg19 view of 
same genomic locus as in (A) showing ChIP-seq tracks for EBNA2 (McClellan et al., 2013), EBNA3 
(McClellan et al., 2013), EBNA3A-TAP, EBNA3C-TAP, the TSS (horizontal arrow), ENCODE ChIP-
seq tracks for H3K4me3 and H3K27ac in CD20+ primary B cells (black) or LCL GM12878 (red) and 
ENCODE ChIP-seq peaks for various transcription factors in GM12878 LCL. The EBNA3A and 
EBNA3C binding site is highlighted by inclusion in a dashed box. 
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Figure 7.11: EBNA3A, EBNA3C and EBNA2 binding sites on AICDA locus are co-occupied by 
multiple transcription factors. 
(A) UCSC genome browser overview of AICDA genomic locus showing ChIP-seq tracks for RBPJ 
(Zhao et al., 2011a), EBNA3A-HA (Schmidt et al., 2014) and EBNA3C-HA (Jiang et al., 2013) aligned 
to hg18. Occupancy levels are merely to indicate the position and are not to scale. (B) Hg19 view of 
same genomic locus as in (A) showing ChIP-seq tracks for EBNA2 (McClellan et al., 2013), EBNA3 
(McClellan et al., 2013), EBNA3A-TAP, EBNA3C-TAP, ENCODE ChIP-seq tracks for H3K4me3 and 
H3K27ac in CD20+ primary B cells (black) or LCL GM12878 (red) and ENCODE ChIP-seq peaks for 
various transcription factors in GM12878 LCL. The EBNA2, EBNA3A and EBNA3C binding site at the 
AICDA regulatory regions II, III, IV, V and VI are highlighted by inclusion in dashed boxes. 
